Haemonetics (HAE) 10-K 22 May 14 2014 FY Annual report Financial data

DOCUMENT_AND_ENTITY_INFORMATIO

DOCUMENT AND ENTITY INFORMATION DOCUMENT AND ENTITY INFORMATION (USD $)	12 Months Ended
	Mar. 29, 2014	Apr. 26, 2014	Sep. 28, 2013
Document And Entity Information [Abstract]	'	'	'
Entity Registrant Name	'HAEMONETICS CORP	'	'
Entity Central Index Key	'0000313143	'	'
Current Fiscal Year End Date	'--03-29	'	'
Entity Filer Category	'Large Accelerated Filer	'	'
Document Type	'10-K	'	'
Document Period End Date	29-Mar-14	'	'
Document Fiscal Year Focus	'2014	'	'
Document Fiscal Period Focus	'FY	'	'
Amendment Flag	'false	'	'
Entity Common Stock, Shares Outstanding	'	52,053,753	'
Entity Well-known Seasoned Issuer	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Public Float	'	'	$2,058,543,720

CONSOLIDATED_STATEMENTS_OF_INC

CONSOLIDATED STATEMENTS OF INCOME (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Income Statement [Abstract]	'	'	'
Net revenues	$938,509	$891,990	$727,844
Cost of goods sold	470,144	463,859	358,604
Gross profit	468,365	428,131	369,240
Operating expenses:	'	'	'
Research and development	54,200	44,394	36,801
Selling, general and administrative	365,127	323,053	243,681
Asset write-down	1,711	4,247	0
Total operating expenses	421,038	371,694	280,482
Operating income	47,327	56,437	88,758
Other (expense) income, net	-10,926	-6,540	740
Income before provision for income taxes	36,401	49,897	89,498
Provision for income taxes	1,253	11,097	22,612
Net income	$35,148	$38,800	$66,886
Net income per share - basic (in dollars per share)	$0.68	$0.76	$1.32
Net income per share - diluted (in dollars per share)	$0.67	$0.74	$1.30
Weighted average shares outstanding	'	'	'
Basic (in shares)	51,611	51,349	50,727
Diluted (in shares)	52,377	52,259	51,590

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Statement of Other Comprehensive Income [Abstract]	'	'	'
Net income	$35,148	$38,800	$66,886
Other comprehensive loss:	'	'	'
Impact of defined benefit plans, net of tax	481	-820	-3,988
Foreign currency translation adjustment	-935	-4,705	-2,813
Unrealized gain on cash flow hedges, net of tax	5,001	4,594	3,140
Reclassifications into earnings of cash flow hedge (gains)/losses, net of tax	-8,570	-2,746	3,230
Other comprehensive loss	-4,023	-3,677	-431
Comprehensive income	$31,125	$35,123	$66,455

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 29, 2014	Mar. 30, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$192,469	$179,120
Accounts receivable, less allowance of $1,676 at March 29, 2014 and $1,727 at March 30, 2013	164,603	170,111
Inventories, net	197,661	183,784
Deferred tax asset, net	14,144	13,782
Prepaid expenses and other current assets	54,099	50,213
Total current assets	622,976	597,010
Net property, plant and equipment	271,437	256,953
Other assets:	'	'
Intangible assets	271,159	264,388
Goodwill	336,768	330,474
Deferred tax asset	1,184	1,751
Other long-term assets	10,654	11,341
Total other assets	619,765	607,954
Total assets	1,514,178	1,461,917
Current liabilities:	'	'
Notes payable and current maturities of long-term debt	45,630	23,150
Accounts payable	53,562	49,893
Accrued payroll and related costs	54,913	45,697
Accrued income taxes	3,113	4,053
Other liabilities	59,710	57,351
Total current liabilities	216,928	180,144
Long-term debt, net of current maturities	392,057	456,944
Long-term deferred tax liability	29,664	29,552
Other long-term liabilities	37,641	26,095
Stockholders’ equity:	'	'
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 52,041,189 shares at March 29, 2014 and 51,031,563 shares at March 30, 2013	520	510
Additional paid-in capital	402,611	365,040
Retained earnings	433,347	398,199
Accumulated other comprehensive income	1,410	5,433
Total stockholders’ equity	837,888	769,182
Total liabilities and stockholders’ equity	$1,514,178	$1,461,917

CONSOLIDATED_BALANCE_SHEETS_PA

CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) (USD $)	Mar. 29, 2014	Mar. 30, 2013
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]	'	'
Accounts receivable, allowance	$1,676	$1,727
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, authorized (in shares)	150,000,000	150,000,000
Common stock, issued (in shares)	52,041,189	51,031,563
Common stock, outstanding (in shares)	52,041,189	51,031,563

CONSOLIDATED_STATEMENT_OF_STOC

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (USD $)	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income/(Loss)
In Thousands, except Share data, unless otherwise specified
Balance, value at Apr. 02, 2011	$686,136	$513	$302,452	$373,630	$9,541
Balance, shares (in shares) at Apr. 02, 2011	'	51,320,000	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Employee stock purchase plan	3,723	2	3,721	'	'
Employee stock purchase plan (in shares)	'	154,000	'	'	'
Exercise of stock options and related tax benefit	17,028	7	17,021	'	'
Exercise of stock options and related tax benefit (in shares)	'	738,000	'	'	'
Shares repurchased	-49,998	-17	-10,248	-39,733	'
Shares repurchased (in shares)	'	-1,704,000	'	'	'
Issuance of restricted stock, net of cancellations	1	1	'	'	'
Issuance of restricted stock, net of cancellations (in shares)	'	96,000	'	'	'
Stock compensation expense	9,286	'	9,286	'	'
Net income	66,886	'	'	66,886	'
Other comprehensive income/(loss)	-431	'	'	'	'
Balance, value at Mar. 31, 2012	732,631	506	322,232	400,783	9,110
Balance, shares (in shares) at Mar. 31, 2012	'	50,604,000	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Employee stock purchase plan	4,142	1	4,141	'	'
Employee stock purchase plan (in shares)	'	151,000	'	'	'
Exercise of stock options and related tax benefit	35,815	14	35,801	'	'
Exercise of stock options and related tax benefit (in shares)	'	1,398,000	'	'	'
Stock-based compensation adjustment related to acquisition	504	'	504	'	'
Shares repurchased	-50,003	-12	-8,607	-41,384	'
Shares repurchased (in shares)	'	-1,236,000	'	'	'
Issuance of restricted stock, net of cancellations	1	1	'	'	'
Issuance of restricted stock, net of cancellations (in shares)	'	115,000	'	'	'
Stock compensation expense	10,969	'	10,969	'	'
Net income	38,800	'	'	'	'
Other comprehensive income/(loss)	-3,677	'	'	'	'
Balance, value at Mar. 30, 2013	769,182	510	365,040	398,199	5,433
Balance, shares (in shares) at Mar. 30, 2013	'	51,032,000	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Employee stock purchase plan	5,229	2	5,227	'	'
Employee stock purchase plan (in shares)	'	161,000	'	'	'
Exercise of stock options and related tax benefit	19,270	7	19,263	'	'
Exercise of stock options and related tax benefit (in shares)	'	740,000	'	'	'
Issuance of restricted stock, net of cancellations	1	1	'	'	'
Issuance of restricted stock, net of cancellations (in shares)	'	108,000	'	'	'
Stock compensation expense	13,081	'	13,081	'	'
Net income	35,148	'	'	'	'
Other comprehensive income/(loss)	-4,023	'	'	'	'
Balance, value at Mar. 29, 2014	$837,888	$520	$402,611	$433,347	$1,410
Balance, shares (in shares) at Mar. 29, 2014	'	52,041,000	'	'	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Cash Flows from Operating Activities:	'	'	'
Net income	$35,148	$38,800	$66,886
Non-cash items:	'	'	'
Depreciation and amortization	81,740	65,481	49,966
Amortization of financing costs	1,505	1,139	0
Stock compensation expense	13,081	10,969	9,286
Deferred tax expense	-202	589	5,878
Purchased in process research and development	3,569	0	0
Loss on sale of property, plant and equipment	293	351	772
Unrealized (gain)/loss from hedging activities	-128	700	166
Changes in fair value of contingent consideration	45	0	-2,154
Asset write-down	2,587	4,247	0
Change in operating assets and liabilities:	'	'	'
Decrease/(increase) in accounts receivable, net	6,154	-38,080	-10,539
Increase in inventories	-12,684	-18,685	-32,528
(Increase)/decrease in prepaid income taxes	1,175	-4,025	3,058
Decrease/(increase) in other assets and other long-term liabilities	3,176	-6,187	3,156
Tax benefit of exercise of stock options	1,649	4,194	1,958
Increase in accounts payable and accrued expenses	2,416	25,581	19,413
Net cash provided by operating activities	139,524	85,074	115,318
Cash Flows from Investing Activities:	'	'	'
Capital expenditures on property, plant and equipment	-73,648	-62,188	-53,198
Proceeds from sale of property, plant and equipment	488	1,968	1,002
Acquisition of Whole Blood Business	0	-535,175	0
Acquisition of Hemerus	-23,124	-1,000	0
Other acquisitions	-9,546	0	0
Net cash used in investing activities	-105,830	-596,395	-52,196
Cash Flows from Financing Activities:	'	'	'
Payments on long-term real estate mortgage	-964	-886	-815
Net (decrease)/increase in short-term loans	-5,521	7,446	-288
Term loan borrowings	0	475,000	0
Payments on long-term real estate mortgage	-37,063	0	0
Debt issuance costs	0	-5,467	0
Proceeds from employee stock purchase plan	5,229	4,142	3,723
Proceeds from exercise of stock options	15,224	27,517	15,475
Excess tax benefit on exercise of stock options	2,395	4,101	1,433
Share repurchase	0	-50,000	-49,998
Net cash (used in)/provided by financing activities	-20,700	461,853	-30,470
Effect of exchange rates on cash and cash equivalents	355	-273	-498
Net Increase/(Decrease) in Cash and Cash Equivalents	13,349	-49,741	32,154
Cash and Cash Equivalents at Beginning of Year	179,120	228,861	196,707
Cash and Cash Equivalents at End of Year	192,469	179,120	228,861
Non-cash Investing and Financing Activities:	'	'	'
Transfers from inventory to fixed assets for placement of Haemonetics equipment	10,584	21,677	18,333
Supplemental Disclosures of Cash Flow Information:	'	'	'
Interest paid	8,942	5,910	414
Income taxes paid	$1,493	$13,178	$10,764

DESCRIPTION_OF_THE_BUSINESS_AN

DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION	12 Months Ended
	Mar. 29, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION	'
	DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION
	Haemonetics is a global healthcare company dedicated to providing innovative blood management solutions for our customers — plasma collectors, blood collectors, and hospitals. Anchored by our strong brand name in medical device systems for the transfusion industry, we also provide information technology platforms and value added services to provide customers with business solutions which support improved clinical outcomes for patients and efficiency in the blood supply chain.
	Our systems automate the collection and processing of donated blood; perform blood diagnostics; salvage and process surgical patient blood; and dispense blood within the hospital. These systems include devices and single-use, proprietary disposable sets that operate only on our specialized equipment. Our manual blood collection and filtration systems enable the manual collection of all blood components while detecting bacteria, thus reducing the risks of infection through transfusion. Our blood processing systems allow users to collect and process only the blood component(s) they target — plasma, platelets, or red blood cells — increasing donor and patient safety as well as collection efficiencies. Our blood diagnostics system assesses the likelihood of a patient’s blood loss allowing clinicians to make informed decisions about a patient’s treatment as it relates to blood loss in surgery. Our surgical blood salvage systems collect blood lost by a patient in surgery, clean the blood, and make it available for reinfusion to the patient, in this way giving the patient the safest blood possible — his or her own. Our blood distribution systems are “smart” refrigerators located throughout hospitals which automate the storage, inventory tracking, and dispositioning of blood in key blood use areas.
	Our information technology platforms are used by blood and plasma collectors to improve the safety and efficiency of blood collection logistics by eliminating previously manual functions at not-for-profit blood centers and commercial plasma centers which are operated by our bio-pharmaceutical customers. Our platforms are also used by hospitals to enable hospital administrators to monitor and measure blood management practices and to manage processes within transfusion services. Our information technology platforms allow all customers to better manage processes across the blood supply chain, comply with regulatory requirements, and identify increased opportunities to reduce costs.
	On November 30, 2012 we completed a two-for-one split of our common stock in the form of a stock dividend. Unless otherwise indicated, all common stock shares and per share information referenced within the Consolidated Financial Statements have been retroactively adjusted to reflect the stock split. The exercise price of each outstanding option has also been proportionately and retroactively adjusted for all periods presented. Par value per share and authorized shares were however not affected by the stock split.
	The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The accompanying consolidated financial statements present separately our financial position, results of operations, cash flows, and changes in shareholders’ equity. All amounts presented, except per share amounts, are stated in thousands of U.S. dollars, unless otherwise indicated.
	We considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated, and these financial statements reflect those material items that arose after the balance sheet date but prior to the issuance of the financial statements that would be considered recognized subsequent events. Refer to Note 20 - Subsequent Events for further information.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS	12 Months Ended
	Mar. 29, 2014
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Fiscal Year
	Our fiscal year ends on the Saturday closest to the last day of March. Fiscal years 2014, 2013 and 2012 each includes 52 weeks with each quarter having 13 weeks.
	Principles of Consolidation
	The accompanying consolidated financial statements include all accounts including those of our subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could vary from the amounts derived from our estimates and assumptions.
	Reclassifications
	Certain reclassifications have been made to prior years' amounts to conform to the current year's presentation.
	Contingencies
	We may become involved in various legal proceedings that arise in the ordinary course of business, including, without limitation, patent infringement, product liability and environmental matters. Accruals recorded for various contingencies including legal proceedings, self-insurance and other claims are based on judgment, the probability of losses and, where applicable, the consideration of opinions of internal and/or external legal counsel and actuarially determined estimates. When a range is established but a best estimate cannot be made, we record the minimum loss contingency amount. These estimates are often initially developed substantially earlier than the ultimate loss is known, and the estimates are reevaluated each accounting period, as additional information is available. When we are initially unable to develop a best estimate of loss, we record the minimum amount of loss, which could be zero. As information becomes known, additional loss provision is recorded when either a best estimate can be made or the minimum loss amount is increased. When events result in an expectation of a more favorable outcome than previously expected, our best estimate is changed to a lower amount. We record receivables from third party insurers when we have determined that existing insurance policies will provide reimbursement. In making this determination, we consider applicable deductibles, policy limits and the historical payment experience of the insurance carriers.
	Revenue Recognition
	Our revenue recognition policy is to recognize revenues from product sales, software and services in accordance with ASC Topic 605, Revenue Recognition, and ASC Topic 985-605, Software. These standards require that revenues are recognized when persuasive evidence of an arrangement exists, product delivery, including customer acceptance, has occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. We may have multiple contracts with the same customer and each contract is typically treated as a separate arrangement. When more than one element such as equipment, disposables, and services are contained in a single arrangement, we allocate revenue between the elements based on each element’s relative selling price, provided that each element meets the criteria for treatment as a separate unit of accounting. An item is considered a separate unit of accounting if it has value to the customer on a stand-alone basis. The selling price of the undelivered elements is determined by the price charged when the element is sold separately, or in cases when the item is not sold separately, by third-party evidence of selling price or by management's best estimate of selling price. For our software arrangements accounted for under the provisions of ASC 985-605, Software, we establish fair value of undelivered elements based upon vendor specific objective evidence.
	Product Revenues
	Product sales consist of the sale of our disposable whole blood and blood component collection sets, equipment devices and the related disposables used with these devices. On product sales to end customers, revenue is recognized when both the title and risk of loss have transferred to the customer as determined by the shipping terms and all obligations have been completed. For product sales to distributors, we recognize revenue for both equipment and disposables upon shipment of these products to our distributors. Our standard contracts with our distributors state that title to the equipment passes to the distributors at point of shipment to a distributor’s location. The distributors are responsible for shipment to the end customer along with installation, training and acceptance of the equipment by the end customer. Payments from distributors are not contingent upon resale of the product.
	Software Revenues
	Our software solutions business provides support to our plasma and blood collection customers and hospitals. We provide information technology platforms and technical support for donor recruitment, blood and plasma testing laboratories, and for efficient and compliant operations of blood and plasma collection centers. For plasma customers, we also provide information technology platforms for managing distribution of plasma from collection centers to plasma fractionation facilities.
	Our software solutions revenues also include revenue from software sales which includes per collection or monthly subscription fees for the license and support of the software as well as hosting services. A significant portion of our software sales are perpetual licenses typically accompanied with significant implementation service fees related to software customization as well as other professional and technical service fees.
	We generally recognize revenue from the sale of perpetual licenses on a percentage-of-completion basis which requires us to make reasonable estimates of the extent of progress toward completion of the contract. These arrangements most often include providing customized implementation services to our customer. We also provide other services, including in some instances hosting, technical support, and maintenance, for the payment of periodic, monthly, or quarterly fees. We recognize these fees and charges as earned, typically as these services are provided during the contract period.
	Non-Income Taxes
	We are required to collect sales or valued added taxes in connection with the sale of certain of our products. We report revenues net of these amounts as they are promptly remitted to the relevant taxing authority.
	We are also required to pay a medical device excise tax relating to U.S. sales of Class I, II and III medical devices. This new excise tax went into effect January 1, 2013, established as part of the March 2010 U.S. healthcare reform legislation, and has been included in selling, general and administrative expenses.
	Translation of Foreign Currencies
	All assets and liabilities of foreign subsidiaries are translated at the rate of exchange at year-end while sales and expenses are translated at an average rate in effect during the year. The net effect of these translation adjustments is shown in the accompanying financial statements as a component of stockholders' equity. Foreign currency transaction gains and losses, including those resulting from inter-company transactions, are charged directly to earnings and included in other income, net on the consolidated statements of income. The impact of foreign exchange on long-term intercompany loans, for which repayment has not been scheduled or planned, are recorded in accumulated other comprehensive income on the consolidated balance sheet.
	Cash and Cash Equivalents
	Cash equivalents include various instruments such as money market funds, U.S. government obligations and commercial paper with maturities of three months or less at date of acquisition. Cash and cash equivalents are recorded at cost, which approximates fair market value. As of March 29, 2014, our cash and cash equivalents consisted of investments in United States Government Agency and institutional money market funds.
	Allowance for Doubtful Accounts
	We establish a specific allowance for customers when it is probable that they will not be able to meet their financial obligation. Customer accounts are reviewed individually on a regular basis and appropriate reserves are established as deemed appropriate. We also maintain a general reserve using a percentage that is established based upon the age of our receivables and our collection history. We establish allowances for balances not yet due and past due accounts based on past experience.
	Property, Plant and Equipment
	Property, plant and equipment is recorded at historical cost. We provide for depreciation and amortization by charges to operations using the straight-line method in amounts estimated to recover the cost of the building and improvements, equipment, and furniture and fixtures over their estimated useful lives as follows:
	Asset Classification		Estimated
			Useful Lives
	Building		30 Years
	Building improvements		5-20 Years
	Plant equipment and machinery		3-15 Years
	Office equipment and information technology		3-10 Years
	Haemonetics equipment		3-7 Years
	We evaluate the depreciation periods of property, plant and equipment to determine whether events or circumstances warrant revised estimates of useful lives. All property, plant and equipment are also tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable.
	Our installed base of devices includes devices owned by us and devices sold to the customer. The asset on our balance sheet entitled Haemonetics equipment consists of medical devices installed at customer sites but owned by Haemonetics. Generally the customer has the right to use it for a period of time as long as they meet the conditions we have established, which among other things, generally include one or more of the following:
	•	Purchase and consumption of a certain level of disposable product
	•	Payment of monthly rental fees
	•	An asset utilization performance metric, such as performing a minimum level of procedures per month per device
	Consistent with the impairment tests noted below for other intangible assets subject to amortization, we review Haemonetics equipment and their related useful lives at least once a year, or more frequently if certain conditions arise, to determine if any adverse conditions exist that would indicate the carrying value of these assets may not be recoverable. To conduct these reviews we estimate the future amount and timing of demand for these devices. Changes in expected demand can result in additional depreciation expense, which is classified as cost of goods sold. Any significant unanticipated changes in demand could impact the value of our devices and our reported operating results.
	Leasehold improvements are depreciated over the lesser of their useful lives or the term of the lease. Maintenance and repairs are expensed to operations as incurred. When equipment and improvements are sold or otherwise disposed of, the asset cost and accumulated depreciation are removed from the accounts, and the resulting gain or loss, if any, is included in the statements of income.
	Goodwill and Intangible Assets
	Intangible assets acquired in a business combination are recorded under the purchase method of accounting at their estimated fair values at the date of acquisition. Goodwill represents the excess purchase price over the fair value of the net tangible and other identifiable intangible assets acquired. We amortize our other intangible assets over their estimated useful lives.
	Goodwill is not amortized. Instead goodwill is reviewed for impairment at least annually in accordance with ASC Topic 350, Intangibles — Goodwill and Other, or on an interim basis between annual tests when events or circumstances indicate that it is more likely than not that the fair value of a reporting unit is less than its carrying value. We perform our annual impairment test on the first day of the fiscal fourth quarter for each of our reporting units. We first perform a qualitative test and if necessary, perform a quantitative test.
	Prior to fiscal 2014 we determined we operated a single operating segment, blood management solutions, based on our chief operating decision maker (“CODM”) primarily using consolidated results to make operating and strategic decisions. Our reporting units for purposes of assessing goodwill impairment prior to fiscal 2014 were medical devices and software. During fiscal 2014 our CODM utilized financial results by operating units organized primarily on geography due to changes in the composition in the executive staff reporting to the CODM. Based on these changes we determined the five operating units noted above represent operating segments as defined under ASC 280 - Segment Reporting. Following this change we determined our reporting units for purposes of assessing goodwill impairment by identifying our operating segments and assessing whether segment management regularly reviews the operating results of any components. Through this process, we concluded that our reporting units were the same as our operating segments, which are the following operating units organized based primarily on geography: North America Plasma, North America Blood Center and Hospital, Europe, Asia-Pacific and Japan. Goodwill was reallocated from the medical device and software reporting units to the new reporting units based on a relative fair value basis.
	The quantitative test is based on a discounted cash flow analysis or other valuation techniques, such as the market approach, for each reporting unit. In fiscal 2014, we determined the fair value of our reporting units based on the market approach. Under the market approach, we estimate the fair value of our reporting units based on a combination of, a) market multiples of current year earnings before interest, taxes, depreciation and amortization (“EBITDA”) and b) net revenues for each individual reporting unit. For the market approach, we use judgment in identifying the relevant comparable-company market multiples, such as recent divestitures/acquisitions, facts and circumstances surrounding the market and growth rates. Management assesses the relevance and reliability of the multiples by considering factors unique to its reporting units, including recent operating results, business plans, economic projections, anticipated future cash flows, and other data. EBITDA and revenue multiples can also be significantly impacted by future growth opportunities for the reporting unit as well as for the company itself, general market and geographic sentiment, and pending or recently completed merger transactions.
	The fair values of our reporting units in fiscal 2012 and 2013 were determined using an income approach. Under the income approach, the fair value of a reporting unit is based on the present value of future cash flows using appropriate discount rates, growth rates, operating margins and future market conditions amongst others. We changed our valuation approach to assessing goodwill impairment in fiscal 2014 in connection with the change in reporting units. ASC 350, Intangibles - Goodwill and Other defines the fair value of a reporting unit as the price that would be received to sell the unit as a whole in an orderly transaction between market participants at the measurement date. We utilized the market approach as we determined relevant comparable information was available, and accordingly such method was an appropriate alternative to the income method based on cost-benefit considerations.
	These tests showed no evidence of impairment to our goodwill for fiscal 2014, 2013 or 2012 and demonstrated that the fair value of each reporting unit exceeded the reporting unit’s carrying value in each period. During March 2014, circumstances arose that indicated a potential impairment. We performed an interim impairment test with the new information and noted that the fair value of our reporting units still exceeded their carrying values.
	We review intangible assets subject to amortization at least annually or more frequently if certain conditions arise to determine if any adverse conditions exist that would indicate that the carrying value of an asset or asset group may not be recoverable, or that a change in the remaining useful life is required. Conditions indicating that an impairment exists include but are not limited to a change in the competitive landscape, internal decisions to pursue new or different technology strategies, a loss of a significant customer or a significant change in the marketplace including prices paid for our products or the size of the market for our products. During March 2014, circumstances arose that indicated a potential impairment of certain intangible assets subject to amortization. We performed the recoverability test described below for the relevant asset group and determined expected undiscounted cash flows exceeded the carrying value of the asset group.
	If an impairment indicator exists, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset (asset group) exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset (asset group), we will write the carrying value down to the fair value in the period identified.
	We generally calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset using a risk-adjusted discount rate. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset (asset group).
	If we determine the estimate of an intangible asset's remaining useful life should be reduced based on our expected use of the asset, the remaining carrying amount of the asset is amortized prospectively over the revised estimated useful life.
	Accounting for the Costs of Computer Software to be Sold, Leased, or Otherwise Marketed
	ASC Topic 985-20, Software, specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers, at which point capitalized costs are amortized over their estimated useful life of seven years. Technological feasibility is established when we have a detailed design of the software and when research and development activities on the underlying device, if applicable, are completed.
	We review the net realizable value of capitalized assets periodically to assess the recoverability of amounts capitalized. In the future, the net realizable value may be adversely affected by the loss of a significant customer or a significant change in the market place, which could result in an impairment being recorded.
	Other Liabilities
	Other liabilities represent items payable within the next twelve months.
	The items included in the fiscal year end balances were:
	(In thousands)	March 29,		March 30,
		2014		2013
VAT liabilities	$	7,114	$	5,121
Forward contracts	1,255		1,786
Deferred revenue	24,777		23,737
All other	26,564		26,707
Total	$	59,710	$	57,351
Research and Development Expenses
All research and development costs are expensed as incurred.
Advertising Costs
All advertising costs are expensed as incurred and are included in selling, general and administrative expenses in the consolidated statements of income. Advertising expenses were $3.6 million, $4.6 million, and $4.5 million for 2014, 2013 and 2012, respectively.
Accounting for Shipping and Handling Costs
Shipping and handling costs are included in selling, general and administrative expenses. Freight is classified in cost of goods sold when the customer is charged for freight and in selling, general and administration when the customer is not explicitly charged for freight.
Income Taxes
The income tax provision is calculated for all jurisdictions in which we operate. The income tax provision process involves calculating current taxes due and assessing temporary differences arising from items which are taxable or deductible in different periods for tax and accounting purposes and are recorded as deferred tax assets and liabilities. Deferred tax assets are evaluated for realizability and a valuation allowance is maintained for the portion of our deferred tax assets that are not more-likely-than-not realizable.
We file income tax returns in all jurisdictions in which we operate. We record a liability for uncertain tax positions taken or expected to be taken in income tax returns. Our financial statements reflect expected future tax consequences of such positions presuming the taxing authorities' full knowledge of the position and all relevant facts. We record a liability for the portion of unrecognized tax benefits claimed which we have determined are not more-likely-than-not realizable. These tax reserves have been established based on management's assessment as to the potential exposure attributable to our uncertain tax positions as well as interest and penalties attributable to these uncertain tax positions. All tax reserves are analyzed quarterly and adjustments are made as events occur that result in changes in judgment.
Derivative Instruments
We account for our derivative financial instruments in accordance with ASC Topic 815, Derivatives and Hedging (“ASC 815”) and ASC Topic 820, Fair Value Measurements and Disclosures (“ASC 820”). In accordance with ASC 815, we record all derivatives on the balance sheet at fair value. The accounting for the change in the fair value of derivatives depends on the intended use of the derivative, whether we have elected to designate a derivative as a hedging instrument for accounting purposes, and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. In addition, ASC 815 provides that, for derivative instruments that qualify for hedge accounting, changes in the fair value are either (a) offset against the change in fair value of the hedged assets, liabilities, or firm commitments through earnings or (b) recognized in equity until the hedged item is recognized in earnings, depending on whether the derivative is being used to hedge changes in fair value or cash flows. The ineffective portion of a derivative’s change in fair value is immediately recognized in earnings. We do not use derivative financial instruments for trading or speculation purposes.
The gains or losses on the forward foreign exchange rate contracts designated as hedges are recorded in net revenues, cost of goods sold, operating expenses and other income in our consolidated statements of income when the underlying hedged transaction affects earnings. The cash flows related to the gains and losses are classified in the consolidated statements of cash flows as part of cash flows from operating activities. For those derivative instruments that are not designated as part of a hedging relationship we record the gains or losses in earnings currently. These gains and losses are intended to offset the gains and losses recorded on net monetary assets or liabilities that are denominated in foreign currencies. We recorded foreign currency losses on designated and non-designated hedges of $0.5 million, $0.8 million, and $0.4 million in fiscal 2014, 2013 and 2012, respectively.
On a quarterly basis, we assess whether the cash flow hedges are highly effective in offsetting changes in the cash flow of the hedged item. We manage the credit risk of the counterparties by dealing only with institutions that we consider financially sound and consider the risk of non-performance to be remote.
Our derivative instruments do not subject our earnings or cash flows to material risk, as gains and losses on these derivatives are intended to offset losses and gains on the item being hedged. We do not enter into derivative transactions for speculative purposes and we do not have any non-derivative instruments that are designated as hedging instruments pursuant to ASC Topic 815.
Stock-Based Compensation
We use the Black-Scholes option-pricing model to calculate the grant-date fair value of our stock options. The following assumptions, which involve the use of judgment by management, are used in the computation of the grant-date fair value of our stock options:
Expected Volatility — We have principally used our historical volatility as a basis to estimate expected volatility in our valuation of stock options.
Expected Term — We estimate the expected term of our options using historical exercise and forfeiture data to determine the amount of stock based compensation to record each period. We believe that this historical data is currently the best estimate of the expected term of our new option grants.
Estimated Forfeiture Rate — Based on an analysis of our historical forfeitures, we have applied an annual forfeiture rate which represents the portion that we expect will be forfeited each year over the vesting period. We reevaluate this analysis periodically and adjust the forfeiture rate as necessary. Ultimately, we will only recognize expense for those shares that vest.
Valuation of Acquisitions
We allocate the amounts we pay for each acquisition to the assets acquired and liabilities assumed based on their estimated fair values at the dates of acquisition, including acquired identifiable intangible assets. We base the estimated fair value of identifiable intangible assets on detailed valuations that use historical information and market assumptions based upon the assumptions of a market participant. We allocate any excess purchase price over the fair value of the net tangible and intangible assets acquired to goodwill.
In certain acquisitions, we have earn-out arrangements or contingent consideration to provide potential future payments to the seller for achieving certain agreed-upon financial targets. We record the contingent consideration at its fair value at the acquisition date. Generally, we have entered into arrangements with contingent consideration that require payments in cash. As such, each quarter, we revalue the contingent consideration obligations associated with certain acquisitions to their then fair value and record the change in the fair value as contingent consideration income or expense. These changes are recorded in selling, general and administrative expense. Increases or decreases in the fair value of the contingent consideration obligations can result from changes in assumed discount periods and rates, changes in the assumed timing and amount of revenue and expense estimates, and changes in assumed probability adjustments with respect to regulatory approval. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, future business and economic conditions, as well as changes in any of the assumptions described above, can materially impact the amount of contingent consideration income or expense we record in any given period.
Concentration of Credit Risk and Significant Customers
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents and accounts receivable. In fiscal 2014, no one customer accounted for more than 10% of our revenues. Sales to one unaffiliated Japanese customer, the Japanese Red Cross Society ("JRC"), amounted to $90.1 million, and $99.5 million for 2013, and 2012, respectively. JRC accounted for 10.7%, 9.0%, and 15.3% of our consolidated accounts receivable at fiscal year ended 2014, 2013, and 2012, respectively.
Certain other markets and industries can expose us to concentrations of credit risk. For example, in our bio-pharmaceutical business, our sales are concentrated with several large customers. As a result, our accounts receivable extended to any one of these bio-pharmaceutical customers can be significant at any point in time. Also, a portion of our trade accounts receivable outside the United States include sales to government-owned or supported healthcare systems in several countries, which are subject to payment delays. Payment is dependent upon the financial stability and creditworthiness of those countries’ national economies. We have not incurred significant losses on government receivables. We continually evaluate all government receivables for potential collection risks associated with the availability of government funding and reimbursement practices. If the financial condition of customers or the countries’ healthcare systems deteriorate such that their ability to make payments is uncertain, allowances may be required in future periods.
Recent Accounting Pronouncements
Guidance to be Implemented
In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-08, “Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity” (“ASU 2014-08”). ASU 2014-08 limits the requirement to report discontinued operations to disposals of components of an entity that represent strategic shifts that have (or will have) a major effect on an entity’s operations and financial results. The amendments also require expanded disclosures concerning discontinued operations and disclosures of certain financial results attributable to a disposal of a significant component of an entity that does not qualify for discontinued operations reporting. The amendments in this ASU are effective prospectively for reporting periods beginning on or after December 15, 2014, with early adoption permitted. The impact on our Financial Statements of adopting ASU 2014-08 is being assessed by management.
Standards Implemented
In February 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2013-02,Comprehensive Income: Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income("ASU 2013-02"). ASU 2013-02 requires an entity to provide information about amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present, either on the face of the financial statements or in a single note; any significant amount reclassified out of accumulated other comprehensive income in its entirety in the period, and the income statement line item affected by the reclassification. For other amounts that are not required under U.S. GAAP to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures required under U.S. GAAP that provide additional detail about those amounts. We adopted this guidance during the three months ended June 29, 2013
In July 2013 FASB issued ASU 2013-10 Derivatives and Hedging (Topic 815): Inclusion of the Fed Funds Effective Swap Rate (or Overnight Index Swap Rate) as a Benchmark Interest Rate for Hedge Accounting Purposes. ASU 2013-10 amends ASC 815 to include the Fed Funds Effective Swap Rate (or Overnight Index Swap Rate) as a benchmark interest rate for hedge accounting purposes in addition to UST and LIBOR. The amendments also remove the restriction on using different benchmark rates for similar hedges. The amendments are effective prospectively for qualifying new or redesignated hedging relationships entered into on or after July 17, 2013. We have evaluated the amendments and conclude that these do not impact our financial statements as we have not entered into transactions with Fed Funds Effective Swap Rate.

ACQUISITIONS

ACQUISITIONS	12 Months Ended
	Mar. 29, 2014
Business Combinations [Abstract]	'
ACQUISITIONS	'
	ACQUISITIONS
	Acquisitions were completed in fiscal 2014 and fiscal 2013 as part of our growth initiatives.
	Fiscal Year 2014 Acquisition
	Hemerus Acquisition
	On April 30, 2013, we completed the acquisition of certain assets of Hemerus Medical, LLC ("Hemerus"), a Minnesota based company that develops innovative technologies for the collection of whole blood and processing and storage of blood components. Hemerus has received U.S Food and Drug Administration (FDA) approval for SOLX® whole blood collection system for eight hour storage of whole blood prior to processing. Hemerus previously received Conformité Européenne or CE Mark in the European Union to market SOLX as the world's first 56-day red blood cell storage solution. We paid $24.1 million and will pay an additional $3.0 million upon a further FDA approval of the SOLX solution for 24 hour storage of whole blood prior to processing. We will also pay up to $14.0 million based on future sales of SOLX-based products through fiscal 2025.
	We acquired Hemerus to complement the portfolio of whole blood collection, filtration and processing product lines we recently acquired and to bring greater efficiency and productivity to whole blood collection and processing. Hemerus manufactures and sells manual blood collection systems and filters and has operations in North America. Revenue from the sale of SOLX will be reported within the blood center disposables product line.
	The assets acquired from Hemerus were recorded at fair value at the date of acquisition.
	The final purchase price allocation is as follows:
	Asset class	Amounts recognized as of March 29, 2014
	Acquired technology	$	22,800
	Trade name	1,900
	Customer relationship	600
	Goodwill	6,425
	Total	$	31,725
	The fair value of the acquired assets and liabilities are reflected in the Consolidated Balance Sheets. The acquired assets are amortized over the estimate of their useful lives on a straight-line basis. We recorded $2.3 million in amortization expense relating to the acquired intangible assets for the fiscal year ended March 29, 2014.
	Goodwill represents the excess of the purchase price over the fair value of the net assets. Goodwill of $6.4 million primarily represents future economic benefits expected to arise from the work force and synergies expected to be gained from the integration of SOLX into our whole blood products. Prior to the acquisition, we had not conducted any business with Hemerus. All of the domestic goodwill is deductible for tax purposes.
	Contingent consideration
	As described above, we will pay the sellers of Hemerus assets up to $14.0 million based on future sales of SOLX. We recognized a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We will revalue this liability each reporting period and record necessary changes in the fair value in our consolidated statements of income. As of March 29, 2014, the maximum amount of future contingent consideration (undiscounted) that we could be required to pay related to future SOLX sales is $14.0 million. Additionally, we will pay $3.0 million upon FDA approval of the SOLX solution for 24 hour storage of whole blood prior to processing. The carrying value of this liability is $7.6 million as of March 29, 2014.
	Contingent consideration liabilities are measured at fair value using projected revenues, discount rates, probabilities of payment and projected payment dates. This Level 3 fair value measurement was performed using a probability-weighted discounted cash flow over a ten year period.
	Increases or decreases in the fair value of our contingent consideration liability can result from changes in discount periods and rates, as well as changes in the timing and amount of revenue estimates or likelihood of earning revenue. Projected revenues are based on our most recent internal operational budgets.
	Fiscal Year 2013 Acquisition
	Whole Blood Acquisition
	On August 1, 2012, we completed the acquisition from Pall Corporation (“Pall”) of substantially all of the assets relating to its blood collection, filtration, processing, storage, and re-infusion product lines, and all of the outstanding equity interest in Pall Mexico Manufacturing, S. de R.L. de C.V., a subsidiary of Pall based in Mexico pursuant to an Asset Purchase Agreement (the “Purchase Agreement”) with Pall. We refer to the acquired business as the “whole blood business.”
	At the closing of the transaction, we paid a total consideration of $535.2 million in cash and $0.5 million in shares following resolution of post-closing adjustments for working capital and historical earnings levels. We anticipate paying an additional $15.0 million upon replication and delivery of certain manufacturing assets of Pall's filter media business to Haemonetics by 2016. Until that time, Pall will manufacture and sell filter media to Haemonetics under a supply agreement.
	We entered into a credit agreement on August 1, 2012 in connection with the transaction which includes a $475.0 million term loan to fund the majority of the cash paid to Pall. See Note 8 for a detailed description of the key terms and provisions of the credit agreement.
	We acquired the whole blood business to provide access to the manual collection and whole blood markets and provide scope for introduction of automated solutions in those markets. The whole blood business manufactures and sells manual blood collection systems and filters and has operations in North America, Europe and Asia Pacific countries. Revenue from the sale of whole blood disposables has been reported within the blood center disposables product line since the date of acquisition.
	The assets and liabilities acquired from Pall were recorded at fair value at the date of acquisition. We completed the allocation of the purchase price to the estimated fair value of the acquired assets and liabilities in June 2013 and is summarized below:
	Asset class	Amounts Recognized as of March 30, 2013
	(In thousands)
	Inventories	$	49,917
	Property, plant and equipment	85,984
	Intangible assets	188,500
	Other assets/liabilities, net	(6,166		)
	Goodwill	216,940
	Fair value of net assets acquired	$	535,175
	The fair value of the acquired assets and liabilities are reflected in the Consolidated Balance Sheets. The $188.5 million of acquired intangible assets was allocated to acquired technology and customer relationships at fair values of $61.0 million and $127.5 million, respectively. The acquired assets are amortized over the estimate of their useful lives of 12 years on a straight-line basis. We adopted the straight-line amortization of 12 years as it best reflects the pattern of benefits. We recorded $15.7 million and $10.5 million in amortization expense relating to the acquired intangible assets for the fiscal years ended March 29, 2014 and March 30, 2013, respectively.
	Goodwill represents the excess of the purchase price over the fair value of the net assets. Goodwill of $216.9 million represents future economic benefits expected to arise from work force at the various plants and locations and significant technological know-how in filter manufacturing. All of the domestic goodwill is deductible for tax purposes.
	Revenue for the acquired whole blood business included in our operating results was $190.7 million in fiscal 2014 and $138.4 million in fiscal 2013.
	The following represents the pro forma consolidated statements of income as if the acquisition had been included in our consolidated results as beginning April 1, 2012:
	(In thousands, except per share amounts)		March 30,
			2013
	Net Sales		$	963,923
	Net Income		$	56,540
	Basic EPS		$	1.1
	Diluted EPS		$	1.08

PRODUCT_WARRANTIES

PRODUCT WARRANTIES	12 Months Ended
	Mar. 29, 2014
Product Warranties Disclosures [Abstract]	'
PRODUCT WARRANTIES	'
	PRODUCT WARRANTIES
	We generally provide a warranty on parts and labor for one year after the sale and installation of each device. We also warrant our disposables products through their use or expiration. We estimate our potential warranty expense based on our historical warranty experience, and we periodically assess the adequacy of our warranty accrual and make adjustments as necessary.
	(In thousands)	March 29,			March 30,
		2014			2013
	Warranty accrual as of the beginning of the year	$	673		$	796
	Warranty provision	1,340			1,180
	Warranty spending	(1,423		)	(1,303		)
	Warranty accrual as of the end of the year	$	590		$	673

INVENTORIES

INVENTORIES	12 Months Ended
	Mar. 29, 2014
Inventory Disclosure [Abstract]	'
INVENTORIES	'
	INVENTORIES
	Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined with the first-in, first-out method.
	(In thousands)	March 29,		March 30,
		2014		2013
	Raw materials	$	72,508	$	70,716
	Work-in-process	7,383		7,829
	Finished goods	117,770		105,239
	Total Inventory	$	197,661	$	183,784

GOODWILL_AND_INTANGIBLE_ASSETS

GOODWILL AND INTANGIBLE ASSETS	12 Months Ended
	Mar. 29, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
GOODWILL AND OTHER INTANGIBLE ASSETS	'
	GOODWILL AND INTANGIBLE ASSETS
	Goodwill
	The changes in the carrying amount of goodwill for fiscal 2014 and 2013 are as follows:
	(In thousands)
	Carrying amount as of March 31, 2012	$	115,058
	Whole blood business acquisition	216,940
	Effects of change in foreign currency exchange rates	(1,524		)
	Carrying amount as of March 30, 2013	$	330,474
	Hemerus acquisition	6,425
	Effects of change in foreign currency exchange rates	(131		)
	Carrying amount as of March 29, 2014	$	336,768
	Intangible Assets
	Intangible assets include the value assigned to license rights and other developed technology, patents, customer contracts and relationships and a trade name. The estimated useful lives for all of these intangible assets are 2 to 19 years. The gross carrying amount of intangible assets and the related accumulated amortization as of March 29, 2014 and March 30, 2013 is as follows:
	(In thousands)	Gross Carrying			Accumulated		Net		Weighted Average
		Amount			Amortization				Useful Life
									(In years)
	As of March 29, 2014
	Patents	$	9,543		$	7,039	$	2,504	9
	Capitalized software	31,750			2,414		29,336		4
	Other developed technology	123,525			36,632		86,893		12
	Customer contracts and related relationships	200,694			52,741		147,953		12
	Trade names	7,341			2,868		4,473		11
	Total intangibles	$	372,853		$	101,694	$	271,159	11
	(In thousands)	Gross Carrying			Accumulated		Net		Weighted Average
		Amount			Amortization				Useful Life
									(In years)
	As of March 30, 2013
	Patents	$	8,706		$	6,397	$	2,309	10
	Capitalized software	25,741			1,364		24,377		6
	Other developed technology	100,586			25,812		74,774		12
	Customer contracts and related relationships	196,365			36,552		159,813		12
	Trade names	5,383			2,268		3,115		10
	Total intangibles	$	336,781		$	72,393	$	264,388	11
	The changes to the net carrying value of our intangible assets from March 30, 2013 to March 29, 2014 reflect the acquisition of Hemerus and other less significant intangible assets, amortization expense and the effect of exchange rate changes in the translation of our intangible assets held by our international subsidiaries.
	Aggregate amortization expense for amortized intangible assets for fiscal year 2014, 2013, and 2012 was $29.2 million, $22.1 million, and $11.4 million, respectively. Future annual amortization expense on intangible assets is as follows:
	Fiscal Year		Amount   (in thousands)
	2015		$	29,162
	2016		$	28,695
	2017		$	28,611
	2018		$	27,766
	2019		$	25,957

DERIVATIVES_AND_FAIR_VALUE_MEA

DERIVATIVES AND FAIR VALUE MEASUREMENTS	12 Months Ended
	Mar. 29, 2014
Derivatives and Fair Value Measurements [Abstract]	'
DERIVATIVES AND FAIR VALUE MEASUREMENTS	'
	DERIVATIVES AND FAIR VALUE MEASUREMENTS
	We manufacture, market and sell our products globally. For the fiscal year ended March 29, 2014, approximately 46.6% of our sales were generated outside the U.S. in local currencies. We also incur certain manufacturing, marketing and selling costs in international markets in local currency.
	Accordingly, our earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates relative to the U.S. Dollar, our reporting currency. We have a program in place that is designed to mitigate our exposure to changes in foreign currency exchange rates. That program includes the use of derivative financial instruments to minimize for a period of time, the unforeseen impact on our financial results from changes in foreign exchange rates. We utilize foreign currency forward contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily the Japanese Yen and the Euro, and to a lesser extent the Swiss Franc, British Pound Sterling, Canadian Dollar and the Mexican Peso. This does not eliminate the volatility of foreign exchange rates, but because we generally enter into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation.
	Designated Foreign Currency Hedge Contracts
	All of our designated foreign currency hedge contracts as of March 29, 2014 and March 30, 2013 were cash flow hedges under ASC Topic 815, Derivatives and Hedging. We record the effective portion of any change in the fair value of designated foreign currency hedge contracts in Other Comprehensive Income in the Statement of Stockholders’ Equity until the related third-party transaction occurs. Once the related third-party transaction occurs, we reclassify the effective portion of any related gain or loss on the designated foreign currency hedge contracts to earnings. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, we would reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. We had designated foreign currency hedge contracts outstanding in the contract amount of $157.9 million as of March 29, 2014 and $133.3 million as of March 30, 2013.
	During fiscal 2014, we recognized net gains of $8.6 million in earnings on our cash flow hedges, compared to recognized net gains of $2.7 million and losses of $3.2 million during fiscal 2013 and 2012, respectively. For the fiscal year ended March 29, 2014, $3.7 million of gains, net of tax, were recorded in Accumulated Other Comprehensive Income to recognize the effective portion of the fair value of any designated foreign currency hedge contracts that are, or previously were, designated as foreign currency cash flow hedges, as compared to net gains of $5.1 million, net of tax, for the fiscal year ended March 30, 2013 and net gains of $3.1 million, net of tax, for the fiscal year ended March 31, 2012. At March 29, 2014, gains of $3.7 million, net of tax, may be reclassified to earnings within the next twelve months. All currency cash flow hedges outstanding as of March 29, 2014 mature within twelve months.
	Non-designated Foreign Currency Contracts
	We manage our exposure to changes in foreign currency on a consolidated basis to take advantage of offsetting transactions and balances. We use foreign currency forward contracts as a part of our strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These foreign currency forward contracts are entered into for periods consistent with currency transaction exposures, generally one month. They are not designated as cash flow or fair value hedges under ASC Topic 815. These forward contracts are marked-to-market with changes in fair value recorded to earnings. We had non-designated foreign currency hedge contracts under ASC Topic 815 outstanding in the contract amount of $72.9 million as of March 29, 2014 and $65.6 million as of March 30, 2013.
	Interest Rate Swaps
	On August 1, 2012, we entered into a Credit Agreement which provided for a $475.0 million term loan (“Term Loan”). Under the terms of this Credit Agreement, the Company may borrow at a spread to an index, including the LIBOR index of 1-month, 3-months, 6-months, etc. From the date of the Credit Agreement, the Company has chosen to borrow against the 1-month USD-LIBOR-BBA rounded up, if necessary, to the nearest 1/16th of 1% (“Adjusted LIBOR”). The terms of the Credit Agreement also allow us to borrow in multiple tranches. As of March 29th 2014, we have four tranches outstanding.
	Accordingly, our earnings and cash flows are exposed to interest rate risk from changes in Adjusted LIBOR. Part of our interest rate risk management strategy includes the use of interest rate swaps to mitigate our exposure to changes in variable interest rates. Our objective in using interest rate swaps is to add stability to interest expense and to manage and reduce the risk inherent in interest rate fluctuations.
	On December 21, 2012, we entered into two interest rate swap agreements ("the swaps"), whereby we receive Adjusted LIBOR and pay an average fixed rate of 0.68% on a total notional value of $250.0 million of debt. The interest rate swaps mature on August 1, 2017. The Company designated the interest rate swaps as a cash flow hedge of variable interest rate risk associated with $250.0 million of indebtedness. For the fiscal years ended March 29, 2014 and March 30, 2013, $1.3 million of gains and $0.8 million of losses, net of tax, were recorded in Accumulated Other Comprehensive Income to recognize the effective portion of the fair value of interest rate swaps that qualify as cash flow hedges, respectively.
	Fair Value of Derivative Instruments
	The following table presents the effect of our derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC Topic 815 in our consolidated statements of income for the fiscal year ended March 29, 2014.
	Derivative Instruments		Amount of				Amount of				Location in	Amount of Gain/(Loss)			Location in
			Gain/(Loss) Recognized				Gain/(Loss)				Statement of Operations	Excluded from			Statement of
			in OCI				Reclassified					Effectiveness			Operations
			(Effective Portion)				from OCI into					Testing (*)
							Earnings
							(Effective Portion)
	(In thousands)
	Designated foreign currency hedge contracts, net of tax		$	3,712			$	8,570			Net revenues, COGS, and SG&A	$	(104	)	Other income (expense), net
	Non-designated foreign currency hedge contracts		—				—					$	(1,359	)	Other income (expense)
	Designated interest rate swaps, net of tax		$	1,289			$	—			Interest income (expense), net	$	—
	(*)		We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.
	We did not have fair value hedges or net investment hedges outstanding as of March 29, 2014 or March 30, 2013. Amounts recognized as deferred tax benefits in fiscal 2014 for designated foreign currency and interest rate swap hedges were $0.1 million and $0.5 million, respectively.
	ASC Topic 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by ASC Topic 820, Fair Value Measurements and Disclosures, by considering the estimated amount we would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, current interest rate curves, interest rate volatilities, the creditworthiness of the counterparty for assets, and our creditworthiness for liabilities. In certain instances, we may utilize financial models to measure fair value. Generally, we use inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of March 29, 2014, we have classified our derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by ASC Topic 815, as discussed below, because these observable inputs are available for substantially the full term of our derivative instruments.
	The following tables present the fair value of our derivative instruments as they appear in our consolidated balance sheets as of March 29, 2014 and March 30, 2013 by type of contract and whether it is a qualifying hedge under ASC Topic 815.
	(In thousands)	Location in		Balance as of March 29, 2014				Balance as of March 30, 2013
		Balance Sheet
	Derivative Assets:
	Designated foreign currency hedge contracts	Other current assets		$	2,574			$	7,030
	Designated interest rate swaps	Other current assets		1,250				—
				$	3,824			$	7,030
	Derivative Liabilities:
	Designated foreign currency hedge contracts	Other current liabilities		$	1,255			$	954
	Designated interest rate swaps	Other current liabilities		—				671
				$	1,255			$	1,625
	For the fiscal years ended March 29, 2014 and March 30, 2013, non-designated foreign currency hedge contracts were not significant and are not disclosed separately in the above table.
	Other Fair Value Measurements
	ASC Topic 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and expands disclosures about fair value measurements. ASC Topic 820 does not require any new fair value measurements; rather, it applies to other accounting pronouncements that require or permit fair value measurements. In accordance with ASC Topic 820, for the fiscal years ended March 29, 2014 and March 30, 2013, we applied the requirements under ASC Topic 820 to our non-financial assets and non-financial liabilities. As we did not have an impairment of any non-financial assets or non-financial liabilities, there was no disclosure required relating to our non-financial assets or non-financial liabilities.
	On a recurring basis, we measure certain financial assets and financial liabilities at fair value, including our money market funds, foreign currency hedge contracts, and contingent consideration. ASC Topic 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. We base fair value upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value.
	ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
	•	Level 1 — Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
	•	Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
	•	Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
	Our money market funds carried at fair value are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.
	Fair Value Measured on a Recurring Basis
	Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of March 29, 2014 and March 30, 2013:
	As of March 29, 2014	Quoted Market Prices for Identical Assets				Significant Other Observable Inputs				Significant Unobservable Inputs			Total
		(Level 1)				(Level 2)				(Level 3)
		(In thousands)				(In thousands)				(In thousands)			(In thousands)
	Assets
	Money market funds	$	135,378			$	—			$	—		$	135,378
	Foreign currency hedge contracts	—				2,574				—			2,574
	Interest rate swap	—				1,250				—			1,250
		$	135,378			$	3,824			$	—		$	139,202
	Liabilities
	Foreign currency hedge contracts	$	—			$	1,255			$	—		$	1,255
	Contingent consideration	—				—				7,645			7,645
		$	—			$	1,255			$	7,645		$	8,900
	As of March 30, 2013	Quoted Market Prices for Identical Assets				Significant Other Observable Inputs				Significant Unobservable Inputs			Total
		(Level 1)				(Level 2)				(Level 3)
	(In thousands)				(In thousands)				(In thousands)			(In thousands)
Assets
Money market funds	$	141,120			$	—			$	—		$	141,120
Forward currency hedge contracts	—				7,030				—			7,030
	$	141,120			$	7,030			$	—		$	148,150
Liabilities
Forward currency hedge contracts	$	—			$	954			$	—		$	954
Interest rate swap	—				671				—			671
	$	—			$	1,625			$	—		$	1,625
For the fiscal years ended March 29, 2014 and March 30, 2013, non-designated foreign currency hedge contracts were not significant and are not disclosed separately in the above tables.
Contingent consideration
Hemerus
A description of the methods used to determine the fair value of the Level 3 liabilities is included within Note 3, Acquisitions. The table below provides a reconciliation of the beginning and ending Level 3 liabilities for the year ended March 29, 2014.
(In thousands)		Fair value measurements using significant unobservable inputs (Level 3)
Contingent consideration as of acquisition date		$	7,600
Fair value adjustment		45
Ending balance		$	7,645
Other Fair Value Disclosures
The Term Loan is carried at amortized cost and accounts receivable and accounts payable are also reported at their cost which approximates fair value.

NOTES_PAYABLE_AND_LONGTERM_DEB

NOTES PAYABLE AND LONG-TERM DEBT	12 Months Ended
	Mar. 29, 2014
Notes Payable and Long-Term Debt [Abstract]	'
NOTES PAYABLE AND LONG-TERM DEBT	'
	NOTES PAYABLE AND LONG-TERM DEBT
	Notes payable and long-term debt consisted of the following:
	(In thousands)	March 29, 2014			March 30, 2013
	Term loan, net of financing fees	$	435,338		471,016
	Real estate mortgage	1,906			2,877
	Bank loans and other borrowings	443			6,201
	Less current portion	(45,630		)	(23,150		)
	Long-term debt	$	392,057		$	456,944
	On August 1, 2012 in connection with the acquisition of the whole blood business, we entered into a credit agreement ("Credit Agreement") with the banks listed below (together, “Lenders”) which provided for a $475.0 million term loan and a $50.0 million revolving loan (the “Revolving Credit Facility,” and together with the Term Loan, (the “Credit Facilities”). The Credit Facilities have a term of five years and mature on August 1, 2017.
	Under the terms of this Credit Agreement, the Company may borrow at a spread to an index, including the LIBOR index of 1-month, 3-months, 6-months, etc. From the date of the Credit Agreement, the Company has chosen to borrow against the 1-month USD-LIBOR-BBA rounded up, if necessary, to the nearest 1/16th of 1%. The terms of the Credit Agreement also allow the Company to borrow in multiple tranches. The Company currently borrows in four tranches.
	At closing, we borrowed the Term Loan and used the proceeds to pay Pall for the acquisition of the assets described in Note 3. The $475.0 million Term Loan bears interest at variable rates determined by Adjusted LIBOR plus a range of 1.125% to 1.500% depending on the achievement of certain leverage ratios. The Revolving Credit Facility bears interest at variable rates similar to the Term Loan. The current margin of the Term Loan is 1.375% over Adjusted LIBOR and our effective interest rate inclusive of prepaid financing costs and other fees was 1.89% as of March 29, 2014.
	Revolving loans may be borrowed, repaid and re-borrowed to fund our working capital needs and for other general corporate purposes. No amounts were outstanding under the Revolving Credit Facility at March 29, 2014. The Term Loan or portions thereof may be prepaid at any time, or from time to time without penalty. Once repaid, such amount may not be re-borrowed.
	Under the Credit Facilities, we are required to maintain a Consolidated Total Leverage Ratio not to exceed 3.0:1.0 and a Consolidated Interest Coverage Ratio not to be less than 4.0:1.0 during periods when the Credit Facilities are outstanding. In addition, we are required to satisfy these covenants, on a pro forma basis, in connection with any new borrowings (including any letter of credit issuances) on the Revolving Credit Facility as of the time of such borrowings. The Consolidated Interest Coverage Ratio is calculated as the Consolidated EBITDA divided by Consolidated Interest Expense while the Consolidated Total Leverage Ratio is calculated as Consolidated Total Debt divided by Consolidated EBITDA. Consolidated EBITDA includes EBITDA adjusted by non-recurring and unusual transactions specifically as defined in the Credit Facilities.
	The Credit Facilities also contain usual and customary non-financial affirmative and negative covenants which include certain restrictions with respect to subsequent indebtedness, liens, loans and investments (including acquisitions), financial reporting obligations, mergers, consolidations, dissolutions or liquidation, asset sales, affiliate transactions, change of our business, capital expenditures, share repurchase and other restricted payments. These covenants are subject to important exceptions and qualifications set forth in the Credit Agreement.
	Any failure to comply with the financial and operating covenants of the Credit Facilities would prevent us from being able to borrow additional funds and would constitute a default, which could result in, among other things, the amounts outstanding including all accrued interest and unpaid fees, becoming immediately due and payable. In addition, the Credit Facilities include customary events of default, in certain cases subject to customary cure periods. As of March 29, 2014, we were in compliance with the covenants.
	Commitment fee
	Pursuant to the Credit Agreement we are required to pay the Lenders, on the last day of each calendar quarter, a commitment fee on the unused portion of the Revolving Credit Facility. The commitment fee is subject to a pricing grid based on our Consolidated Total Leverage Ratio. The commitment fee ranges from 0.175% to 0.300%. The current commitment fee on the undrawn portion of the Revolving Credit Facility is 0.250%.
	We may elect to increase the size of the Revolving Credit Facility from $50.0 million to $100.0 million. Alternatively, we may elect to enter into additional term loans up to a $100.0 million combined limit with the Revolving Credit Facility. These elections are subject to the approval of the Administrative Agent and the identification of additional Lenders or current Lenders willing to increase their loan amounts per the terms and conditions contained in the Credit Agreement.
	Prepayments
	We prepaid $20.0 million of the loan principal in September 2013 resulting in an adjustment of our repayment schedule and outstanding loan balance.
	Debt issuance costs and interest
	Expenses associated with the issuance of the Term Loan were capitalized and are amortized as additional interest expense over the five years using the effective interest method. In connection with the Term Loan, we recorded deferred financing costs of $5.5 million, of which $2.6 million remains as a debt discount. The debt discount is netted against the $437.9 million Term Loan, resulting in a net note payable of $435.3 million. The debt discount will also be amortized as additional interest expense over the life of the term loan.
	Interest expense was $8.9 million and $5.9 million for the fiscal years ended March 29, 2014 and March 30, 2013, respectively. Accrued interest associated with our outstanding debt is included as a component of accrued expenses and other current liabilities in the accompanying consolidated balance sheets. As of March 29, 2014, accrued interest totaled $0.5 million.
	Other Credit Facilities
	The other debt as of March 29, 2014 includes the real estate mortgage loan of $1.9 million and short term bank borrowings of $0.4 million under operating lines of credit.
	In December 2000, we entered into a $10.0 million real estate mortgage agreement (the “Mortgage Agreement”) with an investment firm. The Mortgage Agreement requires principal and interest payments of $0.1 million per month for a period of 180 months, commencing February 1, 2001. The Mortgage Agreement provides for interest to accrue on the unpaid principal balance at a rate of 8.41% per annum. Borrowings under the Mortgage Agreement, with a carrying value of approximately $1.9 million and $2.9 million as of March 29, 2014 and March 30, 2013, respectively, are secured by the land, building and building improvements at our headquarters and manufacturing facility in the U.S.. There are no financial covenants in the terms and conditions of this agreement.
	There are no short term borrowings in Japan in fiscal 2014 and $5.6 million in fiscal 2013 related to fluctuations in their working capital.
	Maturity Profile
	The maturity profile of all gross long-term debt, exclusive of debt discounts, as of March 29, 2014 is presented below:
	Fiscal year (in thousands)		Mortgage Obligation			Term Loan		Bank loans and other borrowings		Total
	2015		$	1,055		$	45,500	$	193	$	46,748
	2016		851			68,250		160		69,261
	2017		—			182,000		71		182,071
	2018		—			142,188		19		142,207
			$	1,906		$	437,938	$	443	$	440,287

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Mar. 29, 2014
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	INCOME TAXES
	Domestic and foreign income before provision for income tax is as follows:
	(In thousands)	March 29,			March 30,				March 31,
		2014			2013				2012
	Domestic	$	(6,859	)	$	17,360			$	40,666
	Foreign	43,260			32,537				48,832
	Total	$	36,401		$	49,897			$	89,498
	The income tax provision contains the following components:
	(In thousands)	March 29,			March 30,				March 31,
		2014			2013				2012
	Current
	Federal	$	(4,896	)	$	3,795			$	8,505
	State	873			1,324				2,275
	Foreign	5,478			5,389				5,954
	Total current	$	1,455		$	10,508			$	16,734
	Deferred
	Federal	(1,785		)	1,644				7,522
	State	207			(229		)		(597		)
	Foreign	1,376			(826		)		(1,047		)
	Total deferred	$	(202	)	$	589			$	5,878
	Total	$	1,253		$	11,097			$	22,612
	Included in the federal income tax provisions for fiscal 2014, 2013 and 2012 are approximately $0.4 million, $1.6 million and $2.2 million, respectively, provided on foreign source income of approximately $1.3 million, $4.5 million and $6.2 million for fiscal years 2014, 2013 and 2012, respectively, for taxes which are payable in the United States.
	Our subsidiary in Puerto Rico has been granted a fifteen year tax grant which expires in 2027. Our qualification for the tax grant is dependent on the continuation of our manufacturing activities in Puerto Rico. We benefit from a reduced tax rate on our earnings in Puerto Rico under the tax grant.
	Tax affected, significant temporary differences comprising the net deferred tax liability are as follows:
	(In thousands)	March 29,			March 30,
		2014			2013
	Depreciation	$	(23,658	)	$	(25,186	)
	Amortization	(18,618		)	(14,776		)
	Inventory	7,371			7,884
	Hedging	321			(162		)
	Accruals, reserves and other	10,368			7,208
	Net operating loss carry-forward	1,507			1,877
	Stock based compensation	8,757			7,834
	Tax credit carry-forward, net	2,660			2,243
	Gross deferred taxes	$	(11,292	)	$	(13,078	)
	Less valuation allowance	(3,083		)	(1,009		)
	Net deferred tax liability	$	(14,375	)	$	(14,087	)
	The valuation allowance increased by $2.1 million during 2014, primarily due to current year operating losses generated in foreign jurisdictions that we have determined are not more-likely-than-not realizable. As of March 29, 2014, we maintain a valuation allowance against certain U.S. tax attributes subject to limitations as a result of ownership changes and a full valuation allowance against the net deferred tax assets of certain foreign subsidiaries.
	At March 29, 2014, we have U.S. federal net operating loss carry-forwards of approximately $3.5 million, U.S. state net operating loss carry-forwards of $14.7 million, federal tax credit carry-forwards of $3.3 million and state tax credit carry-forwards of $1.6 million that are available to reduce future taxable income. The federal net operating losses are subject to an annual limitation due to the ownership change limitations set forth under Internal Revenue Code Sections 382. Certain of the aforementioned amounts have not been recognized because they relate to excess stock based compensation. At March 29, 2014, none of the federal net operating loss carry-forwards, $6.8 million of the state net operating loss carry-forwards, $1.7 million of the federal tax credit carry-forwards and none of the state tax credit carry-forwards relate to excess stock based compensation tax deductions for which the benefit will be recorded to additional paid-in capital when recognized. The state net operating losses begin to expire in 2019. The federal and state tax credits begin to expire in 2023 and 2025, respectively.
	As of March 29, 2014, we have foreign net operating losses of approximately $0.4 million that are available to reduce future income. Substantially all of our foreign net operating loss carry-forwards have unlimited carryover periods.
	Income taxes have not been provided on the undistributed earnings of foreign subsidiaries of approximately $264 million, because such earnings are considered to be indefinitely reinvested in the business. The accumulated earnings in the foreign subsidiaries are primarily utilized to fund working capital requirements as our subsidiaries continue to expand their operations, to service existing debt obligations and to fund future foreign acquisitions. We do not believe it is practicable to estimate the amount of income taxes payable on the earnings that are indefinitely reinvested in foreign operations.
	The income tax provision from operations differs from tax provision computed at the 35% U.S. federal statutory income tax rate due to the following:
	(In thousands)	March 29,						March 30,						March 31,
		2014						2013						2012
	Tax at federal statutory rate	$	12,739		35	%		$	17,464			35	%	$	31,324		35	%
	Domestic manufacturing deduction	—			—	%		(504		)		(1.0	)%	(700		)	(0.8	)%
	Difference between U.S. and foreign tax	(10,846		)	(29.8	)%		(5,584		)		(11.2	)%	(8,539		)	(9.5	)%
	State income taxes net of federal benefit	(252		)	(0.7	)%		718				1.4	%	1,136			1.3	%
	Change in uncertain tax positions	(1,678		)	(4.6	)%		(580		)		(1.2	)%	144			0.2	%
	Intercompany loan deduction	(2,185		)	(6.0	)%		—				—	%	—			—	%
	Non-deductible expenses	1,035			2.8	%		1,178				2.4	%	917			1	%
	Research credits	(688		)	(1.9	)%		(799		)		(1.6	)%	(752		)	(0.9	)%
	Valuation allowance	2,400			6.6	%		—				—	%	—			—	%
	Other, net	728			2	%		(796		)		(1.6	)%	(918		)	(1.0	)%
	Income tax provision	$	1,253		3.4	%		$	11,097			22.2	%	$	22,612		25.3	%
	Unrecognized Tax Benefits
	Unrecognized tax benefits represent uncertain tax positions for which reserves have been established. As of March 29, 2014, we had $5.6 million of unrecognized tax benefits, all of which would impact the effective tax rate, if recognized. As of March 30, 2013, we had $6.9 million of unrecognized tax benefits, of which $6.7 million would impact the effective tax rate, if recognized. At March 31, 2012, we had $6.9 million of unrecognized tax benefits, of which $6.6 million would impact the effective tax rate, if recognized.
	During the fiscal year ended March 29, 2014 our unrecognized tax benefits were increased by $1.3 million due primarily to the release of certain previously established reserves in connection with the closure of tax statutes of limitations.
	The following table summarizes the activity related to our gross unrecognized tax benefits for the fiscal years ended March 29, 2014, March 30, 2013 and March 31, 2012:
	(In thousands)	March 29,			March 30,				March 31,
		2014			2013				2012
	Beginning Balance	$	6,930		$	6,885			$	4,669
	Additions based upon positions related to the current year	—			1,192				1,124
Additions for tax positions of prior years	990			18				1,216
Reductions of tax positions	—			—				(124		)
Settlements with taxing authorities	—			(80		)		—
Closure of statute of limitations	(2,316		)	(1,085		)		—
Ending Balance	$	5,604		$	6,930			$	6,885
As of March 29, 2014 we anticipate that the liability for unrecognized tax benefits for uncertain tax positions could change by up to $1.7 million in the next twelve months, as a result of closure of various statutes of limitations.
Our historic practice has been and continues to be to recognize interest and penalties related to Federal, state and foreign income tax matters in income tax expense. Approximately $0.8 million and $0.8 million of gross interest and penalties were accrued at March 29, 2014 and March 30, 2013, respectively and is not included in the amounts above. There was no benefit for the period ended March 29, 2014, a benefit of $0.1 million for the period ended March 30, 2013 and a provision of $0.3 million for the period ended and March 31, 2012, of accrued interest in our statements of operations.
We conduct business globally and, as a result, file consolidated and separate Federal, state and foreign income tax returns in multiple jurisdictions. In the normal course of business, we are subject to examination by taxing authorities throughout the world. With a few exceptions overseas, we are no longer subject to U.S. federal, state and local, or foreign income tax examinations for years before 2010.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Mar. 29, 2014
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	COMMITMENTS AND CONTINGENCIES
	We lease facilities and certain equipment under operating leases expiring at various dates through fiscal 2020. Facility leases require us to pay certain insurance expenses, maintenance costs and real estate taxes.
	Approximate future basic rental commitments under operating leases as of March 29, 2014 are as follows (in thousands):
	Fiscal Year Ending
	(In thousands)
	2015	$	6,991
	2016	5,141
	2017	3,357
	2018	2,627
	2019 and thereafter	4,812
		$	22,928
	Rent expense in fiscal 2014, 2013, and 2012 was $7.7 million, $7.0 million and $6.1 million, respectively. Some of the Company's operating leases include renewal provisions, escalation clauses and options to purchase the facilities that we lease.
	We are presently engaged in various legal actions, and although our ultimate liability cannot be determined at the present time, we believe that any such liability will not materially affect our consolidated financial position or our results of operations.
	Fenwal (Fresenius) Patent Infringement
	For the past seven years, we have pursued patent infringement lawsuits against Fenwal Inc. seeking an injunction and damages from their infringement of a Haemonetics patent, through the sale of the ALYX brand automated red cell collection system, a competitor of our automated red cell collection systems.
	Most recently, we have pursued a patent infringement action in Germany against Fenwal, and its European and German subsidiary. On September 20, 2010, we filed a patent infringement action in Germany. In response, Fenwal filed an action to invalidate the Haemonetics patent which is the subject of this infringement action on December 1, 2010. In January 2014, we received a final ruling which narrowed the scope of our patent. This ruling will prevent us from further claims of infringement and effectively ends our claims against Fenwal.
	Italian Employment Litigation
	We have recently received notices from employees of the facility in Ascoli-Piceno, Italy where we are discontinuing operations of claimed violations of employment related contracts. Seventy-two employees served actions in February 2014 claiming their working conditions should have been established by the national collective bargaining agreement for the chemical and pharmaceutical industries rather than the one actually used. They claim applying the alternative bargaining agreement would have resulted in slightly higher minimum salaries according to their job functions. Also in February, sixty-eight employees served actions claiming that certain solidarity agreements are void. Solidarity agreements are arrangements between the company, employees and the government to continue full pay and benefits for employees who would otherwise be terminated in times of low demand. As of March 29, 2014, the total amount of damages claimed by the plaintiffs in these matters is approximately $3.5 million, however it is not possible at this point in the proceedings to accurately evaluate the likelihood or amount of any potential losses. As such, no amounts are accrued. We may receive other, similar claims, in the future.

CAPITAL_STOCK

CAPITAL STOCK	12 Months Ended
	Mar. 29, 2014
Capital Stock [Abstract]	'
CAPITAL STOCK	'
	CAPITAL STOCK
	Stock Plans
	The Company has an incentive compensation plan, (the “2005 Incentive Compensation Plan”). The 2005 Incentive Compensation Plan permits the award of non-qualified stock options, incentive stock options, stock appreciation rights, restricted stock, deferred stock/restricted stock units, other stock units and performance shares to the Company’s key employees, officers and directors. The 2005 Incentive Compensation Plan is administered by the Compensation Committee of the Board of Directors (the “Committee”) consisting of three independent members of our Board of Directors.
	The maximum number of shares available for award under the 2005 Incentive Compensation Plan is 15,024,920. The maximum number of shares that may be issued pursuant to incentive stock options may not exceed 500,000. Any shares that are subject to the award of stock options shall be counted against this limit as one (1) share for every one (1) share issued. Any shares that are subject to awards other than stock options shall be counted against this limit as 3.26 shares for every one (1) share granted.
	Each award has different terms under the 2005 Incentive Compensation Plan. Options, Restricted Stock Awards and Restricted Stock Units become exercisable, or in the case of restricted stock, the resale restrictions are released in a manner determined by the Committee, generally over a four year period for employees and one year from grant for non-employee directors, and all options expire not more than 7 years from the date of the grant. The exercise price for options granted under the 2005 Incentive Compensation Plan is determined by the Committee, but in no event shall such exercise price be less than the fair market value of the common stock at the time of the grant. Holders of market stock units are eligible to receive a share of Haemonetics’ stock for each market stock unit based on the performance of the stock through March 31, 2017.  If our stock is below a minimum threshold price of $50 per share during the relevant measurement period, the holders receive no market share units. If the stock achieves certain price levels, the holders are eligible to receive up to three times the “target” amount of market share units. As a result, we may issue up to 848,808 shares at a stock price of $85 per share or higher in connection with these grants.
	At March 29, 2014, there were outstanding options to purchase 3,778,622 shares, 316,737 shares of restricted stock outstanding and 282,936 market stock units outstanding under this plan and 1,794,981 shares available for future grant.
	The Company had a long-term incentive stock option plan and a non-qualified stock option plan, (the “2000 Long-term Incentive Plan”) which permitted the issuance of a maximum of 7,000,000 shares of our common stock pursuant to incentive and non-qualified stock options granted to key employees, officers and directors. The plan was terminated in connection with the adoption of the 2005 Incentive Compensation Plan. At March 29, 2014, there were 55,750 options outstanding under this plan and no further options will be granted under this plan.
	The Company has an Employee Stock Purchase Plan (the “Purchase Plan”) under which a maximum of 1,400,000 shares (subject to adjustment for stock splits and similar changes) of common stock may be purchased by eligible employees. Substantially all of our full-time employees are eligible to participate in the Purchase Plan.
	The Purchase Plan provides for two “purchase periods” within each of our fiscal years, the first commencing on November 1 of each year and continuing through April 30 of the next calendar year, and the second commencing on May 1 of each year and continuing through October 31 of such year. Shares are purchased through an accumulation of payroll deductions (of not less than 2% nor more than 15% of compensation, as defined) for the number of whole shares determined by dividing the balance in the employee’s account on the last day of the purchase period by the purchase price per share for the stock determined under the Purchase Plan. The purchase price for shares is the lower of 85% of the fair market value of the common stock at the beginning of the purchase period, or 85% of such value at the end of the purchase period.
	Stock-based compensation expense of $13.1 million, $11.0 million, and $9.3 million was recognized under ASC Topic 718, Compensation — Stock Compensation, for the fiscal year ended March 29, 2014, March 30, 2013, and March 31, 2012, respectively. The related income tax benefit recognized was $4.3 million, $3.5 million, and $2.7 million for the fiscal year ended March 29, 2014, March 30, 2013, and March 31, 2012, respectively. We recognize stock-based compensation on a straight line basis.
	ASC Topic 718 requires that cash flows relating to the benefits of tax deductions in excess of stock compensation cost recognized be reported as a financing cash flow, rather than as an operating cash flow. This excess tax benefit was $2.4 million, $4.1 million, and $1.4 million for the fiscal year ended March 29, 2014, March 30, 2013, and March 31, 2012, respectively.
	Stock Options
	A summary of stock option activity for the fiscal year ended March 29, 2014 is as follows:
		Options		Weighted			Weighted	Aggregate
		Outstanding		Average			Average	Intrinsic
		(shares)		Exercise Price			Remaining	Value
				per Share			Life (years)	($000’s)
	Outstanding at March 30, 2013	4,069,758		$	29.85		4.31	$	48,061
	Granted	758,705		42
	Exercised	(736,640	)	25.04
	Forfeited	(257,451	)	33.61
	Outstanding at March 29, 2014	3,834,372		$	32.93		4.19	$	9,436
	Exercisable at March 29, 2014	2,147,092		$	28.95		2.98	$	8,446
	Vested or expected to vest at March 29, 2014	3,636,128		$	32.58		4.09	$	9,379
	The total intrinsic value of options exercised was $11.7 million, $20.9 million, and $8.5 million during fiscal 2014, 2013, and 2012, respectively.
	As of March 29, 2014, there was $11.2 million of total unrecognized compensation cost related to non-vested stock options. This cost is expected to be recognized over a weighted average period of 2.55 years.
	The fair value was estimated using the Black-Scholes option-pricing model based on the weighted average of the high and low stock prices at the grant date and the weighted average assumptions specific to the underlying options. Expected volatility assumptions are based on the historical volatility of our common stock. The risk-free interest rate was selected based upon yields of U.S. Treasury issues with a term equal to the expected life of the option being valued. The expected life of the option was estimated with reference to historical exercise patterns, the contractual term of the option and the vesting period. The assumptions utilized for option grants during the periods presented are as follows:
		March 29,		March 30,		March 31,
		2014		2013		2012
	Volatility	24.8	%	26.4	%	27.5	%
	Expected life (years)	4.9		4.9		4.9
	Risk-free interest rate	1.3	%	0.8	%	0.1	%
	Dividend yield	0	%	0	%	0	%
	The weighted average grant date fair value of options to purchase one share granted during 2014, 2013, and 2012 was approximately $10.15, $9.76, and $8.16, respectively.
	We have applied, based on an analysis of our historical forfeitures, an annual forfeiture rate of 8% to all unvested stock options as of March 29, 2014 and March 30, 2013, which represents the portion that we expect will be forfeited each year over the vesting period.
	Employee Stock Purchase Plan
	The fair values of shares purchased under the Employee Stock Purchase Plan are estimated using the Black-Scholes single option-pricing model with the following weighted average assumptions:
		March 29,		March 30,		March 31,
		2014		2013		2012
	Volatility	22.9	%	24.9	%	26.3	%
	Expected life (months)	6		6		6
	Risk-free interest rate	0.1	%	0.2	%	1	%
	Dividend Yield	0	%	0	%	0	%
	The weighted average grant date fair value of the six-month option inherent in the Purchase Plan was approximately $8.25, $8.50, and $7.10 during fiscal 2014, 2013, and 2012, respectively.
	Restricted Stock Awards
	As of March 29, 2014, there was no unrecognized compensation cost related to non-vested restricted stock awards.
	Restricted Stock Units and Market Stock Units
	As of March 29, 2014, there was $14.9 million of total unrecognized compensation cost related to non-vested restricted stock units. This cost is expected to be recognized over a weighted average period of 2.8 years.
	As of March 29, 2014, there were 282,936 market stock units outstanding. We determined the fair value of a market stock units to be $37.42, utilizing a Monte Carlo simulation model based on an expected term of 3.7 years, a risk free rate of 0.9%, volatility of 20% and no dividends.  The grant date fair value of these awards totaled $11.2 million and will be expensed evenly over the 3.7 year period through the cliff-vesting date of March 31, 2017.
	A summary of market stock units and restricted stock units activity for the fiscal year ended March 29, 2014 is as follows:
		Shares		Weighted
				Average
				Market Value
				at Grant Date
	Unvested at March 30, 2013	356,419		$	34.06
	Awarded	462,769		$	32.77
	Released	(119,345	)	$	32.41
	Forfeited	(100,170	)	$	35.79
	Unvested at March 29, 2014	599,673		$	37.7

EARNINGS_PER_SHARE_EPS

EARNINGS PER SHARE ("EPS")	12 Months Ended
	Mar. 29, 2014
Earnings Per Share [Abstract]	'
EARNINGS PER SHARE (EPS)	'
	EARNINGS PER SHARE (“EPS”)
	The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations. Basic EPS is computed by dividing net income by weighted average shares outstanding. Diluted EPS includes the effect of potentially dilutive common shares. The common stock weighted average number of shares has been retroactively adjusted for the stock split.
	(In thousands, except per share amounts)	March 29,		March 30,		March 31,
		2014		2013		2012
	Basic EPS
	Net income	$	35,148	$	38,800	$	66,886
	Weighted average shares	51,611		51,349		50,727
	Basic income per share	$	0.68	$	0.76	$	1.32
	Diluted EPS
	Net income	$	35,148	$	38,800	$	66,886
	Basic weighted average shares	51,611		51,349		50,727
	Net effect of common stock equivalents	766		910		863
	Diluted weighted average shares	52,377		52,259		51,590
	Diluted income per share	$	0.67	$	0.74	$	1.3
	Weighted average shares outstanding, assuming dilution, excludes the impact of 1.1 million, 0.5 million and 1.4 million stock options for fiscal years 2014, 2013 and 2012, respectively, because these securities were anti-dilutive during the noted periods.

PROPERTY_PLANT_AND_EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
	Mar. 29, 2014
Property, Plant and Equipment [Abstract]	'
PROPERTY, PLANT AND EQUIPMENT	'
	PROPERTY, PLANT AND EQUIPMENT
	Property and equipment consisted of the following:
	(In thousands)	29-Mar-14			March 30, 2013
	Land	$	7,168		$	4,216
	Building and building improvements	83,439			78,682
	Plant equipment and machinery	236,539			205,698
	Office equipment and information technology	111,925			103,235
	Haemonetics equipment	262,784			240,889
	Total	701,855			632,720
	Less: accumulated depreciation and amortization	(430,418		)	(375,767		)
	Property, plant and equipment, net	$	271,437		$	256,953
	Depreciation expense was $52.6 million, $43.4 million, and $38.6 million for fiscal 2014, 2013, and 2012, respectively.
	During fiscal 2013, there was a change in the estimated useful lives of Haemonetics equipment which resulted in a fiscal 2013 decrease in depreciation expense of $4.5 million, an increase of $3.3 million in net income, and an increase in basic and diluted earnings per share of $0.09.

RETIREMENT_PLANS

RETIREMENT PLANS	12 Months Ended
	Mar. 29, 2014
Compensation and Retirement Disclosure [Abstract]	'
RETIREMENT PLANS	'
	RETIREMENT PLANS
	Defined Contribution Plans
	We have a Savings Plus Plan that is a 401(k) plan that allows our U.S. employees to accumulate savings on a pre-tax basis. In addition, matching contributions are made to the Plan based upon pre-established rates. Our matching contributions amounted to approximately $6.2 million in 2014, $4.9 million in 2013, and $4.0 million in 2012. Upon Board approval, additional discretionary contributions can also be made. No discretionary contributions were made for the Savings Plan in fiscal 2014, 2013, or 2012.
	Some of our subsidiaries also have defined contribution plans, to which plan both the employee and the employer make contributions. The employer contributions to these plans totaled $0.8 million, $2.4 million, and $0.8 million in fiscal 2014, 2013, and 2012, respectively.
	Defined Benefit Plans
	ASC Topic 715, Compensation — Retirement Benefits, requires an employer to: (a) recognize in its statement of financial position an asset for a plan’s over-funded status or a liability for a plan’s under-funded status; (b) measure a plan’s assets and its obligations that determine its funded status as of the end of the employer’s fiscal year (with limited exceptions); and (c) recognize changes in the funded status of a defined benefit post retirement plan in the year in which the changes occur. Accordingly, the Company is required to report changes in its funded status in comprehensive income on its Statement of Stockholders’ Equity and Comprehensive Income.
	Benefits under these plans are generally based on either career average or final average salaries and creditable years of service as defined in the plans. The annual cost for these plans is determined using the projected unit credit actuarial cost method that includes actuarial assumptions and estimates which are subject to change.
	Some of the our foreign subsidiaries have defined benefit pension plans covering substantially all full time employees at those subsidiaries. Net periodic benefit costs for the plans in the aggregate include the following components:
	(In thousands)	March 29,				March 30,				March 31,
		2014				2013				2012
	Service cost	$	3,351			$	2,759			$	2,545
	Interest cost on benefit obligation	623				639				601
	Expected (return)/loss on plan assets	(435		)		(413		)		2
	Actuarial loss/(gain)	88				196				(385		)
	Amortization of unrecognized prior service cost	182				(14		)		(31		)
	Amortization of unrecognized transition obligation	47				48				221
	Totals	$	3,856			$	3,215			$	2,953
	The activity under those defined benefit plans are as follows:
	(In thousands)	March 29,				March 30,
		2014				2013
	Change in Benefit Obligation:
	Benefit Obligation, beginning of year	$	(30,126	)		$	(27,150	)
	Service cost	(3,351		)		(2,759		)
	Interest cost	(623		)		(639		)
	Benefits paid	4,474				3,210
	Actuarial (loss)/gain	55				(1,364		)
	Employee and plan participants contribution	(2,963		)		(2,926		)
	Plan Amendments	419				—
	Foreign currency changes	(506		)		1,502
	Benefit obligation, end of year	$	(32,621	)		$	(30,126	)
	Change in Plan Assets:
	Fair value of plan assets, beginning of year	$	19,577			$	18,185
	Company contributions	2,241				2,381
	Benefits paid	(4,641		)		(3,210		)
	Gain/(Loss) on plan assets	100				397
	Employee and plan participants contributions	3,087				2,926
	Foreign currency changes	(383		)		(1,102		)
	Fair value of Plan Assets, end of year	$	19,981			$	19,577
	Funded Status	$	(12,640	)		$	(10,549	)
	Unrecognized net actuarial loss/(gain)	5,899				5,418
	Unrecognized initial obligation	94				184
	Unrecognized prior service cost	(422		)		138
	Net amount recognized	$	(7,069	)		$	(4,809	)
	One of the benefit plans is funded by benefit payments made by the Company. Accordingly that plan has no assets included in the information presented above. The total liability for this plan was $7.4 million and $5.4 million as of March 29, 2014 and March 30, 2013, respectively.
	The accumulated benefit obligation for all plans was $30.9 million and $28.1 million for the fiscal year ended March 29, 2014 and March 30, 2013, respectively.
	The projected benefit obligation, accumulated benefit obligation, and fair value of plan assets for the pension plans with an accumulated benefit obligation in excess of plan assets were $32.6 million, $30.9 million and $20.0 million, respectively, as of March 29, 2014 and $30.1 million, $28.1 million and $19.6 million, respectively, as of March 30, 2013. There were no plans where the plan assets were greater than the accumulated benefit obligation as of March 29, 2014 and March 30, 2013.
	The components of the change recorded in our accumulated other comprehensive income related to our defined benefit plans, net of tax, are as follows (in thousands):
	Balance, April 2, 2011	$	(265	)
	Obligation at transition	30
	Actuarial loss	(3,701		)
	Prior service cost	(317		)
	Balance as of March 31, 2012	$	(4,253	)
	Obligation at transition	556
	Actuarial loss	(1,237		)
	Prior service cost	(139		)
	Balance as of March 30, 2013	$	(5,073	)
	Obligation at transition	172
	Actuarial loss	(129		)
	Prior service cost	438
	Balance as of March 29, 2014	$	(4,592	)
	We expect to amortize $0.2 million from accumulated other comprehensive loss during 2014.
	The weighted average rates used to determine the net periodic benefit costs and projected benefit obligations were as follows:
		March 29,			March 30,			March 31,
2014		2013			2012
Discount rate	2.02	%		1.97	%		2.4	%
Rate of increased salary levels	1.57	%		1.42	%		1.5	%
Expected long-term rate of return on assets	1.94	%		1.92	%		2.1	%
Assumptions for expected long-term rate of return on plan assets are based upon actual historical returns, future expectations of returns for each asset class and the effect of periodic target asset allocation rebalancing. The results are adjusted for the payment of reasonable expenses of the plan from plan assets.
We have no other material obligation for post-retirement or post-employment benefits.
Our investment policy for pension plans is to balance risk and return through a diversified portfolio to reduce interest rate and market risk. Maturities are managed so that sufficient liquidity exists to meet immediate and future benefit payment requirements.
ASC Topic 820, Fair Value Measurements and Disclosures, provides guidance for reporting and measuring the plan assets of our defined benefit pension plan at fair value as of March 29, 2014. Using the same three-level valuation hierarchy for disclosure of fair value measurements as described in Note 7, all of the assets of the Company’s plan are classified within Level 2 of the fair value hierarchy because the plan assets are primarily insurance contracts.
Expected benefit payments for both plans are estimated using the same assumptions used in determining the company’s benefit obligation at March 29, 2014. Benefit payments will depend on future employment and compensation levels, average years employed and average life spans, among other factors, and changes in any of these factors could significantly affect these estimated future benefit payments.
Estimated future benefit payments during the next five years and in the aggregate for the five fiscal years thereafter, are as follows (in thousands):
Expected Benefit Payments
Fiscal Year 2015	$	2,023
Fiscal Year 2016	$	1,897
Fiscal Year 2017	$	1,907
Fiscal Year 2018	$	1,578
Fiscal Year 2019	$	1,645
Fiscal Year 2020-2024	$	8,295
The Company's contributions for fiscal 2015 are expected to be consistent with current year.

SEGMENT_INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Mar. 29, 2014
Segment Reporting [Abstract]	'
SEGMENT INFORMATION	'
	SEGMENT INFORMATION
	Segment Definition Criteria
	We manage a global business which designs, manufactures and markets blood management solutions.  Our solutions are marketed through operating units organized based primarily on geography: North America Plasma, North America Blood Center and Hospital, Europe, Asia Pacific and Japan. Prior to fiscal 2014 we determined we operated a single operating segment, blood management solutions, based on our CODM primarily using consolidated results to make operating and strategic decisions. During fiscal 2014 our CODM utilized financial results by operating units organized primarily on geography due to changes in the composition in the executive staff reporting to the CODM. Based on these changes we determined the five operating units noted above represent operating segments as defined under ASC 280 - Segment Reporting.
	ASC 280 - Segment Reporting permits aggregation of segments which are economically similar as well as similar in all of the following areas: (i) the nature of the products and services, (ii) the nature of the production processes, (iii) the type or class of customer for their products and services, (iv) the methods used to distribute their products or provide their services, and (v) the nature of the regulatory environment. We determined each operating segment is similar based on the criteria of ASC 280 and accordingly aggregate our five operating segments into one reportable segment. This conclusion is consistent with how our chief operating decision-maker views the business. Our chief operating decision maker primarily uses consolidated results to make operating and strategic decisions.
	Enterprise Wide Disclosures About Product and Services
	We have four global product families: plasma, blood center, hospital, and software solutions.
	Our products include whole blood disposables, equipment devices and the related disposables used with these devices. Disposables include part of plasma, blood center, and hospital product families. Plasma consists of the disposables used to perform apheresis for the separation of whole blood components and subsequent collection of plasma to be used as a raw material for biologically derived pharmaceuticals. Blood center consists of disposables which separate whole blood for the subsequent collection of platelets, plasma, red cells, or a combination of these components for transfusion to patients as well as disposables for manual whole blood collection. Hospital consists of surgical disposables (principally the Cell Saver® autologous blood recovery system targeted to procedures that involve rapid, high volume blood loss such as cardiovascular surgeries), the OrthoPAT® orthopedic perioperative autotransfusion system designed to operate both during and after surgery to recover and wash the patient’s red cells to prepare them for reinfusion, and diagnostics products (principally the TEG® Thrombelastograph® hemostasis analyzer used to help assess a surgical patient’s hemostasis during and after surgery).
	Software solutions include information technology platforms that assist blood centers, plasma centers, and hospitals to more effectively manage regulatory compliance and operational efficiency.
	Revenues from External Customers:
	(In thousands)	March 29,		March 30,		March 31,
		2014		2013		2012
	Disposable revenues
	Plasma disposables	$	291,895	$	268,900	$	258,061
	Blood center disposables
	Platelet	156,643		169,602		167,946
	Red cell	42,378		49,733		48,034
	Whole blood	190,698		138,436		—
		389,719		357,771		215,980
	Hospital disposables
	Surgical	66,876		73,508		66,619
	OrthoPAT	25,042		30,230		31,186
	Diagnostics	33,302		27,356		23,087
		125,220		131,094		120,892
	Disposables revenue	806,834		757,765		594,933
	Software solutions	70,441		69,952		70,557
	Equipment & other	61,234		64,273		62,354
	Total revenues	$	938,509	$	891,990	$	727,844
	Enterprise Wide Disclosures About Product and Services
	Year Ended (in thousands)
	March 29, 2014	United		Other		Total		Japan		Other		Total		Total
		States		North		North				Asia		Europe		Consolidated
				America		America
	Net revenues	$	500,719	$	9,557	$	510,276	$	108,679	$	94,762	$	224,792	$	938,509
	Total Assets	$	810,409	$	225,998	$	1,036,407	$	53,207	$	53,055	$	371,509	$	1,514,178
	Long-Lived Assets	$	519,396	$	211,624	$	731,020	$	11,522	$	17,269	$	131,391	$	891,202
	March 30, 2013	United		Other		Total		Japan		Other		Total		Total
		States		North		North				Asia		Europe		Consolidated
				America		America
	Net revenues	$	454,874	$	6,851	$	461,725	$	120,726	$	84,860	$	224,679	$	891,990
	Total Assets	$	830,754	$	225,849	$	1,056,603	$	44,189	$	41,037	$	320,088	$	1,461,917
	Long-Lived Assets	$	503,606	$	209,439	$	713,045	$	12,977	$	8,076	$	117,717	$	851,815
	March 31, 2012	United		Other		Total		Japan		Other		Total		Total
		States		North		North				Asia		Europe		Consolidated
				America		America
	Net revenues	$	352,160	$	512	$	352,672	$	124,381	$	67,223	$	183,568	$	727,844
	Total Assets	$	634,171	$	15,365	$	649,536	$	50,509	$	27,353	$	183,737	$	911,135
	Long-Lived Assets	$	305,370	$	12,796	$	318,166	$	13,128	$	3,961	$	38,009	$	373,264
	The Long-Lived Assets reported above include Goodwill, Intangibles and Net Property, Plant and Equipment.

RESTRUCTURING

RESTRUCTURING	12 Months Ended
	Mar. 29, 2014
Restructuring and Related Activities [Abstract]	'
RESTRUCTURING	'
	RESTRUCTURING
	On an ongoing basis, we review the global economy, the healthcare industry, and the markets in which we compete. From these reviews we identify opportunities to improve efficiencies, enhance commercial capabilities, better align our resources and offer customers better comprehensive solutions. In order to realize these opportunities, from time to time, we undertake restructuring and other initiatives to transform our business.
	On May 1, 2013, we announced that our Board of Directors has approved a plan to pursue identified VCC opportunities. These include: (i) investment in product line extensions, next generation products and growth platforms; (ii) enhancement of commercial execution capabilities by implementing go-to-market and other strategies to enable global profitable revenue growth; and (iii) transformation of the manufacturing network to best support these commercial strategies while optimizing expense levels. Collectively, these are opportunities to position us for optimal growth and increased competitiveness.
	Our manufacturing network transformation plan, part of our larger VCC activities previously announced, now includes (i) discontinuing manufacturing activities at our Braintree, Massachusetts and Ascoli-Piceno, Italy facilities, (ii) consulting with employee representatives regarding ceasing operations and closure of our manufacturing facility in Bothwell, Scotland, (iii) creating a technology center of excellence for product development, (iv) expansion of our current facility in Tijuana, Mexico, (v) engaging Sanmina Corporation as a contract manufacturer to produce certain medical equipment, and (vi) building a new manufacturing facility in Malaysia closer to our customers in Asia.
	We estimate we will incur approximately $74.0 million of restructuring and restructuring related expense and spend approximately $58.0 million on these initiatives in fiscal 2015. We estimate we will spend an additional $10 to $15 million to complete these initiatives through fiscal 2017.
	For the year ended March 29, 2014, we incurred $49.1 million of restructuring and restructuring related charges of which approximately $25.4 million has been paid to date and approximately $18.2 million is payable within the next twelve months. The majority of these costs relate to the discontinuation of manufacturing activities in Braintree, Massachusetts and Ascoli-Piceno, Italy, and were incurred in fiscal 2014. The substantial majority of restructuring expenses have been included as a component of selling, general and administrative expense in the accompanying consolidated statements of income and comprehensive income.
	The following summarizes the restructuring activity for the fiscal year ended March 29, 2014, March 30, 2013, and March 31, 2012, respectively:
	(In thousands)	Balance at March 30, 2013		Cost		Payments			Less Non-Cash Adjustments			Restructuring Accrual Balance at March 29, 2014
				Incurred
	Severance and other employee costs	$	3,089	$	31,492	$	(11,673	)	$	—		$	22,908
	Facility related costs	173		14,254		(13,699		)	—			728
	Accelerated depreciation	—		2,390		—			(2,390		)	—
	Asset write-down	—		915		—			(915		)	—
		$	3,262	$	49,051	$	(25,372	)	$	(3,305	)	$	23,636
	(In thousands)	Balance at March 31, 2012		Cost		Payments			Less Non-Cash Adjustments			Restructuring Accrual Balance at March 30, 2013
				Incurred
	Severance and other employee costs	$	1,461	$	6,214	$	(4,586	)	$	—		$	3,089
	Facility related costs	533		431		(791		)	—			173
	Asset write down	—		4,247		—			(4,247		)	—
		$	1,994	$	10,892	$	(5,377	)	$	(4,247	)	$	3,262
	(In thousands)	Balance at April 2, 2011		Cost		Payments			Less Non-Cash Adjustments			Restructuring Accrual Balance at March 31, 2012
				Incurred
	Severance and other employee costs	$	2,782	$	4,112	$	(5,433	)	$	—		$	1,461
	Facility related costs	889		1,746		(2,102		)	—			533
		$	3,671	$	5,858	$	(7,535	)	$	—		$	1,994
	We deployed significant financial resources for these activities.  Many of the activities necessary to complete the VCC initiatives include severance and other costs which qualify as restructuring expenses under ASC 420, Exit or Disposal Cost Obligations.  We incurred $49.1 million in severance, asset write-offs and other restructuring charges in fiscal 2014. In addition, we also incurred $35.7 million of costs that do not constitute restructuring under ASC 420, which we refer to as "Transformation Costs". These costs consist primarily of expenditures directly related to our transformation activities including program management, integration and product line transfer teams, infrastructure related costs, accelerated depreciation and asset disposals.
	The table below presents transformation and restructuring costs recorded in cost of goods sold, research and development, selling, general and administrative expenses and interest and other expense in our statements of income and comprehensive income for the periods presented. The majority of expenses recorded as Transformation Costs in the prior year relate to the integration of the whole blood acquisition. Transformation Costs in the current year are associated with our VCC initiatives as well as completion of the integration of the whole blood acquisition.
	Transformation costs
	(in thousands)	March 29, 2014		March 30, 2013		March 31, 2012
	Integration and other costs	$	30,701	$	60,878	$	11,206
	Accelerated depreciation	4,203		687		677
	Asset disposal	796		—		—
	Total	$	35,700	$	61,565	$	11,883
	Restructuring costs
	(in thousands)	March 29, 2014		March 30, 2013		March 31, 2012
	Severance and other employee costs	$	31,492	$	6,214	$	4,112
	Other costs	14,254		431		1,746
	Accelerated depreciation	2,390		—		—
	Asset disposal	915		4,247		—
	Total	$	49,051	$	10,892	$	5,858
	Total restructuring and transformation	$	84,751	$	72,457	$	17,741

CAPITALIZATION_OF_SOFTWARE_DEV

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	12 Months Ended
	Mar. 29, 2014
Capitalization of Software and Development Costs [Abstract]	'
CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	'
	CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS
	The cost of software that is developed or obtained for internal use is accounted for pursuant to ASC Topic 350, Intangibles — Goodwill and Other. Pursuant to ASC Topic 350, the Company capitalizes costs incurred during the application development stage of software developed for internal use, and expenses costs incurred during the preliminary project and the post-implementation operation stages of development. The capitalized costs are included as a component of property, plant and equipment in the consolidated financial statements.
	For costs incurred related to the development of software to be sold, leased, or otherwise marketed, the Company applies the provisions of ASC Topic 985-20, Software, which specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers.
	We capitalized $6.0 million and $6.2 million in software development costs for ongoing initiatives during the fiscal years ended March 29, 2014 and March 30, 2013, respectively. At March 29, 2014 and March 30, 2013, we have a total of $31.7 million and $25.7 million, respectively, of software costs capitalized, of which $15.6 million and $20.0 million, respectively, related to in process software development initiatives. In connection with these development activities, we capitalized interest of $0.4 million and $0.3 million in fiscal 2014 and 2013, respectively. We amortize capitalized costs when the products are released for sale. During fiscal 2014, $10.4 million of capitalized costs related to three projects were placed into service, compared to $1.7 million of capitalized costs placed into service during fiscal 2013. Amortization of capitalized software development cost expense was $1.1 million, $0.9 million and $0.7 million for fiscal 2014, 2013 and 2012 respectively. The costs capitalized for each project are included in intangible assets in the consolidated financial statements.

SUMMARY_OF_QUARTERLY_DATA_UNAU

SUMMARY OF QUARTERLY DATA (UNAUDITED)	12 Months Ended
	Mar. 29, 2014
Quarterly Financial Data [Abstract]	'
SUMMARY OF QUARTERLY DATA (UNAUDITED)	'
	SUMMARY OF QUARTERLY DATA (UNAUDITED)
	(In thousands)	Three months ended
	Fiscal 2014	June 29,			September 28,		December 28,		March 29,
		2013			2013		2013		2014
	Net revenues	$	219,543		$	235,755	$	242,120	$	241,091
	Gross profit	$	111,412		$	119,884	$	121,629	$	115,440
	Operating (loss) income	$	(6,608	)	$	23,430	$	17,860	$	12,645
	Net (loss) income	$	(7,874	)	$	16,548	$	16,290	$	10,184
	Per share data:
	Net (loss) Income:
	Basic	$	(0.15	)	$	0.32	$	0.31	$	0.2
	Diluted	$	(0.15	)	$	0.32	$	0.31	$	0.19
		Three months ended
	Fiscal 2013	June 30,			September 29,		December 29,		March 30,
		2012			2012		2012		2013
	Net revenues	$	176,475		$	218,178	$	247,395	$	249,942
	Gross profit	$	90,113		$	101,762	$	113,115	$	123,141
	Operating income	$	13,079		$	9,901	$	15,747	$	17,710
	Net income	$	9,787		$	6,547	$	9,904	$	12,562
	Per share data:
	Net Income:
	Basic	$	0.19		$	0.13	$	0.19	$	0.24
	Diluted	$	0.19		$	0.13	$	0.19	$	0.24

ACCUMULATED_OTHER_COMPREHENSIV

ACCUMULATED OTHER COMPREHENSIVE INCOME	12 Months Ended
	Mar. 29, 2014
Stockholders' Equity Note [Abstract]	'
ACCUMULATED OTHER COMPREHENSIVE INCOME	'
	ACCUMULATED OTHER COMPREHENSIVE INCOME
	The following is a roll-forward of the components of Accumulated Other Comprehensive Income, net of tax, for the years ended March 29, 2014 and March 30, 2013:
	(In thousands)	Foreign currency			Defined benefit plans			Net Unrealized Gain/loss on Derivatives			Total
	Balance as of March 31, 2012	$	8,838		$	(4,253	)	$	4,525		$	9,110
	Other comprehensive (loss)/income before reclassifications	(4,705		)	(1,002		)	4,594			(1,113		)
	Amounts reclassified from Accumulated Other Comprehensive Income	—			182			(2,746		)	(2,564		)
	Net current period other comprehensive (loss)/income	(4,705		)	(820		)	1,848			(3,677		)
	Balance as of March 30, 2013	$	4,133		$	(5,073	)	$	6,373		$	5,433
	Other comprehensive (loss)/income before reclassifications	(935		)	223			5,001			4,547
	Amounts reclassified from Accumulated Other Comprehensive Income	—			258			(8,570		)	(8,570		)
	Net current period other comprehensive (loss)/income	(935		)	481			(3,569		)	(4,023		)
	Balance as of March 29, 2014	$	3,198		$	(4,592	)	$	2,804		$	1,410
	The details about the amount reclassified from Accumulated Other Comprehensive Income for the years ended March 29, 2014 and March 30, 2013 are as follows:
	(In thousands)	Amounts Reclassified from Other Comprehensive Income						Affected Line in the
								Statement of Income
	Derivative instruments reclassified to income statement	Year ended March 29, 2014			Year ended March 30, 2013
	Realized net gain on derivatives	$	8,960		$	4,403		Revenue, cost of goods sold, other income
	Income tax effect	(390		)	(1,657		)	Provision for income taxes
	Net of taxes	$	8,570		$	2,746
	Pension items reclassified to income statement
	Realized net loss on pension assets	$	317		$	230		Other income
	Income tax effect	(59		)	(48		)	Provision for income taxes
	Net of taxes	$	258		$	182

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Mar. 29, 2014
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	SUBSEQUENT EVENTS
	On April 28, 2104, we announced that the Board of Directors has approved the repurchase of up to $100 million of shares, consistent with its loan covenants.

VALUATION_AND_QUALIFYING_ACCOU

VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Mar. 29, 2014
Valuation and Qualifying Accounts [Abstract]	'
VALUATION AND QUALIFYING ACCOUNTS	'
	SCHEDULE II
	HAEMONETICS CORPORATION
	VALUATION AND QUALIFYING ACCOUNTS
	(In thousands)	Balance at		Charged to			Write-Offs			Balance at End
		Beginning of		Costs and			(Net of Recoveries)			of Fiscal Year
		Fiscal Year		Expenses
	For Year Ended March 29, 2014
	Allowance for Doubtful Accounts	$	1,727	$	186		$	(237	)	$	1,676
	For Year Ended March 30, 2013
	Allowance for Doubtful Accounts	$	1,480	$	446		$	(199	)	$	1,727
	For Year Ended March 31, 2012
	Allowance for Doubtful Accounts	$	1,799	$	(39	)	$	(280	)	$	1,480

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Policies)	12 Months Ended
	Mar. 29, 2014
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
Fiscal Year	'
	Our fiscal year ends on the Saturday closest to the last day of March. Fiscal years 2014, 2013 and 2012 each includes 52 weeks with each quarter having 13 weeks.
Principles of Consolidation	'
	The accompanying consolidated financial statements include all accounts including those of our subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	'
	The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could vary from the amounts derived from our estimates and assumptions.
Reclassifications	'
	Certain reclassifications have been made to prior years' amounts to conform to the current year's presentation.
Contingencies	'
	We may become involved in various legal proceedings that arise in the ordinary course of business, including, without limitation, patent infringement, product liability and environmental matters. Accruals recorded for various contingencies including legal proceedings, self-insurance and other claims are based on judgment, the probability of losses and, where applicable, the consideration of opinions of internal and/or external legal counsel and actuarially determined estimates. When a range is established but a best estimate cannot be made, we record the minimum loss contingency amount. These estimates are often initially developed substantially earlier than the ultimate loss is known, and the estimates are reevaluated each accounting period, as additional information is available. When we are initially unable to develop a best estimate of loss, we record the minimum amount of loss, which could be zero. As information becomes known, additional loss provision is recorded when either a best estimate can be made or the minimum loss amount is increased. When events result in an expectation of a more favorable outcome than previously expected, our best estimate is changed to a lower amount. We record receivables from third party insurers when we have determined that existing insurance policies will provide reimbursement. In making this determination, we consider applicable deductibles, policy limits and the historical payment experience of the insurance carriers.
Revenue Recognition	'
	Our revenue recognition policy is to recognize revenues from product sales, software and services in accordance with ASC Topic 605, Revenue Recognition, and ASC Topic 985-605, Software. These standards require that revenues are recognized when persuasive evidence of an arrangement exists, product delivery, including customer acceptance, has occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. We may have multiple contracts with the same customer and each contract is typically treated as a separate arrangement. When more than one element such as equipment, disposables, and services are contained in a single arrangement, we allocate revenue between the elements based on each element’s relative selling price, provided that each element meets the criteria for treatment as a separate unit of accounting. An item is considered a separate unit of accounting if it has value to the customer on a stand-alone basis. The selling price of the undelivered elements is determined by the price charged when the element is sold separately, or in cases when the item is not sold separately, by third-party evidence of selling price or by management's best estimate of selling price. For our software arrangements accounted for under the provisions of ASC 985-605, Software, we establish fair value of undelivered elements based upon vendor specific objective evidence.
Product Revenues	'
	Product sales consist of the sale of our disposable whole blood and blood component collection sets, equipment devices and the related disposables used with these devices. On product sales to end customers, revenue is recognized when both the title and risk of loss have transferred to the customer as determined by the shipping terms and all obligations have been completed. For product sales to distributors, we recognize revenue for both equipment and disposables upon shipment of these products to our distributors. Our standard contracts with our distributors state that title to the equipment passes to the distributors at point of shipment to a distributor’s location. The distributors are responsible for shipment to the end customer along with installation, training and acceptance of the equipment by the end customer. Payments from distributors are not contingent upon resale of the product.
Software Revenues	'
	Our software solutions business provides support to our plasma and blood collection customers and hospitals. We provide information technology platforms and technical support for donor recruitment, blood and plasma testing laboratories, and for efficient and compliant operations of blood and plasma collection centers. For plasma customers, we also provide information technology platforms for managing distribution of plasma from collection centers to plasma fractionation facilities.
	Our software solutions revenues also include revenue from software sales which includes per collection or monthly subscription fees for the license and support of the software as well as hosting services. A significant portion of our software sales are perpetual licenses typically accompanied with significant implementation service fees related to software customization as well as other professional and technical service fees.
	We generally recognize revenue from the sale of perpetual licenses on a percentage-of-completion basis which requires us to make reasonable estimates of the extent of progress toward completion of the contract. These arrangements most often include providing customized implementation services to our customer. We also provide other services, including in some instances hosting, technical support, and maintenance, for the payment of periodic, monthly, or quarterly fees. We recognize these fees and charges as earned, typically as these services are provided during the contract period.
Non-Income Taxes	'
	We are required to collect sales or valued added taxes in connection with the sale of certain of our products. We report revenues net of these amounts as they are promptly remitted to the relevant taxing authority.
	We are also required to pay a medical device excise tax relating to U.S. sales of Class I, II and III medical devices. This new excise tax went into effect January 1, 2013, established as part of the March 2010 U.S. healthcare reform legislation, and has been included in selling, general and administrative expenses.
Translation of Foreign Currencies	'
	All assets and liabilities of foreign subsidiaries are translated at the rate of exchange at year-end while sales and expenses are translated at an average rate in effect during the year. The net effect of these translation adjustments is shown in the accompanying financial statements as a component of stockholders' equity. Foreign currency transaction gains and losses, including those resulting from inter-company transactions, are charged directly to earnings and included in other income, net on the consolidated statements of income. The impact of foreign exchange on long-term intercompany loans, for which repayment has not been scheduled or planned, are recorded in accumulated other comprehensive income on the consolidated balance sheet.
Cash and Cash Equivalents	'
	Cash equivalents include various instruments such as money market funds, U.S. government obligations and commercial paper with maturities of three months or less at date of acquisition. Cash and cash equivalents are recorded at cost, which approximates fair market value. As of March 29, 2014, our cash and cash equivalents consisted of investments in United States Government Agency and institutional money market funds.
Allowance for Doubtful Accounts	'
	We establish a specific allowance for customers when it is probable that they will not be able to meet their financial obligation. Customer accounts are reviewed individually on a regular basis and appropriate reserves are established as deemed appropriate. We also maintain a general reserve using a percentage that is established based upon the age of our receivables and our collection history. We establish allowances for balances not yet due and past due accounts based on past experience.
Property, Plant and Equipment	'
	Property, plant and equipment is recorded at historical cost. We provide for depreciation and amortization by charges to operations using the straight-line method in amounts estimated to recover the cost of the building and improvements, equipment, and furniture and fixtures over their estimated useful lives as follows:
	Asset Classification		Estimated
			Useful Lives
	Building		30 Years
	Building improvements		5-20 Years
	Plant equipment and machinery		3-15 Years
	Office equipment and information technology		3-10 Years
	Haemonetics equipment		3-7 Years
	We evaluate the depreciation periods of property, plant and equipment to determine whether events or circumstances warrant revised estimates of useful lives. All property, plant and equipment are also tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable.
	Our installed base of devices includes devices owned by us and devices sold to the customer. The asset on our balance sheet entitled Haemonetics equipment consists of medical devices installed at customer sites but owned by Haemonetics. Generally the customer has the right to use it for a period of time as long as they meet the conditions we have established, which among other things, generally include one or more of the following:
	•	Purchase and consumption of a certain level of disposable product
	•	Payment of monthly rental fees
	•	An asset utilization performance metric, such as performing a minimum level of procedures per month per device
	Consistent with the impairment tests noted below for other intangible assets subject to amortization, we review Haemonetics equipment and their related useful lives at least once a year, or more frequently if certain conditions arise, to determine if any adverse conditions exist that would indicate the carrying value of these assets may not be recoverable. To conduct these reviews we estimate the future amount and timing of demand for these devices. Changes in expected demand can result in additional depreciation expense, which is classified as cost of goods sold. Any significant unanticipated changes in demand could impact the value of our devices and our reported operating results.
	Leasehold improvements are depreciated over the lesser of their useful lives or the term of the lease. Maintenance and repairs are expensed to operations as incurred. When equipment and improvements are sold or otherwise disposed of, the asset cost and accumulated depreciation are removed from the accounts, and the resulting gain or loss, if any, is included in the statements of income.
Goodwill and Other Intangible Assets	'
	Intangible assets acquired in a business combination are recorded under the purchase method of accounting at their estimated fair values at the date of acquisition. Goodwill represents the excess purchase price over the fair value of the net tangible and other identifiable intangible assets acquired. We amortize our other intangible assets over their estimated useful lives.
	Goodwill is not amortized. Instead goodwill is reviewed for impairment at least annually in accordance with ASC Topic 350, Intangibles — Goodwill and Other, or on an interim basis between annual tests when events or circumstances indicate that it is more likely than not that the fair value of a reporting unit is less than its carrying value. We perform our annual impairment test on the first day of the fiscal fourth quarter for each of our reporting units. We first perform a qualitative test and if necessary, perform a quantitative test.
	Prior to fiscal 2014 we determined we operated a single operating segment, blood management solutions, based on our chief operating decision maker (“CODM”) primarily using consolidated results to make operating and strategic decisions. Our reporting units for purposes of assessing goodwill impairment prior to fiscal 2014 were medical devices and software. During fiscal 2014 our CODM utilized financial results by operating units organized primarily on geography due to changes in the composition in the executive staff reporting to the CODM. Based on these changes we determined the five operating units noted above represent operating segments as defined under ASC 280 - Segment Reporting. Following this change we determined our reporting units for purposes of assessing goodwill impairment by identifying our operating segments and assessing whether segment management regularly reviews the operating results of any components. Through this process, we concluded that our reporting units were the same as our operating segments, which are the following operating units organized based primarily on geography: North America Plasma, North America Blood Center and Hospital, Europe, Asia-Pacific and Japan. Goodwill was reallocated from the medical device and software reporting units to the new reporting units based on a relative fair value basis.
	The quantitative test is based on a discounted cash flow analysis or other valuation techniques, such as the market approach, for each reporting unit. In fiscal 2014, we determined the fair value of our reporting units based on the market approach. Under the market approach, we estimate the fair value of our reporting units based on a combination of, a) market multiples of current year earnings before interest, taxes, depreciation and amortization (“EBITDA”) and b) net revenues for each individual reporting unit. For the market approach, we use judgment in identifying the relevant comparable-company market multiples, such as recent divestitures/acquisitions, facts and circumstances surrounding the market and growth rates. Management assesses the relevance and reliability of the multiples by considering factors unique to its reporting units, including recent operating results, business plans, economic projections, anticipated future cash flows, and other data. EBITDA and revenue multiples can also be significantly impacted by future growth opportunities for the reporting unit as well as for the company itself, general market and geographic sentiment, and pending or recently completed merger transactions.
	The fair values of our reporting units in fiscal 2012 and 2013 were determined using an income approach. Under the income approach, the fair value of a reporting unit is based on the present value of future cash flows using appropriate discount rates, growth rates, operating margins and future market conditions amongst others. We changed our valuation approach to assessing goodwill impairment in fiscal 2014 in connection with the change in reporting units. ASC 350, Intangibles - Goodwill and Other defines the fair value of a reporting unit as the price that would be received to sell the unit as a whole in an orderly transaction between market participants at the measurement date. We utilized the market approach as we determined relevant comparable information was available, and accordingly such method was an appropriate alternative to the income method based on cost-benefit considerations.
	These tests showed no evidence of impairment to our goodwill for fiscal 2014, 2013 or 2012 and demonstrated that the fair value of each reporting unit exceeded the reporting unit’s carrying value in each period. During March 2014, circumstances arose that indicated a potential impairment. We performed an interim impairment test with the new information and noted that the fair value of our reporting units still exceeded their carrying values.
	We review intangible assets subject to amortization at least annually or more frequently if certain conditions arise to determine if any adverse conditions exist that would indicate that the carrying value of an asset or asset group may not be recoverable, or that a change in the remaining useful life is required. Conditions indicating that an impairment exists include but are not limited to a change in the competitive landscape, internal decisions to pursue new or different technology strategies, a loss of a significant customer or a significant change in the marketplace including prices paid for our products or the size of the market for our products. During March 2014, circumstances arose that indicated a potential impairment of certain intangible assets subject to amortization. We performed the recoverability test described below for the relevant asset group and determined expected undiscounted cash flows exceeded the carrying value of the asset group.
	If an impairment indicator exists, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset (asset group) exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset (asset group), we will write the carrying value down to the fair value in the period identified.
	We generally calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset using a risk-adjusted discount rate. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset (asset group).
	If we determine the estimate of an intangible asset's remaining useful life should be reduced based on our expected use of the asset, the remaining carrying amount of the asset is amortized prospectively over the revised estimated useful life.
Accounting for the Costs of Computer Software to be Sold, Leased, or Otherwise Marketed	'
	ASC Topic 985-20, Software, specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers, at which point capitalized costs are amortized over their estimated useful life of seven years. Technological feasibility is established when we have a detailed design of the software and when research and development activities on the underlying device, if applicable, are completed.
	We review the net realizable value of capitalized assets periodically to assess the recoverability of amounts capitalized. In the future, the net realizable value may be adversely affected by the loss of a significant customer or a significant change in the market place, which could result in an impairment being recorded.
Other Liabilities	'
	Other liabilities represent items payable within the next twelve months.
	The items included in the fiscal year end balances were:
	(In thousands)	March 29,		March 30,
		2014		2013
	VAT liabilities	$	7,114	$	5,121
	Forward contracts	1,255		1,786
	Deferred revenue	24,777		23,737
	All other	26,564		26,707
	Total	$	59,710	$	57,351
Research and Development Expenses	'
	All research and development costs are expensed as incurred.
Advertising Costs	'
	All advertising costs are expensed as incurred and are included in selling, general and administrative expenses in the consolidated statements of income.
Accounting for Shipping and Handling Costs	'
	Shipping and handling costs are included in selling, general and administrative expenses. Freight is classified in cost of goods sold when the customer is charged for freight and in selling, general and administration when the customer is not explicitly charged for freight.
Income Taxes	'
	The income tax provision is calculated for all jurisdictions in which we operate. The income tax provision process involves calculating current taxes due and assessing temporary differences arising from items which are taxable or deductible in different periods for tax and accounting purposes and are recorded as deferred tax assets and liabilities. Deferred tax assets are evaluated for realizability and a valuation allowance is maintained for the portion of our deferred tax assets that are not more-likely-than-not realizable.
	We file income tax returns in all jurisdictions in which we operate. We record a liability for uncertain tax positions taken or expected to be taken in income tax returns. Our financial statements reflect expected future tax consequences of such positions presuming the taxing authorities' full knowledge of the position and all relevant facts. We record a liability for the portion of unrecognized tax benefits claimed which we have determined are not more-likely-than-not realizable. These tax reserves have been established based on management's assessment as to the potential exposure attributable to our uncertain tax positions as well as interest and penalties attributable to these uncertain tax positions. All tax reserves are analyzed quarterly and adjustments are made as events occur that result in changes in judgment.
Derivative Instruments	'
	We account for our derivative financial instruments in accordance with ASC Topic 815, Derivatives and Hedging (“ASC 815”) and ASC Topic 820, Fair Value Measurements and Disclosures (“ASC 820”). In accordance with ASC 815, we record all derivatives on the balance sheet at fair value. The accounting for the change in the fair value of derivatives depends on the intended use of the derivative, whether we have elected to designate a derivative as a hedging instrument for accounting purposes, and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. In addition, ASC 815 provides that, for derivative instruments that qualify for hedge accounting, changes in the fair value are either (a) offset against the change in fair value of the hedged assets, liabilities, or firm commitments through earnings or (b) recognized in equity until the hedged item is recognized in earnings, depending on whether the derivative is being used to hedge changes in fair value or cash flows. The ineffective portion of a derivative’s change in fair value is immediately recognized in earnings. We do not use derivative financial instruments for trading or speculation purposes.
	The gains or losses on the forward foreign exchange rate contracts designated as hedges are recorded in net revenues, cost of goods sold, operating expenses and other income in our consolidated statements of income when the underlying hedged transaction affects earnings. The cash flows related to the gains and losses are classified in the consolidated statements of cash flows as part of cash flows from operating activities. For those derivative instruments that are not designated as part of a hedging relationship we record the gains or losses in earnings currently. These gains and losses are intended to offset the gains and losses recorded on net monetary assets or liabilities that are denominated in foreign currencies. We recorded foreign currency losses on designated and non-designated hedges of $0.5 million, $0.8 million, and $0.4 million in fiscal 2014, 2013 and 2012, respectively.
	On a quarterly basis, we assess whether the cash flow hedges are highly effective in offsetting changes in the cash flow of the hedged item. We manage the credit risk of the counterparties by dealing only with institutions that we consider financially sound and consider the risk of non-performance to be remote.
	Our derivative instruments do not subject our earnings or cash flows to material risk, as gains and losses on these derivatives are intended to offset losses and gains on the item being hedged. We do not enter into derivative transactions for speculative purposes and we do not have any non-derivative instruments that are designated as hedging instruments pursuant to ASC Topic 815.
Stock-Based Compensation	'
	We use the Black-Scholes option-pricing model to calculate the grant-date fair value of our stock options. The following assumptions, which involve the use of judgment by management, are used in the computation of the grant-date fair value of our stock options:
	Expected Volatility — We have principally used our historical volatility as a basis to estimate expected volatility in our valuation of stock options.
	Expected Term — We estimate the expected term of our options using historical exercise and forfeiture data to determine the amount of stock based compensation to record each period. We believe that this historical data is currently the best estimate of the expected term of our new option grants.
	Estimated Forfeiture Rate — Based on an analysis of our historical forfeitures, we have applied an annual forfeiture rate which represents the portion that we expect will be forfeited each year over the vesting period. We reevaluate this analysis periodically and adjust the forfeiture rate as necessary. Ultimately, we will only recognize expense for those shares that vest.
Valuation of Acquisitions	'
	We allocate the amounts we pay for each acquisition to the assets acquired and liabilities assumed based on their estimated fair values at the dates of acquisition, including acquired identifiable intangible assets. We base the estimated fair value of identifiable intangible assets on detailed valuations that use historical information and market assumptions based upon the assumptions of a market participant. We allocate any excess purchase price over the fair value of the net tangible and intangible assets acquired to goodwill.
	In certain acquisitions, we have earn-out arrangements or contingent consideration to provide potential future payments to the seller for achieving certain agreed-upon financial targets. We record the contingent consideration at its fair value at the acquisition date. Generally, we have entered into arrangements with contingent consideration that require payments in cash. As such, each quarter, we revalue the contingent consideration obligations associated with certain acquisitions to their then fair value and record the change in the fair value as contingent consideration income or expense. These changes are recorded in selling, general and administrative expense. Increases or decreases in the fair value of the contingent consideration obligations can result from changes in assumed discount periods and rates, changes in the assumed timing and amount of revenue and expense estimates, and changes in assumed probability adjustments with respect to regulatory approval. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, future business and economic conditions, as well as changes in any of the assumptions described above, can materially impact the amount of contingent consideration income or expense we record in any given period.
Concentration of Credit Risk and Significant Customers	'
	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents and accounts receivable. In fiscal 2014, no one customer accounted for more than 10% of our revenues. Sales to one unaffiliated Japanese customer, the Japanese Red Cross Society ("JRC"), amounted to $90.1 million, and $99.5 million for 2013, and 2012, respectively. JRC accounted for 10.7%, 9.0%, and 15.3% of our consolidated accounts receivable at fiscal year ended 2014, 2013, and 2012, respectively.
	Certain other markets and industries can expose us to concentrations of credit risk. For example, in our bio-pharmaceutical business, our sales are concentrated with several large customers. As a result, our accounts receivable extended to any one of these bio-pharmaceutical customers can be significant at any point in time. Also, a portion of our trade accounts receivable outside the United States include sales to government-owned or supported healthcare systems in several countries, which are subject to payment delays. Payment is dependent upon the financial stability and creditworthiness of those countries’ national economies. We have not incurred significant losses on government receivables. We continually evaluate all government receivables for potential collection risks associated with the availability of government funding and reimbursement practices. If the financial condition of customers or the countries’ healthcare systems deteriorate such that their ability to make payments is uncertain, allowances may be required in future periods.
Recent Accounting Pronouncements	'
	Guidance to be Implemented
	In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-08, “Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity” (“ASU 2014-08”). ASU 2014-08 limits the requirement to report discontinued operations to disposals of components of an entity that represent strategic shifts that have (or will have) a major effect on an entity’s operations and financial results. The amendments also require expanded disclosures concerning discontinued operations and disclosures of certain financial results attributable to a disposal of a significant component of an entity that does not qualify for discontinued operations reporting. The amendments in this ASU are effective prospectively for reporting periods beginning on or after December 15, 2014, with early adoption permitted. The impact on our Financial Statements of adopting ASU 2014-08 is being assessed by management.
	Standards Implemented
	In February 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2013-02,Comprehensive Income: Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income("ASU 2013-02"). ASU 2013-02 requires an entity to provide information about amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present, either on the face of the financial statements or in a single note; any significant amount reclassified out of accumulated other comprehensive income in its entirety in the period, and the income statement line item affected by the reclassification. For other amounts that are not required under U.S. GAAP to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures required under U.S. GAAP that provide additional detail about those amounts. We adopted this guidance during the three months ended June 29, 2013
	In July 2013 FASB issued ASU 2013-10 Derivatives and Hedging (Topic 815): Inclusion of the Fed Funds Effective Swap Rate (or Overnight Index Swap Rate) as a Benchmark Interest Rate for Hedge Accounting Purposes. ASU 2013-10 amends ASC 815 to include the Fed Funds Effective Swap Rate (or Overnight Index Swap Rate) as a benchmark interest rate for hedge accounting purposes in addition to UST and LIBOR. The amendments also remove the restriction on using different benchmark rates for similar hedges. The amendments are effective prospectively for qualifying new or redesignated hedging relationships entered into on or after July 17, 2013. We have evaluated the amendments and conclude that these do not impact our financial statements as we have not entered into transactions with Fed Funds Effective Swap Rate.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Tables)	12 Months Ended
	Mar. 29, 2014
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
Schedule of Property, Plant and Equipment Estimated Useful Lives	'
	Property, plant and equipment is recorded at historical cost. We provide for depreciation and amortization by charges to operations using the straight-line method in amounts estimated to recover the cost of the building and improvements, equipment, and furniture and fixtures over their estimated useful lives as follows:
	Asset Classification		Estimated
			Useful Lives
	Building		30 Years
	Building improvements		5-20 Years
	Plant equipment and machinery		3-15 Years
	Office equipment and information technology		3-10 Years
	Haemonetics equipment		3-7 Years
Schedule of Other Accrued Liabilities	'
	The items included in the fiscal year end balances were:
	(In thousands)	March 29,		March 30,
		2014		2013
	VAT liabilities	$	7,114	$	5,121
	Forward contracts	1,255		1,786
	Deferred revenue	24,777		23,737
	All other	26,564		26,707
	Total	$	59,710	$	57,351

ACQUISITIONS_Tables

ACQUISITIONS (Tables)	12 Months Ended
	Mar. 29, 2014
Business Combinations [Abstract]	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	'
	We completed the allocation of the purchase price to the estimated fair value of the acquired assets and liabilities in June 2013 and is summarized below:
	Asset class	Amounts Recognized as of March 30, 2013
	(In thousands)
	Inventories	$	49,917
	Property, plant and equipment	85,984
	Intangible assets	188,500
	Other assets/liabilities, net	(6,166		)
	Goodwill	216,940
	Fair value of net assets acquired	$	535,175
	The final purchase price allocation is as follows:
	Asset class	Amounts recognized as of March 29, 2014
	Acquired technology	$	22,800
	Trade name	1,900
	Customer relationship	600
	Goodwill	6,425
	Total	$	31,725
Business Acquisition, Pro Forma Information	'
	The following represents the pro forma consolidated statements of income as if the acquisition had been included in our consolidated results as beginning April 1, 2012:
	(In thousands, except per share amounts)		March 30,
			2013
	Net Sales		$	963,923
	Net Income		$	56,540
	Basic EPS		$	1.1
	Diluted EPS		$	1.08

PRODUCT_WARRANTIES_Tables

PRODUCT WARRANTIES (Tables)	12 Months Ended
	Mar. 29, 2014
Product Warranties Disclosures [Abstract]	'
Schedule of Product Warranty Liability	'
	We estimate our potential warranty expense based on our historical warranty experience, and we periodically assess the adequacy of our warranty accrual and make adjustments as necessary.
	(In thousands)	March 29,			March 30,
		2014			2013
	Warranty accrual as of the beginning of the year	$	673		$	796
	Warranty provision	1,340			1,180
	Warranty spending	(1,423		)	(1,303		)
	Warranty accrual as of the end of the year	$	590		$	673

INVENTORIES_Tables

INVENTORIES (Tables)	12 Months Ended
	Mar. 29, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventories	'
	Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined with the first-in, first-out method.
	(In thousands)	March 29,		March 30,
		2014		2013
	Raw materials	$	72,508	$	70,716
	Work-in-process	7,383		7,829
	Finished goods	117,770		105,239
	Total Inventory	$	197,661	$	183,784

GOODWILL_AND_INTANGIBLE_ASSETS1

GOODWILL AND INTANGIBLE ASSETS (Tables)	12 Months Ended
	Mar. 29, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Goodwill	'
	The changes in the carrying amount of goodwill for fiscal 2014 and 2013 are as follows:
	(In thousands)
	Carrying amount as of March 31, 2012	$	115,058
	Whole blood business acquisition	216,940
	Effects of change in foreign currency exchange rates	(1,524		)
	Carrying amount as of March 30, 2013	$	330,474
	Hemerus acquisition	6,425
	Effects of change in foreign currency exchange rates	(131		)
	Carrying amount as of March 29, 2014	$	336,768
Schedule of Amoritized Intangibles	'
	The gross carrying amount of intangible assets and the related accumulated amortization as of March 29, 2014 and March 30, 2013 is as follows:
	(In thousands)	Gross Carrying			Accumulated		Net		Weighted Average
		Amount			Amortization				Useful Life
									(In years)
	As of March 29, 2014
	Patents	$	9,543		$	7,039	$	2,504	9
	Capitalized software	31,750			2,414		29,336		4
	Other developed technology	123,525			36,632		86,893		12
	Customer contracts and related relationships	200,694			52,741		147,953		12
	Trade names	7,341			2,868		4,473		11
	Total intangibles	$	372,853		$	101,694	$	271,159	11
	(In thousands)	Gross Carrying			Accumulated		Net		Weighted Average
		Amount			Amortization				Useful Life
									(In years)
	As of March 30, 2013
	Patents	$	8,706		$	6,397	$	2,309	10
	Capitalized software	25,741			1,364		24,377		6
	Other developed technology	100,586			25,812		74,774		12
	Customer contracts and related relationships	196,365			36,552		159,813		12
	Trade names	5,383			2,268		3,115		10
	Total intangibles	$	336,781		$	72,393	$	264,388	11
Schedule of Future Amortization Expense	'
	Future annual amortization expense on intangible assets is as follows:
	Fiscal Year		Amount   (in thousands)
	2015		$	29,162
	2016		$	28,695
	2017		$	28,611
	2018		$	27,766
	2019		$	25,957

DERIVATIVES_AND_FAIR_VALUE_MEA1

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Mar. 29, 2014
Derivatives and Fair Value Measurements [Abstract]	'
Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments	'
	The following table presents the effect of our derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC Topic 815 in our consolidated statements of income for the fiscal year ended March 29, 2014.
	Derivative Instruments		Amount of				Amount of				Location in	Amount of Gain/(Loss)			Location in
			Gain/(Loss) Recognized				Gain/(Loss)				Statement of Operations	Excluded from			Statement of
			in OCI				Reclassified					Effectiveness			Operations
			(Effective Portion)				from OCI into					Testing (*)
							Earnings
							(Effective Portion)
	(In thousands)
	Designated foreign currency hedge contracts, net of tax		$	3,712			$	8,570			Net revenues, COGS, and SG&A	$	(104	)	Other income (expense), net
	Non-designated foreign currency hedge contracts		—				—					$	(1,359	)	Other income (expense)
	Designated interest rate swaps, net of tax		$	1,289			$	—			Interest income (expense), net	$	—
	(*)		We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.
Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets	'
	The following tables present the fair value of our derivative instruments as they appear in our consolidated balance sheets as of March 29, 2014 and March 30, 2013 by type of contract and whether it is a qualifying hedge under ASC Topic 815.
	(In thousands)	Location in		Balance as of March 29, 2014				Balance as of March 30, 2013
		Balance Sheet
	Derivative Assets:
	Designated foreign currency hedge contracts	Other current assets		$	2,574			$	7,030
	Designated interest rate swaps	Other current assets		1,250				—
				$	3,824			$	7,030
	Derivative Liabilities:
	Designated foreign currency hedge contracts	Other current liabilities		$	1,255			$	954
	Designated interest rate swaps	Other current liabilities		—				671
				$	1,255			$	1,625
Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis	'
	Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of March 29, 2014 and March 30, 2013:
	As of March 29, 2014	Quoted Market Prices for Identical Assets				Significant Other Observable Inputs				Significant Unobservable Inputs			Total
		(Level 1)				(Level 2)				(Level 3)
		(In thousands)				(In thousands)				(In thousands)			(In thousands)
	Assets
	Money market funds	$	135,378			$	—			$	—		$	135,378
	Foreign currency hedge contracts	—				2,574				—			2,574
	Interest rate swap	—				1,250				—			1,250
		$	135,378			$	3,824			$	—		$	139,202
	Liabilities
	Foreign currency hedge contracts	$	—			$	1,255			$	—		$	1,255
	Contingent consideration	—				—				7,645			7,645
		$	—			$	1,255			$	7,645		$	8,900
	As of March 30, 2013	Quoted Market Prices for Identical Assets				Significant Other Observable Inputs				Significant Unobservable Inputs			Total
		(Level 1)				(Level 2)				(Level 3)
		(In thousands)				(In thousands)				(In thousands)			(In thousands)
	Assets
	Money market funds	$	141,120			$	—			$	—		$	141,120
	Forward currency hedge contracts	—				7,030				—			7,030
		$	141,120			$	7,030			$	—		$	148,150
	Liabilities
	Forward currency hedge contracts	$	—			$	954			$	—		$	954
	Interest rate swap	—				671				—			671
		$	—			$	1,625			$	—		$	1,625

NOTES_PAYABLE_AND_LONGTERM_DEB1

NOTES PAYABLE AND LONG-TERM DEBT (Tables)	12 Months Ended
	Mar. 29, 2014
Notes Payable and Long-Term Debt [Abstract]	'
Schedule of Notes Payable and Long-Term Debt	'
	Notes payable and long-term debt consisted of the following:
	(In thousands)	March 29, 2014			March 30, 2013
	Term loan, net of financing fees	$	435,338		471,016
	Real estate mortgage	1,906			2,877
	Bank loans and other borrowings	443			6,201
	Less current portion	(45,630		)	(23,150		)
	Long-term debt	$	392,057		$	456,944
Schedule of Notes Payable and Long-Term Debt Maturities	'
	The maturity profile of all gross long-term debt, exclusive of debt discounts, as of March 29, 2014 is presented below:
	Fiscal year (in thousands)		Mortgage Obligation			Term Loan		Bank loans and other borrowings		Total
	2015		$	1,055		$	45,500	$	193	$	46,748
	2016		851			68,250		160		69,261
	2017		—			182,000		71		182,071
	2018		—			142,188		19		142,207
			$	1,906		$	437,938	$	443	$	440,287

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Mar. 29, 2014
Income Tax Disclosure [Abstract]	'
Schedule Domestic and Foreign Income Before Provision for Income Tax	'
	Domestic and foreign income before provision for income tax is as follows:
	(In thousands)	March 29,			March 30,				March 31,
		2014			2013				2012
	Domestic	$	(6,859	)	$	17,360			$	40,666
	Foreign	43,260			32,537				48,832
	Total	$	36,401		$	49,897			$	89,498
Schedule of Income Tax Provision Components	'
	The income tax provision contains the following components:
	(In thousands)	March 29,			March 30,				March 31,
		2014			2013				2012
	Current
	Federal	$	(4,896	)	$	3,795			$	8,505
	State	873			1,324				2,275
	Foreign	5,478			5,389				5,954
	Total current	$	1,455		$	10,508			$	16,734
	Deferred
	Federal	(1,785		)	1,644				7,522
	State	207			(229		)		(597		)
	Foreign	1,376			(826		)		(1,047		)
	Total deferred	$	(202	)	$	589			$	5,878
	Total	$	1,253		$	11,097			$	22,612
Schedule of Net Deferred Tax Asset	'
	Tax affected, significant temporary differences comprising the net deferred tax liability are as follows:
	(In thousands)	March 29,			March 30,
		2014			2013
	Depreciation	$	(23,658	)	$	(25,186	)
	Amortization	(18,618		)	(14,776		)
	Inventory	7,371			7,884
	Hedging	321			(162		)
	Accruals, reserves and other	10,368			7,208
	Net operating loss carry-forward	1,507			1,877
	Stock based compensation	8,757			7,834
	Tax credit carry-forward, net	2,660			2,243
	Gross deferred taxes	$	(11,292	)	$	(13,078	)
	Less valuation allowance	(3,083		)	(1,009		)
	Net deferred tax liability	$	(14,375	)	$	(14,087	)
Schedule of Effective Income Tax Rate Reconciliation	'
	The income tax provision from operations differs from tax provision computed at the 35% U.S. federal statutory income tax rate due to the following:
	(In thousands)	March 29,						March 30,						March 31,
		2014						2013						2012
	Tax at federal statutory rate	$	12,739		35	%		$	17,464			35	%	$	31,324		35	%
	Domestic manufacturing deduction	—			—	%		(504		)		(1.0	)%	(700		)	(0.8	)%
	Difference between U.S. and foreign tax	(10,846		)	(29.8	)%		(5,584		)		(11.2	)%	(8,539		)	(9.5	)%
	State income taxes net of federal benefit	(252		)	(0.7	)%		718				1.4	%	1,136			1.3	%
	Change in uncertain tax positions	(1,678		)	(4.6	)%		(580		)		(1.2	)%	144			0.2	%
	Intercompany loan deduction	(2,185		)	(6.0	)%		—				—	%	—			—	%
	Non-deductible expenses	1,035			2.8	%		1,178				2.4	%	917			1	%
	Research credits	(688		)	(1.9	)%		(799		)		(1.6	)%	(752		)	(0.9	)%
	Valuation allowance	2,400			6.6	%		—				—	%	—			—	%
	Other, net	728			2	%		(796		)		(1.6	)%	(918		)	(1.0	)%
	Income tax provision	$	1,253		3.4	%		$	11,097			22.2	%	$	22,612		25.3	%
Summary of Gross Unrecognized Tax Benefits	'
	The following table summarizes the activity related to our gross unrecognized tax benefits for the fiscal years ended March 29, 2014, March 30, 2013 and March 31, 2012:
	(In thousands)	March 29,			March 30,				March 31,
		2014			2013				2012
	Beginning Balance	$	6,930		$	6,885			$	4,669
	Additions based upon positions related to the current year	—			1,192				1,124
	Additions for tax positions of prior years	990			18				1,216
	Reductions of tax positions	—			—				(124		)
	Settlements with taxing authorities	—			(80		)		—
	Closure of statute of limitations	(2,316		)	(1,085		)		—
	Ending Balance	$	5,604		$	6,930			$	6,885

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Mar. 29, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Approximate Future Basic Rental Commitments under Operating Leases	'
	Approximate future basic rental commitments under operating leases as of March 29, 2014 are as follows (in thousands):
	Fiscal Year Ending
	(In thousands)
	2015	$	6,991
	2016	5,141
	2017	3,357
	2018	2,627
	2019 and thereafter	4,812
		$	22,928

CAPITAL_STOCK_Tables

CAPITAL STOCK (Tables)	12 Months Ended
	Mar. 29, 2014
Capital Stock [Abstract]	'
Schedule of Summary of Stock Option Activity	'
	A summary of stock option activity for the fiscal year ended March 29, 2014 is as follows:
		Options		Weighted			Weighted	Aggregate
		Outstanding		Average			Average	Intrinsic
		(shares)		Exercise Price			Remaining	Value
				per Share			Life (years)	($000’s)
	Outstanding at March 30, 2013	4,069,758		$	29.85		4.31	$	48,061
	Granted	758,705		42
	Exercised	(736,640	)	25.04
	Forfeited	(257,451	)	33.61
	Outstanding at March 29, 2014	3,834,372		$	32.93		4.19	$	9,436
	Exercisable at March 29, 2014	2,147,092		$	28.95		2.98	$	8,446
	Vested or expected to vest at March 29, 2014	3,636,128		$	32.58		4.09	$	9,379
Schedule of Assumptions Utilized for Estimating Fair Value of Option Grants	'
	The assumptions utilized for option grants during the periods presented are as follows:
		March 29,		March 30,		March 31,
		2014		2013		2012
	Volatility	24.8	%	26.4	%	27.5	%
	Expected life (years)	4.9		4.9		4.9
	Risk-free interest rate	1.3	%	0.8	%	0.1	%
	Dividend yield	0	%	0	%	0	%
Schedule of Assumptions Used to Estimate Fair Value of Shares Purchased Under ESPP	'
	The fair values of shares purchased under the Employee Stock Purchase Plan are estimated using the Black-Scholes single option-pricing model with the following weighted average assumptions:
		March 29,		March 30,		March 31,
		2014		2013		2012
	Volatility	22.9	%	24.9	%	26.3	%
	Expected life (months)	6		6		6
	Risk-free interest rate	0.1	%	0.2	%	1	%
	Dividend Yield	0	%	0	%	0	%
	The weighted average rates used to determine the net periodic benefit costs and projected benefit obligations were as follows:
		March 29,		March 30,		March 31,
		2014		2013		2012
	Discount rate	2.02	%	1.97	%	2.4	%
	Rate of increased salary levels	1.57	%	1.42	%	1.5	%
	Expected long-term rate of return on assets	1.94	%	1.92	%	2.1	%
Schedule of Summary of Restricted Stock Units Activity	'
	A summary of market stock units and restricted stock units activity for the fiscal year ended March 29, 2014 is as follows:
		Shares		Weighted
				Average
				Market Value
				at Grant Date
	Unvested at March 30, 2013	356,419		$	34.06
	Awarded	462,769		$	32.77
	Released	(119,345	)	$	32.41
	Forfeited	(100,170	)	$	35.79
	Unvested at March 29, 2014	599,673		$	37.7

EARNINGS_PER_SHARE_EPS_Tables

EARNINGS PER SHARE ("EPS") (Tables)	12 Months Ended
	Mar. 29, 2014
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share Reconciliation	'
	(In thousands, except per share amounts)	March 29,		March 30,		March 31,
		2014		2013		2012
	Basic EPS
	Net income	$	35,148	$	38,800	$	66,886
	Weighted average shares	51,611		51,349		50,727
	Basic income per share	$	0.68	$	0.76	$	1.32
	Diluted EPS
	Net income	$	35,148	$	38,800	$	66,886
	Basic weighted average shares	51,611		51,349		50,727
	Net effect of common stock equivalents	766		910		863
	Diluted weighted average shares	52,377		52,259		51,590
	Diluted income per share	$	0.67	$	0.74	$	1.3

PROPERTY_PLANT_AND_EQUIPMENT_T

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	Mar. 29, 2014
Property, Plant and Equipment [Abstract]	'
Schedule of Property, Plant and Equipment	'
	Property and equipment consisted of the following:
	(In thousands)	29-Mar-14			March 30, 2013
	Land	$	7,168		$	4,216
	Building and building improvements	83,439			78,682
	Plant equipment and machinery	236,539			205,698
	Office equipment and information technology	111,925			103,235
	Haemonetics equipment	262,784			240,889
	Total	701,855			632,720
	Less: accumulated depreciation and amortization	(430,418		)	(375,767		)
	Property, plant and equipment, net	$	271,437		$	256,953

RETIREMENT_PLANS_Tables

RETIREMENT PLANS (Tables)	12 Months Ended
	Mar. 29, 2014
Compensation and Retirement Disclosure [Abstract]	'
Schedule of Components of Net Periodic Benefit Costs of Defined Benefit Pension Plans	'
	Some of the our foreign subsidiaries have defined benefit pension plans covering substantially all full time employees at those subsidiaries. Net periodic benefit costs for the plans in the aggregate include the following components:
	(In thousands)	March 29,				March 30,				March 31,
		2014				2013				2012
	Service cost	$	3,351			$	2,759			$	2,545
	Interest cost on benefit obligation	623				639				601
	Expected (return)/loss on plan assets	(435		)		(413		)		2
	Actuarial loss/(gain)	88				196				(385		)
	Amortization of unrecognized prior service cost	182				(14		)		(31		)
	Amortization of unrecognized transition obligation	47				48				221
	Totals	$	3,856			$	3,215			$	2,953
Schedule of Activity Under Defined Benefit Plans	'
	The activity under those defined benefit plans are as follows:
	(In thousands)	March 29,				March 30,
		2014				2013
	Change in Benefit Obligation:
	Benefit Obligation, beginning of year	$	(30,126	)		$	(27,150	)
	Service cost	(3,351		)		(2,759		)
	Interest cost	(623		)		(639		)
	Benefits paid	4,474				3,210
	Actuarial (loss)/gain	55				(1,364		)
	Employee and plan participants contribution	(2,963		)		(2,926		)
	Plan Amendments	419				—
	Foreign currency changes	(506		)		1,502
	Benefit obligation, end of year	$	(32,621	)		$	(30,126	)
	Change in Plan Assets:
	Fair value of plan assets, beginning of year	$	19,577			$	18,185
	Company contributions	2,241				2,381
	Benefits paid	(4,641		)		(3,210		)
	Gain/(Loss) on plan assets	100				397
	Employee and plan participants contributions	3,087				2,926
	Foreign currency changes	(383		)		(1,102		)
	Fair value of Plan Assets, end of year	$	19,981			$	19,577
	Funded Status	$	(12,640	)		$	(10,549	)
	Unrecognized net actuarial loss/(gain)	5,899				5,418
	Unrecognized initial obligation	94				184
	Unrecognized prior service cost	(422		)		138
	Net amount recognized	$	(7,069	)		$	(4,809	)
Schedule of Components of Change Recorded in Accumulated Other Comprehensive Income Related to Defined Benefit Plans, Net of Tax	'
	The components of the change recorded in our accumulated other comprehensive income related to our defined benefit plans, net of tax, are as follows (in thousands):
	Balance, April 2, 2011	$	(265	)
	Obligation at transition	30
	Actuarial loss	(3,701		)
	Prior service cost	(317		)
	Balance as of March 31, 2012	$	(4,253	)
	Obligation at transition	556
	Actuarial loss	(1,237		)
	Prior service cost	(139		)
	Balance as of March 30, 2013	$	(5,073	)
	Obligation at transition	172
	Actuarial loss	(129		)
	Prior service cost	438
	Balance as of March 29, 2014	$	(4,592	)
Schedule of Weighted Average Rates Used to Determine Net Periodic Benefit Costs	'
	The fair values of shares purchased under the Employee Stock Purchase Plan are estimated using the Black-Scholes single option-pricing model with the following weighted average assumptions:
		March 29,			March 30,			March 31,
		2014			2013			2012
	Volatility	22.9	%		24.9	%		26.3	%
	Expected life (months)	6			6			6
	Risk-free interest rate	0.1	%		0.2	%		1	%
	Dividend Yield	0	%		0	%		0	%
	The weighted average rates used to determine the net periodic benefit costs and projected benefit obligations were as follows:
		March 29,			March 30,			March 31,
		2014			2013			2012
	Discount rate	2.02	%		1.97	%		2.4	%
	Rate of increased salary levels	1.57	%		1.42	%		1.5	%
	Expected long-term rate of return on assets	1.94	%		1.92	%		2.1	%
Schedule of Estimated Future Benefit Payments	'
	Estimated future benefit payments during the next five years and in the aggregate for the five fiscal years thereafter, are as follows (in thousands):
	Expected Benefit Payments
	Fiscal Year 2015	$	2,023
	Fiscal Year 2016	$	1,897
	Fiscal Year 2017	$	1,907
	Fiscal Year 2018	$	1,578
	Fiscal Year 2019	$	1,645
	Fiscal Year 2020-2024	$	8,295

SEGMENT_INFORMATION_Tables

SEGMENT INFORMATION (Tables)	12 Months Ended
	Mar. 29, 2014
Segment Reporting [Abstract]	'
Schedule of Revenues from External Customers	'
	Revenues from External Customers:
	(In thousands)	March 29,		March 30,		March 31,
		2014		2013		2012
	Disposable revenues
	Plasma disposables	$	291,895	$	268,900	$	258,061
	Blood center disposables
	Platelet	156,643		169,602		167,946
	Red cell	42,378		49,733		48,034
	Whole blood	190,698		138,436		—
		389,719		357,771		215,980
	Hospital disposables
	Surgical	66,876		73,508		66,619
	OrthoPAT	25,042		30,230		31,186
	Diagnostics	33,302		27,356		23,087
		125,220		131,094		120,892
	Disposables revenue	806,834		757,765		594,933
	Software solutions	70,441		69,952		70,557
	Equipment & other	61,234		64,273		62,354
	Total revenues	$	938,509	$	891,990	$	727,844
Enterprise Wide Disclosures about Product and Services	'
	Enterprise Wide Disclosures About Product and Services
	Year Ended (in thousands)
	March 29, 2014	United		Other		Total		Japan		Other		Total		Total
		States		North		North				Asia		Europe		Consolidated
				America		America
	Net revenues	$	500,719	$	9,557	$	510,276	$	108,679	$	94,762	$	224,792	$	938,509
	Total Assets	$	810,409	$	225,998	$	1,036,407	$	53,207	$	53,055	$	371,509	$	1,514,178
	Long-Lived Assets	$	519,396	$	211,624	$	731,020	$	11,522	$	17,269	$	131,391	$	891,202
	March 30, 2013	United		Other		Total		Japan		Other		Total		Total
		States		North		North				Asia		Europe		Consolidated
				America		America
	Net revenues	$	454,874	$	6,851	$	461,725	$	120,726	$	84,860	$	224,679	$	891,990
	Total Assets	$	830,754	$	225,849	$	1,056,603	$	44,189	$	41,037	$	320,088	$	1,461,917
	Long-Lived Assets	$	503,606	$	209,439	$	713,045	$	12,977	$	8,076	$	117,717	$	851,815
	March 31, 2012	United		Other		Total		Japan		Other		Total		Total
		States		North		North				Asia		Europe		Consolidated
				America		America
	Net revenues	$	352,160	$	512	$	352,672	$	124,381	$	67,223	$	183,568	$	727,844
	Total Assets	$	634,171	$	15,365	$	649,536	$	50,509	$	27,353	$	183,737	$	911,135
	Long-Lived Assets	$	305,370	$	12,796	$	318,166	$	13,128	$	3,961	$	38,009	$	373,264

RESTRUCTURING_Tables

RESTRUCTURING (Tables)	12 Months Ended
	Mar. 29, 2014													Mar. 30, 2013
Restructuring and Related Activities [Abstract]	'													'
Schedule of Restructuring Reserve by Type of Cost	'													'
	The following summarizes the restructuring activity for the fiscal year ended March 29, 2014, March 30, 2013, and March 31, 2012, respectively:													Transformation Costs in the current year are associated with our VCC initiatives as well as completion of the integration of the whole blood acquisition.
	(In thousands)	Balance at March 30, 2013		Cost		Payments			Less Non-Cash Adjustments			Restructuring Accrual Balance at March 29, 2014		Transformation costs
				Incurred										(in thousands)	March 29, 2014		March 30, 2013		March 31, 2012
	Severance and other employee costs	$	3,089	$	31,492	$	(11,673	)	$	—		$	22,908	Integration and other costs	$	30,701	$	60,878	$	11,206
	Facility related costs	173		14,254		(13,699		)	—			728		Accelerated depreciation	4,203		687		677
	Accelerated depreciation	—		2,390		—			(2,390		)	—		Asset disposal	796		—		—
	Asset write-down	—		915		—			(915		)	—		Total	$	35,700	$	61,565	$	11,883
		$	3,262	$	49,051	$	(25,372	)	$	(3,305	)	$	23,636
														Restructuring costs
														(in thousands)	March 29, 2014		March 30, 2013		March 31, 2012
														Severance and other employee costs	$	31,492	$	6,214	$	4,112
	(In thousands)	Balance at March 31, 2012		Cost		Payments			Less Non-Cash Adjustments			Restructuring Accrual Balance at March 30, 2013		Other costs	14,254		431		1,746
				Incurred
	Severance and other employee costs	$	1,461	$	6,214	$	(4,586	)	$	—		$	3,089	Accelerated depreciation	2,390		—		—
	Facility related costs	533		431		(791		)	—			173		Asset disposal	915		4,247		—
	Asset write down	—		4,247		—			(4,247		)	—		Total	$	49,051	$	10,892	$	5,858
		$	1,994	$	10,892	$	(5,377	)	$	(4,247	)	$	3,262
														Total restructuring and transformation	$	84,751	$	72,457	$	17,741
	(In thousands)	Balance at April 2, 2011		Cost		Payments			Less Non-Cash Adjustments			Restructuring Accrual Balance at March 31, 2012
				Incurred
	Severance and other employee costs	$	2,782	$	4,112	$	(5,433	)	$	—		$	1,461
	Facility related costs	889		1,746		(2,102		)	—			533
		$	3,671	$	5,858	$	(7,535	)	$	—		$	1,994

SUMMARY_OF_QUARTERLY_DATA_UNAU1

SUMMARY OF QUARTERLY DATA (UNAUDITED) (Tables)	12 Months Ended
	Mar. 29, 2014
Quarterly Financial Data [Abstract]	'
Schedule of Quarterly Data	'
	(In thousands)	Three months ended
	Fiscal 2014	June 29,			September 28,		December 28,		March 29,
		2013			2013		2013		2014
	Net revenues	$	219,543		$	235,755	$	242,120	$	241,091
	Gross profit	$	111,412		$	119,884	$	121,629	$	115,440
	Operating (loss) income	$	(6,608	)	$	23,430	$	17,860	$	12,645
	Net (loss) income	$	(7,874	)	$	16,548	$	16,290	$	10,184
	Per share data:
	Net (loss) Income:
	Basic	$	(0.15	)	$	0.32	$	0.31	$	0.2
	Diluted	$	(0.15	)	$	0.32	$	0.31	$	0.19
		Three months ended
	Fiscal 2013	June 30,			September 29,		December 29,		March 30,
		2012			2012		2012		2013
	Net revenues	$	176,475		$	218,178	$	247,395	$	249,942
	Gross profit	$	90,113		$	101,762	$	113,115	$	123,141
	Operating income	$	13,079		$	9,901	$	15,747	$	17,710
	Net income	$	9,787		$	6,547	$	9,904	$	12,562
	Per share data:
	Net Income:
	Basic	$	0.19		$	0.13	$	0.19	$	0.24
	Diluted	$	0.19		$	0.13	$	0.19	$	0.24

ACCUMULATED_OTHER_COMPREHENSIV1

ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)	12 Months Ended
	Mar. 29, 2014
Stockholders' Equity Note [Abstract]	'
Schedule of Accumulated Other Comprehensive Income (Loss)	'
	The following is a roll-forward of the components of Accumulated Other Comprehensive Income, net of tax, for the years ended March 29, 2014 and March 30, 2013:
	(In thousands)	Foreign currency			Defined benefit plans			Net Unrealized Gain/loss on Derivatives			Total
	Balance as of March 31, 2012	$	8,838		$	(4,253	)	$	4,525		$	9,110
	Other comprehensive (loss)/income before reclassifications	(4,705		)	(1,002		)	4,594			(1,113		)
	Amounts reclassified from Accumulated Other Comprehensive Income	—			182			(2,746		)	(2,564		)
	Net current period other comprehensive (loss)/income	(4,705		)	(820		)	1,848			(3,677		)
	Balance as of March 30, 2013	$	4,133		$	(5,073	)	$	6,373		$	5,433
	Other comprehensive (loss)/income before reclassifications	(935		)	223			5,001			4,547
	Amounts reclassified from Accumulated Other Comprehensive Income	—			258			(8,570		)	(8,570		)
	Net current period other comprehensive (loss)/income	(935		)	481			(3,569		)	(4,023		)
	Balance as of March 29, 2014	$	3,198		$	(4,592	)	$	2,804		$	1,410
Reclassification out of Accumulated Other Comprehensive Income	'
	The details about the amount reclassified from Accumulated Other Comprehensive Income for the years ended March 29, 2014 and March 30, 2013 are as follows:
	(In thousands)	Amounts Reclassified from Other Comprehensive Income						Affected Line in the
								Statement of Income
	Derivative instruments reclassified to income statement	Year ended March 29, 2014			Year ended March 30, 2013
	Realized net gain on derivatives	$	8,960		$	4,403		Revenue, cost of goods sold, other income
	Income tax effect	(390		)	(1,657		)	Provision for income taxes
	Net of taxes	$	8,570		$	2,746
	Pension items reclassified to income statement
	Realized net loss on pension assets	$	317		$	230		Other income
	Income tax effect	(59		)	(48		)	Provision for income taxes
	Net of taxes	$	258		$	182

DESCRIPTION_OF_THE_BUSINESS_AN1

DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION (Details)	0 Months Ended
	Nov. 30, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Stock split in form of dividend, conversion ratio	2

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Details) (USD $)	12 Months Ended
	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Summary of Significant Accounting Pronouncements [Line Items]	'	'	'
Term of each fiscal year	'1 year	'1 year	'1 year
Term of each fiscal quarter	'91 days	'91 days	'91 days
Cash and cash equivalents maximum maturity period	'3 months	'	'
Goodwill impairment	$0	$0	$0
Intangible asset impairment	0	0	0
Other Liabilities	'	'	'
VAT liabilities	7,114,000	5,121,000	'
Forward contracts	1,255,000	1,786,000	'
Deferred revenue	24,777,000	23,737,000	'
All other	26,564,000	26,707,000	'
Other liabilities	59,710,000	57,351,000	'
Advertising expense	3,600,000	4,600,000	4,500,000
Foreign currency losses	500,000	800,000	400,000
Building	'	'	'
Summary of Significant Accounting Pronouncements [Line Items]	'	'	'
Property, plant and equipment, useful life	'30 years	'	'
Sales [Member] | Customer Concentration Risk [Member]	'	'	'
Other Liabilities	'	'	'
Concentration risk, number of customers	0	'	'
Japanese Red Cross Society [Member] | Sales [Member] | Customer Concentration Risk [Member]	'	'	'
Other Liabilities	'	'	'
Concentration risk, number of customers	'	1	1
Credit risk, accounts receivable	'	$90,100,000	$99,500,000
Japanese Red Cross Society [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]	'	'	'
Other Liabilities	'	'	'
Concentration risk (as a percent)	10.70%	9.00%	15.30%
Minimum | Building improvements	'	'	'
Summary of Significant Accounting Pronouncements [Line Items]	'	'	'
Property, plant and equipment, useful life	'5 years	'	'
Minimum | Plant equipment and machinery	'	'	'
Summary of Significant Accounting Pronouncements [Line Items]	'	'	'
Property, plant and equipment, useful life	'3 years	'	'
Minimum | Office equipment and information technology	'	'	'
Summary of Significant Accounting Pronouncements [Line Items]	'	'	'
Property, plant and equipment, useful life	'3 years	'	'
Minimum | Haemonetics equipment	'	'	'
Summary of Significant Accounting Pronouncements [Line Items]	'	'	'
Property, plant and equipment, useful life	'3 years	'	'
Maximum | Building improvements	'	'	'
Summary of Significant Accounting Pronouncements [Line Items]	'	'	'
Property, plant and equipment, useful life	'20 years	'	'
Maximum | Plant equipment and machinery	'	'	'
Summary of Significant Accounting Pronouncements [Line Items]	'	'	'
Property, plant and equipment, useful life	'15 years	'	'
Maximum | Office equipment and information technology	'	'	'
Summary of Significant Accounting Pronouncements [Line Items]	'	'	'
Property, plant and equipment, useful life	'10 years	'	'
Maximum | Haemonetics equipment	'	'	'
Summary of Significant Accounting Pronouncements [Line Items]	'	'	'
Property, plant and equipment, useful life	'7 years	'	'

ACQUISITIONS_Details

ACQUISITIONS (Details) (USD $)

3 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Mar. 29, 2014

Dec. 28, 2013

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Dec. 29, 2012

Sep. 29, 2012

Jun. 30, 2012

Mar. 29, 2014

Mar. 30, 2013

Mar. 31, 2012

Mar. 29, 2014

Apr. 30, 2013

Mar. 29, 2014

Mar. 29, 2014

Mar. 29, 2014

Mar. 29, 2014

Mar. 30, 2013

Mar. 29, 2014

Mar. 29, 2014

Mar. 30, 2013

Aug. 01, 2012

Mar. 30, 2013

Mar. 30, 2013

Mar. 29, 2014

Mar. 30, 2013

Aug. 01, 2012

Hemerus Medical, LLC [Member]

Hemerus Medical, LLC [Member]

Hemerus Medical, LLC [Member]

Hemerus Medical, LLC [Member]

Hemerus Medical, LLC [Member]

Hemerus Medical, LLC [Member]

Hemerus Medical, LLC [Member]

Hemerus Medical, LLC [Member]

Pall Corporation [Member]

Pall Corporation [Member]

Pall Corporation [Member]

Pall Corporation [Member]

Pall Corporation [Member]

Pall Corporation [Member]

Pall Corporation [Member]

Pall Corporation [Member]

Acquired technology

Trade names

Customer relationship

FDA Approval of SOLX [Member]

FDA Approval of SOLX [Member]

Future Sales of SOLX [Member]

Acquired technology

Customer relationship

Acquired Technology and Customer Relationships

Acquired Technology and Customer Relationships

Replication and Delivery of Certain Manufacturing Assets [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consideration paid

'

'

'

'

'

'

'

'

'

'

'

'

$24,100,000

'

'

'

'

'

'

'

'

$535,200,000

'

'

'

'

'

Contingent consideration, maximum

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,000,000

'

14,000,000

'

'

'

'

'

'

'

15,000,000

Allocation of purchase price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Inventories

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

49,917,000

'

'

'

'

'

'

Property, plant and equipment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

85,984,000

'

'

'

'

'

'

Intangible assets

'

'

'

'

'

'

'

'

'

'

'

'

'

22,800,000

1,900,000

600,000

'

'

'

'

188,500,000

'

61,000,000

127,500,000

'

'

'

Other assets/liabilities, net

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-6,166,000

'

'

'

'

'

'

Goodwill

336,768,000

'

'

'

330,474,000

'

'

'

336,768,000

330,474,000

115,058,000

6,425,000

'

'

'

'

'

'

'

'

216,940,000

'

'

'

'

'

'

Fair value of net assets acquired

'

'

'

'

'

'

'

'

'

'

'

31,725,000

'

'

'

'

'

'

'

'

535,175,000

'

'

'

'

'

'

Amortization expense

'

'

'

'

'

'

'

'

29,200,000

22,100,000

11,400,000

2,300,000

'

'

'

'

'

'

'

'

'

'

'

'

15,700,000

10,500,000

'

Consideration transfered in shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

Contingent consideration amount owed

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,645,000

7,600,000

'

'

'

'

'

'

'

'

'

Long-term debt

440,287,000

'

'

'

'

'

'

'

440,287,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Useful life

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'12 years

'12 years

'

Net revenues

241,091,000

242,120,000

235,755,000

219,543,000

249,942,000

247,395,000

218,178,000

176,475,000

938,509,000

891,990,000

727,844,000

'

'

'

'

'

'

'

'

190,698,000

138,400,000

'

'

'

'

'

'

Net Sales

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

963,923,000

'

'

'

'

'

'

Net Income

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$56,540,000

'

'

'

'

'

'

Basic EPS

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,100

'

'

'

'

'

'

Diluted EPS

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,080

'

'

'

'

'

'

PRODUCT_WARRANTIES_Schedule_of

PRODUCT WARRANTIES (Schedule of Product Warranty Liability) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013
Product Warranties Disclosures [Abstract]	'	'
General warranty period on parts and labor	'1 year	'
Product Warranties [Roll Forward]	'	'
Warranty accrual as of the beginning of the year	$673	$796
Warranty provision	1,340	1,180
Warranty spending	-1,423	-1,303
Warranty accrual as of the end of the year	$590	$673

INVENTORIES_Schedule_of_Invent

INVENTORIES (Schedule of Inventories) (Details) (USD $)	Mar. 29, 2014	Mar. 30, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$72,508	$70,716
Work-in-process	7,383	7,829
Finished goods	117,770	105,239
Total Inventory	$197,661	$183,784

GOODWILL_AND_INTANGIBLE_ASSETS2

GOODWILL AND INTANGIBLE ASSETS Schedule of Goodwill (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013
Goodwill [Roll Forward]	'	'
Goodwill, carrying amount	$330,474	$115,058
Acquisitions	6,425	216,940
Effect of change in foreign currency exchange rates	-131	-1,524
Goodwill, carrying amount	$336,768	$330,474

GOODWILL_AND_INTANGIBLE_ASSETS3

GOODWILL AND INTANGIBLE ASSETS Intangible Assets (Details) (USD $)	12 Months Ended
	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Intangible Assets	'	'	'
Gross Carrying Amount	$372,853,000	$336,781,000	'
Accumulated Amortization	101,694,000	72,393,000	'
Net	271,159,000	264,388,000	'
Weighted average useful life	'11 years	'11 years	'
Aggregate amortization expense	29,200,000	22,100,000	11,400,000
Future amortization expense, year one	29,162,000	'	'
Future amortization expense, year two	28,695,000	'	'
Future amortization expense, year three	28,611,000	'	'
Future amortization expense, year four	27,766,000	'	'
Future amortization expense, year five	25,957,000	'	'
Patents	'	'	'
Intangible Assets	'	'	'
Gross Carrying Amount	9,543,000	8,706,000	'
Accumulated Amortization	7,039,000	6,397,000	'
Net	2,504,000	2,309,000	'
Weighted average useful life	'9 years	'10 years	'
Capitalized software	'	'	'
Intangible Assets	'	'	'
Gross Carrying Amount	31,750,000	25,741,000	'
Accumulated Amortization	2,414,000	1,364,000	'
Net	29,336,000	24,377,000	'
Weighted average useful life	'4 years	'6 years	'
Other developed technology	'	'	'
Intangible Assets	'	'	'
Gross Carrying Amount	123,525,000	100,586,000	'
Accumulated Amortization	36,632,000	25,812,000	'
Net	86,893,000	74,774,000	'
Weighted average useful life	'12 years	'12 years	'
Customer contracts and related relationships	'	'	'
Intangible Assets	'	'	'
Gross Carrying Amount	200,694,000	196,365,000	'
Accumulated Amortization	52,741,000	36,552,000	'
Net	147,953,000	159,813,000	'
Weighted average useful life	'12 years	'12 years	'
Trade names	'	'	'
Intangible Assets	'	'	'
Gross Carrying Amount	7,341,000	5,383,000	'
Accumulated Amortization	2,868,000	2,268,000	'
Net	$4,473,000	$3,115,000	'
Weighted average useful life	'11 years	'10 years	'
Minimum	'	'	'
Intangible Assets	'	'	'
Weighted average useful life	'2 years	'	'
Maximum	'	'	'
Intangible Assets	'	'	'
Weighted average useful life	'19 years	'	'

DERIVATIVES_AND_FAIR_VALUE_MEA2

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Narrative) (Details) (USD $)

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Mar. 29, 2014

Mar. 30, 2013

Mar. 31, 2012

Mar. 29, 2014

Dec. 29, 2012

Mar. 29, 2014

Mar. 29, 2014

Mar. 30, 2013

Mar. 29, 2014

Mar. 29, 2014

Mar. 30, 2013

Mar. 31, 2012

Dec. 29, 2012

Mar. 29, 2014

Mar. 30, 2013

Mar. 29, 2014

Mar. 30, 2013

Mar. 31, 2012

Mar. 29, 2014

Mar. 30, 2013

Mar. 29, 2014

Mar. 30, 2013

Mar. 29, 2014

Credit Agreement

Credit Agreement

Foreign Exchange Contract

Designated as Hedging Instrument

Designated as Hedging Instrument

Designated as Hedging Instrument

Designated as Hedging Instrument

Designated as Hedging Instrument

Designated as Hedging Instrument

Designated as Hedging Instrument

Not Designated as Hedging Instrument

Not Designated as Hedging Instrument

Net Revenues Cost Of Goods Sold And Selling General And Administrative Expense [Member]

Net Revenues Cost Of Goods Sold And Selling General And Administrative Expense [Member]

Net Revenues Cost Of Goods Sold And Selling General And Administrative Expense [Member]

Other income (expense), net

Other income (expense), net

Hemerus Medical, LLC [Member]

Hemerus Medical, LLC [Member]

Hemerus Medical, LLC [Member]

Foreign Exchange Contract

Foreign Exchange Contract

Interest Rate Swap

Cash Flow Hedging

Cash Flow Hedging

Cash Flow Hedging

Interest Rate Swap

Foreign Exchange Contract

Foreign Exchange Contract

Designated as Hedging Instrument

Designated as Hedging Instrument

Designated as Hedging Instrument

Designated as Hedging Instrument

Designated as Hedging Instrument

FDA Approval of SOLX [Member]

FDA Approval of SOLX [Member]

FDA Approval of SOLX [Member]

Foreign Exchange Contract

Foreign Exchange Contract

Foreign Exchange Contract

Interest Rate Swap

Interest Rate Swap

Fair Value Adjustment

Derivative [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Adjusted libor rounding percentage

'

'

'

'

0.63%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of sales generated outside the US

'

'

'

'

'

46.60%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maturity period for foreign currency contracts (in years)

'

'

'

'

'

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Designated foreign currency hedge contracts outstanding

'

'

'

'

'

'

$157,900,000

$133,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gain (loss) on cash flow hedge in earnings

'

'

'

'

'

'

'

'

'

8,600,000

2,700,000

-3,200,000

'

'

'

'

'

'

'

'

'

'

'

Amount of Loss Recognized in OCI (Effective Portion)

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

3,712,000

5,104,000

3,140,000

1,289,000

800,000

'

'

'

Deferred tax benefit

-202,000

589,000

5,878,000

'

'

'

-100,000

'

-500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non-designated foreign currency hedge contracts outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

72,900,000

65,600,000

'

'

'

'

'

'

'

'

Long-term debt

440,287,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Variable rate basis

'LIBOR

'

'

'1-month USD-LIBOR-BBA

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration income

-45,000

0

2,154,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative, Fixed Interest Rate

'

'

'

'

'

'

'

'

'

'

'

'

0.68%

'

'

'

'

'

'

'

'

'

'

Derivative, Notional Amount

'

'

'

'

'

'

'

'

'

'

'

'

250,000,000

'

'

'

'

'

'

'

'

'

'

Contingent consideration amount owed

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$7,645,000

$7,600,000

$45,000

DERIVATIVES_AND_FAIR_VALUE_MEA3

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Designated as Hedging Instrument | Foreign Exchange Contract | Net revenues, COGS, and SG&A	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Amount of Loss Recognized in OCI (Effective Portion)	$3,712	$5,104	$3,140
Amount of Loss Reclassifiedfrom OCI into Earnings (Effective Portion)	8,570	'	'
Designated as Hedging Instrument | Foreign Exchange Contract | Interest income (expense), net	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Amount Excluded from Effectiveness Testing	-104	'	'
Designated as Hedging Instrument | Interest Rate Swap	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Amount Excluded from Effectiveness Testing	0	'	'
Designated as Hedging Instrument | Interest Rate Swap | Other income (expense), net	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Amount of Loss Recognized in OCI (Effective Portion)	1,289	800	'
Amount of Loss Reclassifiedfrom OCI into Earnings (Effective Portion)	0	'	'
Not Designated as Hedging Instrument | Foreign Exchange Contract	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Amount of Loss Recognized in OCI (Effective Portion)	0	'	'
Amount of Loss Reclassifiedfrom OCI into Earnings (Effective Portion)	0	'	'
Not Designated as Hedging Instrument | Foreign Exchange Contract | Interest income (expense), net	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Amount Excluded from Effectiveness Testing	($1,359)	'	'

DERIVATIVES_AND_FAIR_VALUE_MEA4

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets) (Details) (USD $)	Mar. 29, 2014	Mar. 30, 2013
In Thousands, unless otherwise specified
Derivative Liabilities:	'	'
Derivative Liabilities	$1,255	$1,786
Designated as Hedging Instrument	'	'
Derivative Assets:	'	'
Derivative Assets	3,824	7,030
Derivative Liabilities:	'	'
Derivative Liabilities	1,255	1,625
Designated as Hedging Instrument | Foreign Exchange Contract | Other Current Assets	'	'
Derivative Assets:	'	'
Derivative Assets	2,574	7,030
Designated as Hedging Instrument | Foreign Exchange Contract | Other Current Liabilities	'	'
Derivative Liabilities:	'	'
Derivative Liabilities	1,255	954
Designated as Hedging Instrument | Interest Rate Swap | Other Current Assets	'	'
Derivative Assets:	'	'
Derivative Assets	1,250	0
Designated as Hedging Instrument | Interest Rate Swap | Other Current Liabilities	'	'
Derivative Liabilities:	'	'
Derivative Liabilities	$0	$671

DERIVATIVES_AND_FAIR_VALUE_MEA5

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis) (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Mar. 29, 2014	Mar. 30, 2013
In Thousands, unless otherwise specified
Assets	'	'
Money market funds	$135,378	$141,120
Foreign currency hedge contracts	2,574	7,030
Interest rate swap	1,250	'
Assets, Fair Value Disclosure, Total	139,202	148,150
Liabilities	'	'
Foreign currency hedge contracts	1,255	954
Other liability	7,645	671
Liabilities, Fair Value Disclosure, Total	8,900	1,625
Quoted Market Prices for Identical Assets (Level 1)	'	'
Assets	'	'
Money market funds	135,378	141,120
Foreign currency hedge contracts	0	0
Interest rate swap	0	'
Assets, Fair Value Disclosure, Total	135,378	141,120
Liabilities	'	'
Foreign currency hedge contracts	0	0
Other liability	0	0
Liabilities, Fair Value Disclosure, Total	0	0
Significant Other Observable Inputs (Level 2)	'	'
Assets	'	'
Money market funds	0	0
Foreign currency hedge contracts	2,574	7,030
Interest rate swap	1,250	'
Assets, Fair Value Disclosure, Total	3,824	7,030
Liabilities	'	'
Foreign currency hedge contracts	1,255	954
Other liability	0	671
Liabilities, Fair Value Disclosure, Total	1,255	1,625
Significant Unobservable Inputs (Level 3)	'	'
Assets	'	'
Money market funds	0	0
Foreign currency hedge contracts	0	0
Interest rate swap	0	'
Assets, Fair Value Disclosure, Total	0	0
Liabilities	'	'
Foreign currency hedge contracts	0	0
Other liability	7,645	0
Liabilities, Fair Value Disclosure, Total	$7,645	$0

NOTES_PAYABLE_AND_LONGTERM_DEB2

NOTES PAYABLE AND LONG-TERM DEBT (Schedule of Notes Payable and Long-Term Debt) (Details) (USD $)	Mar. 29, 2014	Mar. 30, 2013
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'
Long-term debt	$440,287	'
Less current portion	-45,630	-23,150
Long term debt	392,057	456,944
Term loan, net of financing fees	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	435,338	471,016
Real estate mortgage	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	1,906	2,877
Bank loans and other borrowings	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	$443	$6,201

NOTES_PAYABLE_AND_LONGTERM_DEB3

NOTES PAYABLE AND LONG-TERM DEBT (Narrative) (Details) (USD $)

12 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Mar. 29, 2014

Mar. 30, 2013

Mar. 31, 2012

Mar. 29, 2014

Mar. 30, 2013

Aug. 01, 2012

Aug. 01, 2012

Aug. 01, 2012

Mar. 29, 2014

Mar. 30, 2013

Mar. 29, 2014

Aug. 01, 2012

Mar. 29, 2014

Mar. 29, 2014

Mar. 29, 2014

Dec. 29, 2012

Dec. 31, 2000

Mar. 29, 2014

Mar. 30, 2013

Dec. 02, 2000

Term Loan

Term Loan

Term Loan

Term Loan

Term Loan

Term loan, net of financing fees

Term loan, net of financing fees

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Credit Agreement

Credit Agreement

Mortgage Obligation

Mortgage Obligation

Mortgage Obligation

Mortgage Obligation

Minimum

Maximum

Minimum

Maximum

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Face amount of debt

'

'

'

'

'

$437,900,000

'

'

'

'

'

$50,000,000

'

'

'

'

'

'

'

$10,000,000

Term of debt

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'180 months

'

'

Variable rate basis

'LIBOR

'

'

'

'

'

'

'

'

'

'

'

'

'

'1-month USD-LIBOR-BBA

'

'

'

'

'

Adjusted libor rounding percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.63%

'

'

'

'

Basis spread on variable rate

'

'

'

'

'

1.38%

1.13%

1.50%

'

'

'

'

'

'

'

'

'

'

'

'

Effective interest rate

'

'

'

'

'

1.89%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Credit facility outstanding

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

Consolidated total leverage ratio

'

'

'

'

'

'

'

'

'

'

3

'

'

'

'

'

'

'

'

'

Consolidated interest coverage ratio

'

'

'

'

'

'

'

'

'

'

4

'

'

'

'

'

'

'

'

'

Commitment fee

'

'

'

'

'

'

'

'

'

'

0.25%

'

0.18%

0.30%

'

'

'

'

'

'

Expanded borrowing capacity

'

'

'

'

'

'

'

'

'

'

'

'

50,000,000

100,000,000

'

'

'

'

'

'

Expanded borrowing capacity including term loans

'

'

'

'

'

'

'

'

'

'

100,000,000

'

'

'

'

'

'

'

'

'

Prepayments

'

'

'

'

20,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred finance costs

'

'

'

5,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt discount

'

'

'

-2,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest paid

8,942,000

5,910,000

414,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest payable

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term debt

440,287,000

'

'

437,938,000

'

475,000,000

'

'

435,338,000

471,016,000

'

'

'

'

'

'

'

1,906,000

2,900,000

'

Monthly principal and interest payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

Stated percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.41%

Short-term debt

$0

$5,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

NOTES_PAYABLE_AND_LONGTERM_DEB4

NOTES PAYABLE AND LONG-TERM DEBT (Schedule of Notes Payable and Long-Term Debt Maturities) (Details) (USD $)	Mar. 29, 2014	Mar. 29, 2014	Mar. 30, 2013	Mar. 29, 2014	Aug. 01, 2012	Mar. 29, 2014	Mar. 30, 2013
In Thousands, unless otherwise specified		Mortgage Obligation	Mortgage Obligation	Term Loan	Term Loan	Bank loans and other borrowings	Bank loans and other borrowings
Debt Instrument [Line Items]	'	'	'	'	'	'	'
2015	$46,748	$1,055	'	$45,500	'	$193	'
2016	69,261	851	'	68,250	'	160	'
2017	182,071	0	'	182,000	'	71	'
2018	142,207	0	'	142,188	'	19	'
Long-term debt	$440,287	$1,906	$2,900	$437,938	$475,000	$443	$6,201

INCOME_TAXES_Narrative_Details

INCOME TAXES (Narrative) (Details) (USD $)	12 Months Ended
	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011
Income Taxes [Line Items]	'	'	'	'
Foregin source income	$43,260,000	$32,537,000	$48,832,000	'
Valuation allowance	2,400,000	0	0	'
Undistributed foreign earnings of subsidiaries	264,000,000	'	'	'
U.S. federal statutory income tax rate	35.00%	35.00%	35.00%	'
Unrecognized tax benefits	5,604,000	6,930,000	6,885,000	4,669,000
Unrecognized tax benefits that will impact effective tax rate	5,604,000	6,700,000	6,600,000	'
Unrecognized tax benefits, increases from closure of statute of limitations	1,300,000	'	'	'
Unrecognized tax positions possible change in the next twelve months	1,700,000	'	'	'
Accrued interest and penalties	800,000	800,000	'	'
Accrued interest in statements of operations	0	100,000	300,000	'
Internal Revenue Service (IRS) [Member]	'	'	'	'
Income Taxes [Line Items]	'	'	'	'
Foreign income tax provision	400,000	1,600,000	2,200,000	'
Foregin source income	1,300,000	4,500,000	6,200,000	'
Operating loss carry-forwards	3,500,000	'	'	'
Tax credit carry-forwards	3,300,000	'	'	'
Internal Revenue Service (IRS) [Member] | Excess Stock-based Compensation Deduction [Member]	'	'	'	'
Income Taxes [Line Items]	'	'	'	'
Operating loss carry-forwards	0	'	'	'
Tax credit carry-forwards	1,700,000	'	'	'
State and Local Jurisdiction [Member]	'	'	'	'
Income Taxes [Line Items]	'	'	'	'
Operating loss carry-forwards	14,700,000	'	'	'
Tax credit carry-forwards	1,600,000	'	'	'
State and Local Jurisdiction [Member] | Excess Stock-based Compensation Deduction [Member]	'	'	'	'
Income Taxes [Line Items]	'	'	'	'
Operating loss carry-forwards	6,800,000	'	'	'
Tax credit carry-forwards	0	'	'	'
Foreign Tax Authority [Member]	'	'	'	'
Income Taxes [Line Items]	'	'	'	'
Valuation allowance	2,100,000	'	'	'
Operating loss carry-forwards	$400,000	'	'	'

INCOME_TAXES_Schedule_Domestic

INCOME TAXES (Schedule Domestic and Foreign Income Before Provision for Income Tax) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Income Tax Disclosure [Abstract]	'	'	'
Domestic	($6,859)	$17,360	$40,666
Foreign	43,260	32,537	48,832
Income before provision for income taxes	$36,401	$49,897	$89,498

INCOME_TAXES_Schedule_of_Incom

INCOME TAXES (Schedule of Income Tax Provision Components) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Current	'	'	'
Federal	($4,896)	$3,795	$8,505
State	873	1,324	2,275
Foreign	5,478	5,389	5,954
Total current	1,455	10,508	16,734
Deferred	'	'	'
Federal	-1,785	1,644	7,522
State	207	-229	-597
Foreign	1,376	-826	-1,047
Total deferred	-202	589	5,878
Total	$1,253	$11,097	$22,612

INCOME_TAXES_Schedule_of_Net_D

INCOME TAXES (Schedule of Net Deferred Tax Asset) (Details) (USD $)	Mar. 29, 2014	Mar. 30, 2013
In Thousands, unless otherwise specified
Income Tax Disclosure [Abstract]	'	'
Depreciation	($23,658)	($25,186)
Amortization	-18,618	-14,776
Inventory	7,371	7,884
Hedging	321	-162
Accruals, reserves and other	10,368	7,208
Net operating loss carry-forward	1,507	1,877
Stock based compensation	8,757	7,834
Tax credit carry-forward, net	2,660	2,243
Gross deferred taxes	-11,292	-13,078
Less valuation allowance	-3,083	-1,009
Net deferred tax liability	($14,375)	($14,087)

INCOME_TAXES_Schedule_of_Effec

INCOME TAXES (Schedule of Effective Income Tax Rate Reconciliation) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Income Tax Disclosure [Abstract]	'	'	'
Tax at federal statutory rate	$12,739	$17,464	$31,324
Tax at federal statutory rate	35.00%	35.00%	35.00%
Domestic manufacturing deduction	0	-504	-700
Domestic manufacturing deduction	0.00%	-1.00%	-0.80%
Difference between U.S. and foreign tax	-10,846	-5,584	-8,539
Difference between U.S. and foreign tax	-29.80%	-11.20%	-9.50%
State income taxes net of federal benefit	-252	718	1,136
State income taxes net of federal benefit	-0.70%	1.40%	1.30%
Change in uncertain tax positions	-1,678	-580	144
Change in uncertain tax positions	-4.60%	-1.20%	0.20%
Intercompany loan deduction	-2,185	0	0
Intercompany loan deduction	-6.00%	0.00%	0.00%
Non-deductible expenses	1,035	1,178	917
Non-deductible expenses	2.80%	2.40%	1.00%
Research credits	-688	-799	-752
Research credits	-1.90%	-1.60%	-0.90%
Valuation allowance	2,400	0	0
Valuation allowance	6.60%	0.00%	0.00%
Other, net	728	-796	-918
Other, net	2.00%	-1.60%	-1.00%
Total	$1,253	$11,097	$22,612
Income tax provision	3.40%	22.20%	25.30%

INCOME_TAXES_Summary_of_Gross_

INCOME TAXES (Summary of Gross Unrecognized Tax Benefits) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]	'	'	'
Beginning Balance	$6,930	$6,885	$4,669
Additions based upon positions related to the current year	0	1,192	1,124
Additions for tax positions of prior years	990	18	1,216
Reductions of tax positions	0	0	-124
Settlements with taxing authorities	0	-80	0
Closure of statute of limitations	-2,316	-1,085	0
Ending Balance	$5,604	$6,930	$6,885

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Schedule of Approximate Future Basic Rental Commitments under Operating Leases) (Details) (USD $)	Mar. 29, 2014
In Thousands, unless otherwise specified
Commitments and Contingencies Disclosure [Abstract]	'
2015	$6,991
2017	5,141
2018	3,357
2017	2,627
2019 and thereafter	4,812
Operating Leases, Future Minimum Payments Due	$22,928

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) (USD $)	3 Months Ended	12 Months Ended			1 Months Ended
In Millions, unless otherwise specified	Mar. 29, 2014	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012	Feb. 28, 2014	Feb. 28, 2014
					Employment Contracts [Member]	Solidarity Agreements [Member]
					Employees	Employees
Loss Contingencies [Line Items]	'	'	'	'	'	'
Rent expense	'	$7.70	$7	$6.10	'	'
Number of employees making claims	'	'	'	'	72	68
Damages sought	$3.50	'	'	'	'	'

CAPITAL_STOCK_Narrative_Detail

CAPITAL STOCK (Narrative) (Details) (USD $)	12 Months Ended
	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock-based compensation expense recognized	$13,100,000	$11,000,000	$9,300,000
Income tax benefit recognized related to stock-based compensation	4,300,000	3,500,000	2,700,000
Excess tax benefit on exercise of stock options	2,395,000	4,101,000	1,433,000
Stock Options [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Options outstanding (in shares)	3,834,372	4,069,758	'
Total intrinsic value of options exercised	11,700,000	20,900,000	8,500,000
Total unrecognized compensation cost related to non vested awards	11,200,000	'	'
Total unrecognized compensation cost related to non vested stock options, weighted average period of recognition (in years)	'2 years 6 months 18 days	'	'
Weighted average grant date fair value of options granted (in dollars per share)	$10.15	$9.76	$8.16
Annual unvested stock option forfeiture rate (as a percent)	8.00%	8.00%	'
Expected life (years)	'4 years 10 months 24 days	'4 years 10 months 24 days	'4 years 10 months 24 days
Risk-free interest rate	1.30%	0.80%	0.10%
Volatility	24.80%	26.40%	27.50%
Dividend Yield	0.00%	0.00%	0.00%
Restricted Stock [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Total unrecognized compensation cost related to non vested awards	0	'	'
Performance Shares [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Maximum number of shares available for award (in shares)	848,808	'	'
Weighted Average Market Value at Grant Date (in dollars per share), Awarded	$85	'	'
Equity instruments other than options outstanding (in shares)	282,936	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Performance Shares Threshold	$50	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Performance Shares Received Below Threshold	0	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Performance Shares Target Multiplier	3	'	'
Share Price	$37.42	'	'
Expected life (years)	'3 years 8 months 12 days	'	'
Risk-free interest rate	0.90%	'	'
Volatility	20.00%	'	'
Dividend Yield	0.00%	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Total Fair Value	11,200,000	'	'
Options to Purchase [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Options outstanding (in shares)	3,778,622	'	'
Restricted Stock Units (RSUs) [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Weighted Average Market Value at Grant Date (in dollars per share), Awarded	$32.77	'	'
Equity instruments other than options outstanding (in shares)	599,673	356,419	'
Total unrecognized compensation cost related to non vested awards	$14,900,000	'	'
Total unrecognized compensation cost related to non vested stock options, weighted average period of recognition (in years)	'2 years 9 months	'	'
Long-term Incentive Plan 2000 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Maximum number of shares available for award (in shares)	7,000,000	'	'
Long-term Incentive Plan 2000 [Member] | Stock Options [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Maximum number of shares available for grant (in shares)	0	'	'
Options outstanding (in shares)	55,750	'	'
Incentive Compensation Plan 2005 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Number of members on board of directors (in board members)	3	'	'
Maximum number of shares available for award (in shares)	15,024,920	'	'
Maximum number of shares available for grant (in shares)	1,794,981	'	'
Number of equity instruments other than options counted against maximum number of award shares for every share granted (in shares)	3.26	'	'
Maximum number of years from grant date that options expire (in years)	'7 years	'	'
Incentive Compensation Plan 2005 [Member] | Stock Options [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Maximum number of shares available for award (in shares)	500,000	'	'
Number of options counted against maximum number of award shares for every share option issued (in shares)	1	'	'
Incentive Compensation Plan 2005 [Member] | Restricted Stock [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Period in which awards become exercisable for employees (in years)	'4 years	'	'
Period after grant that awards become exercisable for non-employee directors (in years)	'1 year	'	'
Equity instruments other than options outstanding (in shares)	316,737	'	'
Employee Stock Purchase Plan [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Maximum number of shares available for award (in shares)	1,400,000	'	'
Number of purchase periods (in purchase periods)	2	'	'
Percentage of purchase price for shares of common stock at fair market value (as a percent)	85.00%	'	'
Weighted average grant date fair value of the six-month option inherent in the Purchase Plan (in dollars per share)	$8.25	$8.50	$7.10
Expected life (years)	'6 months	'6 months	'6 months
Risk-free interest rate	0.10%	0.20%	1.00%
Volatility	22.90%	24.90%	26.30%
Dividend Yield	0.00%	0.00%	0.00%
Employee Stock Purchase Plan [Member] | Minimum	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Percentage of shares purchased through payroll deductions (as a percent)	2.00%	'	'
Employee Stock Purchase Plan [Member] | Maximum	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Percentage of shares purchased through payroll deductions (as a percent)	15.00%	'	'

CAPITAL_STOCK_Schedule_of_Summ

CAPITAL STOCK (Schedule of Summary of Stock Option Activity) (Details) (Stock Options [Member], USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013
Stock Options [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'	'
Options Outstanding, (in shares), Beginning Balance	4,069,758	'
Options Outstanding, (in shares), Granted	758,705	'
Options Outstanding, (in shares), Exercised	-736,640	'
Options Outstanding, (in shares), Forfeited	-257,451	'
Options Outstanding, (in shares), Ending Balance	3,834,372	4,069,758
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]	'	'
Weighted Average Exercise Price (in dollars per share), Beginning Balance	$29.85	'
Weighted Average Exercise Price (in dollars per share), Granted	$42	'
Weighted Average Exercise Price (in dollars per share), Exercised	$25.04	'
Weighted Average Exercise Price (in dollars per share), Forfeited	$33.61	'
Weighted Average Exercise Price (in dollars per share), Ending Balance	$32.93	$29.85
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]	'	'
Weighted Average Remaining Life, Beginning Balance	'4 years 2 months 9 days	'4 years 3 months 22 days
Aggregate Intrinsic Value, Beginning Balance	$48,061	'
Weighted Average Remaining Life, Ending Balance	'4 years 2 months 9 days	'4 years 3 months 22 days
Aggregate Intrinsic Value, Ending Balance	9,436	48,061
Options Outstanding, (in shares), Exercisable and End of Period	2,147,092	'
Weighted Average Exercise Price (in dollars per share), Exercisable at End of Period	$28.95	'
Weighted Average Remaining Life, Exercisable at End of Period	'2 years 11 months 23 days	'
Aggregate Intrinsic Value, Exercisable at End of Period	8,446	'
Options Outstanding, (in shares), Vested and Expected to Vest at End of Period	3,636,128	'
Weighted Average Exercise Price (in dollars per share), Vested or Expected to Vest at End of Period	$32.58	'
Weighted Average Remaining Life, Vested or Expected to Vest at End of Period	'4 years 1 month 2 days	'
Aggregate Intrinsic Value, Vested and Expected to Vest at End of Period	$9,379	'

CAPITAL_STOCK_Schedule_of_Assu

CAPITAL STOCK (Schedule of Assumptions Utilized for Estimating Fair Value of Option Grants) (Details) (Stock Options [Member])	12 Months Ended
	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Stock Options [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Volatility	24.80%	26.40%	27.50%
Expected life (years)	'4 years 10 months 24 days	'4 years 10 months 24 days	'4 years 10 months 24 days
Risk-free interest rate	1.30%	0.80%	0.10%
Dividend Yield	0.00%	0.00%	0.00%

CAPITAL_STOCK_Schedule_of_Assu1

CAPITAL STOCK (Schedule of Assumptions Used to Estimate Fair Value of Shares Purchased Under ESPP) (Details) (Employee Stock Purchase Plan [Member])	12 Months Ended
	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Employee Stock Purchase Plan [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Volatility	22.90%	24.90%	26.30%
Expected life (months)	'6 months	'6 months	'6 months
Risk-free interest rate	0.10%	0.20%	1.00%
Dividend Yield	0.00%	0.00%	0.00%

CAPITAL_STOCK_Schedule_of_Summ1

CAPITAL STOCK (Schedule of Summary of Restricted Stock Units Activity) (Details) (Restricted Stock Units (RSUs) [Member], USD $)	12 Months Ended
	Mar. 29, 2014
Restricted Stock Units (RSUs) [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]	'
Shares, Beginning Balance	356,419
Shares, Awarded	462,769
Shares, Released	-119,345
Shares, Forfeited	-100,170
Shares, Ending Balance	599,673
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]	'
Weighted Average Market Value at Grant Date (in dollars per share), Beginning Balance	$34.06
Weighted Average Market Value at Grant Date (in dollars per share), Awarded	$32.77
Weighted Average Market Value at Grant Date (in dollars per share), Released	$32.41
Weighted Average Market Value at Grant Date (in dollars per share), Forfeited	$35.79
Weighted Average Market Value at Grant Date (in dollars per share), Ending Balance	$37.70

EARNINGS_PER_SHARE_EPS_Schedul

EARNINGS PER SHARE ("EPS") (Schedule of Earnings Per Share Reconciliation) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 29, 2014	Dec. 28, 2013	Sep. 28, 2013	Jun. 29, 2013	Mar. 30, 2013	Dec. 29, 2012	Sep. 29, 2012	Jun. 30, 2012	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Basic EPS	'	'	'	'	'	'	'	'	'	'	'
Net income	$10,184	$16,290	$16,548	($7,874)	$12,562	$9,904	$6,547	$9,787	$35,148	$38,800	$66,886
Basic weighted average shares (in shares)	'	'	'	'	'	'	'	'	51,611,000	51,349,000	50,727,000
Basic income per share (in dollars per share)	$0.20	$0.31	$0.32	($0.15)	$0.24	$0.19	$0.13	$0.19	$0.68	$0.76	$1.32
Diluted EPS	'	'	'	'	'	'	'	'	'	'	'
Net income	$10,184	$16,290	$16,548	($7,874)	$12,562	$9,904	$6,547	$9,787	$35,148	$38,800	$66,886
Basic weighted average shares (in shares)	'	'	'	'	'	'	'	'	51,611,000	51,349,000	50,727,000
Net effect of common stock equivalents (in shares)	'	'	'	'	'	'	'	'	766,000	910,000	863,000
Diluted weighted average shares (in shares)	'	'	'	'	'	'	'	'	52,377,000	52,259,000	51,590,000
Diluted income per share (in dollars per share)	$0.19	$0.31	$0.32	($0.15)	$0.24	$0.19	$0.13	$0.19	$0.67	$0.74	$1.30
Stock options excluded from computation of weighted average shares outstanding (in shares)	'	'	'	'	'	'	'	'	1,100,000	500,000	1,400,000

PROPERTY_PLANT_AND_EQUIPMENT_D

PROPERTY, PLANT AND EQUIPMENT (Details) (USD $)	3 Months Ended								12 Months Ended
	Mar. 29, 2014	Dec. 28, 2013	Sep. 28, 2013	Jun. 29, 2013	Mar. 30, 2013	Dec. 29, 2012	Sep. 29, 2012	Jun. 30, 2012	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Property, Plant and Equipment [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total	$701,855,000	'	'	'	$632,720,000	'	'	'	$701,855,000	$632,720,000	'
Less: accumulated depreciation and amortization	430,418,000	'	'	'	375,767,000	'	'	'	430,418,000	375,767,000	'
Net property, plant and equipment	271,437,000	'	'	'	256,953,000	'	'	'	271,437,000	256,953,000	'
Depreciation expense	'	'	'	'	'	'	'	'	52,600,000	43,400,000	38,600,000
Net income	10,184,000	16,290,000	16,548,000	-7,874,000	12,562,000	9,904,000	6,547,000	9,787,000	35,148,000	38,800,000	66,886,000
Basic income per share (in dollars per share)	$0.20	$0.31	$0.32	($0.15)	$0.24	$0.19	$0.13	$0.19	$0.68	$0.76	$1.32
Land	'	'	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total	7,168,000	'	'	'	4,216,000	'	'	'	7,168,000	4,216,000	'
Building and building improvements	'	'	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total	83,439,000	'	'	'	78,682,000	'	'	'	83,439,000	78,682,000	'
Plant equipment and machinery	'	'	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total	236,539,000	'	'	'	205,698,000	'	'	'	236,539,000	205,698,000	'
Office equipment and information technology	'	'	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total	111,925,000	'	'	'	103,235,000	'	'	'	111,925,000	103,235,000	'
Haemonetics equipment	'	'	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total	262,784,000	'	'	'	240,889,000	'	'	'	262,784,000	240,889,000	'
Service Life [Member]	'	'	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Depreciation expense	'	'	'	'	'	'	'	'	'	-4,500,000	'
Net income	'	'	'	'	'	'	'	'	'	$3,300,000	'
Basic income per share (in dollars per share)	'	'	'	'	'	'	'	'	'	$0.09	'

RETIREMENT_PLANS_Narrative_Det

RETIREMENT PLANS (Narrative) (Details) (USD $)

3 Months Ended

12 Months Ended

12 Months Ended

Mar. 29, 2014

Mar. 29, 2014

Mar. 30, 2013

Mar. 31, 2012

Mar. 29, 2014

Mar. 30, 2013

Mar. 31, 2012

Mar. 29, 2014

Mar. 30, 2013

Mar. 31, 2012

Mar. 29, 2014

Mar. 30, 2013

Savings Plus Plan [Member]

Savings Plus Plan [Member]

Savings Plus Plan [Member]

Defined Contribution Plans [Member]

Defined Contribution Plans [Member]

Defined Contribution Plans [Member]

Benefit Plan Funded Through Assets of the Company [Member]

Benefit Plan Funded Through Assets of the Company [Member]

Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Company contributions

'

$2,241,000

$2,381,000

'

$6,200,000

$4,900,000

$4,000,000

$800,000

$2,400,000

$800,000

'

'

Benefit obligation

32,621,000

32,621,000

30,126,000

27,150,000

'

'

'

'

'

'

7,400,000

5,400,000

Projected benefit obligation

32,600,000

32,600,000

30,100,000

'

'

'

'

'

'

'

'

'

Accumulated benefit obligation

30,900,000

30,900,000

28,100,000

'

'

'

'

'

'

'

'

'

Fair value of plan assets

19,981,000

19,981,000

19,577,000

18,185,000

'

'

'

'

'

'

'

'

Amount expected to be amortized from accumulated other comprehensive loss in next fiscal year

$200,000

'

'

'

'

'

'

'

'

'

'

'

RETIREMENT_PLANS_Schedule_of_C

RETIREMENT PLANS (Schedule of Components of Net Periodic Benefit Costs of Defined Benefit Pension Plans) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Compensation and Retirement Disclosure [Abstract]	'	'	'
Service cost	$3,351	$2,759	$2,545
Interest cost on benefit obligation	623	639	601
Expected (return)/loss on plan assets	-435	-413	2
Actuarial loss/(gain)	88	196	-385
Amortization of unrecognized prior service cost	182	-14	-31
Amortization of unrecognized transition obligation	47	48	221
Totals	$3,856	$3,215	$2,953

RETIREMENT_PLANS_Schedule_of_A

RETIREMENT PLANS (Schedule of Activity Under Defined Benefit Plans) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Change in Benefit Obligation:	'	'	'
Benefit Obligation, beginning of year	($30,126)	($27,150)	'
Service cost	-3,351	-2,759	-2,545
Interest cost	-623	-639	-601
Benefits paid	4,474	3,210	'
Actuarial (loss)/gain	55	-1,364	'
Employee and plan participants contribution	-2,963	-2,926	'
Plan Amendments	419	0	'
Foreign currency changes	-506	1,502	'
Benefit obligation, end of year	-32,621	-30,126	-27,150
Change in Plan Assets:	'	'	'
Fair value of plan assets, beginning of year	19,577	18,185	'
Company contributions	2,241	2,381	'
Benefits paid	-4,641	-3,210	'
Gain/(Loss) on plan assets	100	397	'
Employee and plan participants contributions	3,087	2,926	'
Employee and plan participants contributions	2,963	2,926	'
Foreign currency changes	-383	-1,102	'
Fair value of Plan Assets, end of year	19,981	19,577	18,185
Funded Status	-12,640	-10,549	'
Unrecognized net actuarial loss/(gain)	5,899	5,418	'
Unrecognized initial obligation	94	184	'
Unrecognized prior service cost	-422	138	'
Net amount recognized	($7,069)	($4,809)	'

RETIREMENT_PLANS_Schedule_of_C1

RETIREMENT PLANS (Schedule of Components of Change Recorded in Accumulated Other Comprehensive Income Related to Defined Benefit Plans, Net of Tax) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Components of Change Recorded in Accumulated Other Comprehensive Income Related to Defined Benefit Plans, Net of Tax [Roll Forward]	'	'	'
Impact of Defined Benefit Plans, Net of Tax, Balance	($5,073)	($4,253)	($265)
Obligation at transition	172	556	30
Actuarial loss	-129	-1,237	-3,701
Prior service cost	438	-139	-317
Impact of Defined Benefit Plans, Net of Tax, Balance	($4,592)	($5,073)	($4,253)

RETIREMENT_PLANS_Schedule_of_W

RETIREMENT PLANS (Schedule of Weighted Average Rates Used to Determine Net Periodic Benefit Costs) (Details)	12 Months Ended
	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Compensation and Retirement Disclosure [Abstract]	'	'	'
Discount rate	2.02%	1.97%	2.40%
Rate of increased salary levels	1.57%	1.42%	1.50%
Expected long-term rate of return on assets	1.94%	1.92%	2.10%

RETIREMENT_PLANS_Schedule_of_E

RETIREMENT PLANS (Schedule of Estimated Future Benefit Payments) (Details) (USD $)	Mar. 29, 2014
In Thousands, unless otherwise specified
Expected Benefit Payments	'
Fiscal Year 2015	$2,023
Fiscal Year 2016	1,897
Fiscal Year 2017	1,907
Fiscal Year 2018	1,578
Fiscal Year 2019	1,645
Fiscal Year 2020-2024	$8,295

SEGMENT_INFORMATION_Revenues_f

SEGMENT INFORMATION (Revenues from External Customers) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2014	Dec. 28, 2013	Sep. 28, 2013	Jun. 29, 2013	Mar. 30, 2013	Dec. 29, 2012	Sep. 29, 2012	Jun. 30, 2012	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
									segment
Segment Reporting [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Number of Reportable Segments	'	'	'	'	'	'	'	'	1	'	'
Number of Operating Segments	'	'	'	'	'	'	'	'	5	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	$241,091	$242,120	$235,755	$219,543	$249,942	$247,395	$218,178	$176,475	$938,509	$891,990	$727,844
Reportable Segment	'	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	'	'	'	'	'	'	'	'	806,834	757,765	594,933
Reportable Segment | Plasma disposables	'	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	'	'	'	'	'	'	'	'	291,895	268,900	258,061
Reportable Segment | Blood center disposables	'	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	'	'	'	'	'	'	'	'	389,719	357,771	215,980
Reportable Segment | Platelet	'	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	'	'	'	'	'	'	'	'	156,643	169,602	167,946
Reportable Segment | Red cell	'	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	'	'	'	'	'	'	'	'	42,378	49,733	48,034
Reportable Segment | Whole blood	'	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	'	'	'	'	'	'	'	'	'	138,436	0
Reportable Segment | Hospital disposables	'	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	'	'	'	'	'	'	'	'	125,220	131,094	120,892
Reportable Segment | Surgical	'	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	'	'	'	'	'	'	'	'	66,876	73,508	66,619
Reportable Segment | OrthoPAT	'	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	'	'	'	'	'	'	'	'	25,042	30,230	31,186
Reportable Segment | Diagnostics	'	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	'	'	'	'	'	'	'	'	33,302	27,356	23,087
Reportable Segment | Software solutions	'	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	'	'	'	'	'	'	'	'	70,441	69,952	70,557
Reportable Segment | Equipment & other	'	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	'	'	'	'	'	'	'	'	$61,234	$64,273	$62,354

SEGMENT_INFORMATION_Enterprise

SEGMENT INFORMATION (Enterprise Wide Disclosures about Product and Services) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Net revenues	$938,509	$891,990	$727,844
Total Assets	1,514,178	1,461,917	911,135
Long-Lived Assets	891,202	851,815	373,264
United States	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Net revenues	500,719	454,874	352,160
Total Assets	810,409	830,754	634,171
Long-Lived Assets	519,396	503,606	305,370
Other North America	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Net revenues	9,557	6,851	512
Total Assets	225,998	225,849	15,365
Long-Lived Assets	211,624	209,439	12,796
Total North America	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Net revenues	510,276	461,725	352,672
Total Assets	1,036,407	1,056,603	649,536
Long-Lived Assets	731,020	713,045	318,166
Japan	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Net revenues	108,679	120,726	124,381
Total Assets	53,207	44,189	50,509
Long-Lived Assets	11,522	12,977	13,128
Other Asia	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Net revenues	94,762	84,860	67,223
Total Assets	53,055	41,037	27,353
Long-Lived Assets	17,269	8,076	3,961
Total Europe	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Net revenues	224,792	224,679	183,568
Total Assets	371,509	320,088	183,737
Long-Lived Assets	$131,391	$117,717	$38,009

RESTRUCTURING_Narrative_Detail

RESTRUCTURING (Narrative) (Details) (USD $)	3 Months Ended	12 Months Ended
	Dec. 28, 2013	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Expected cost	$74,000,000	'	'	'
Expected cost in cash	58,000,000	'	'	'
Restructuring charges incurred	'	49,051,000	10,892,000	5,858,000
Asset write down	'	3,305,000	4,247,000	0
Transformation costs	'	35,700,000	61,565,000	11,883,000
Payments	'	-25,372,000	-5,377,000	-7,535,000
Restructuring charges in next twelve months	'	18,200,000	'	'
Minimum	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Expected cost	10,000,000	'	'	'
Maximum	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Expected cost	$15,000,000	'	'	'

RESTRUCTURING_Schedule_of_Rest

RESTRUCTURING (Schedule of Restructuring Reserve by Type of Cost) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Restructuring Reserve [Roll Forward]	'	'	'
Beginning Balance	$3,262	$1,994	$3,671
Cost Incurred	49,051	10,892	5,858
Payments	-25,372	-5,377	-7,535
Asset Write down	-3,305	-4,247	0
Ending Balance	23,636	3,262	1,994
Transformation costs	35,700	61,565	11,883
Total restructuring and transformation	84,751	72,457	17,741
Integration and other costs	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'
Transformation costs	30,701	60,878	11,206
Accelerated depreciation	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'
Transformation costs	4,203	687	677
Asset disposal	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'
Transformation costs	796	0	0
Employee-related costs	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'
Beginning Balance	3,089	1,461	2,782
Cost Incurred	31,492	6,214	4,112
Payments	-11,673	-4,586	-5,433
Asset Write down	0	0	0
Ending Balance	22,908	3,089	1,461
Facility-related costs	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'
Beginning Balance	173	533	889
Cost Incurred	14,254	431	1,746
Payments	-13,699	-791	-2,102
Asset Write down	0	0	0
Ending Balance	728	173	533
Accelerated depreciation	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'
Beginning Balance	0	'	'
Cost Incurred	2,390	0	0
Payments	0	'	'
Asset Write down	-2,390	'	'
Ending Balance	0	0	'
Asset disposal	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'
Cost Incurred	915	4,247	0
Asset write-down	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'
Beginning Balance	0	0	'
Cost Incurred	915	4,247	'
Payments	0	'	'
Asset Write down	-915	-4,247	'
Ending Balance	0	0	'
Other Restructuring [Member]	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'
Cost Incurred	$14,254	$431	$1,746

CAPITALIZATION_OF_SOFTWARE_DEV1

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS (Narrative) (Details) (USD $)	12 Months Ended			3 Months Ended
	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012	Jun. 29, 2013	Mar. 30, 2013
				Three Projects Placed Into Service [Member]	Three Projects Placed Into Service [Member]
Schedule of Capitalization [Line Items]	'	'	'	'	'
Capitalized software development costs for ongoing initiatives	$6,000,000	$6,200,000	'	$10,400,000	$1,700,000
Software costs capitalized, net	31,700,000	25,742,000	'	'	'
Total costs capitalized related to in process software development initiatives	15,600,000	20,000,000	'	'	'
Interest costs capitalized	400,000	300,000	'	'	'
Amortization of capitalized software development cost expense	$1,100,000	$900,000	$700,000	'	'

SUMMARY_OF_QUARTERLY_DATA_UNAU2

SUMMARY OF QUARTERLY DATA (UNAUDITED) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 29, 2014	Dec. 28, 2013	Sep. 28, 2013	Jun. 29, 2013	Mar. 30, 2013	Dec. 29, 2012	Sep. 29, 2012	Jun. 30, 2012	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Quarterly Financial Data [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Net revenues	$241,091	$242,120	$235,755	$219,543	$249,942	$247,395	$218,178	$176,475	$938,509	$891,990	$727,844
Gross profit	115,440	121,629	119,884	111,412	123,141	113,115	101,762	90,113	468,365	428,131	369,240
Operating (loss) income	12,645	17,860	23,430	-6,608	17,710	15,747	9,901	13,079	47,327	56,437	88,758
Net income	$10,184	$16,290	$16,548	($7,874)	$12,562	$9,904	$6,547	$9,787	$35,148	$38,800	$66,886
Per share data:	'	'	'	'	'	'	'	'	'	'	'
Basic income per share (in dollars per share)	$0.20	$0.31	$0.32	($0.15)	$0.24	$0.19	$0.13	$0.19	$0.68	$0.76	$1.32
Diluted income per share (in dollars per share)	$0.19	$0.31	$0.32	($0.15)	$0.24	$0.19	$0.13	$0.19	$0.67	$0.74	$1.30

ACCUMULATED_OTHER_COMPREHENSIV2

ACCUMULATED OTHER COMPREHENSIVE INCOME (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'
Accumulated Other Comprehensive Income, Balance	$5,433	$9,110	'
Other comprehensive income before reclassifications	4,547	-1,113	'
Amounts reclassified from Accumulated Other Comprehensive Income	-8,570	-2,564	'
Other comprehensive loss	-4,023	-3,677	-431
Accumulated Other Comprehensive Income, Balance	1,410	5,433	9,110
Foreign currency	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'
Accumulated Other Comprehensive Income, Balance	4,133	8,838	'
Other comprehensive income before reclassifications	-935	-4,705	'
Amounts reclassified from Accumulated Other Comprehensive Income	0	0	'
Other comprehensive loss	-935	-4,705	'
Accumulated Other Comprehensive Income, Balance	3,198	4,133	'
Defined benefit plans	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'
Accumulated Other Comprehensive Income, Balance	-5,073	-4,253	'
Other comprehensive income before reclassifications	223	-1,002	'
Amounts reclassified from Accumulated Other Comprehensive Income	258	182	'
Other comprehensive loss	481	-820	'
Accumulated Other Comprehensive Income, Balance	-4,592	-5,073	'
Net Unrealized Gain/loss on Derivatives	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'
Accumulated Other Comprehensive Income, Balance	6,373	4,525	'
Other comprehensive income before reclassifications	5,001	4,594	'
Amounts reclassified from Accumulated Other Comprehensive Income	-8,570	-2,746	'
Other comprehensive loss	-3,569	1,848	'
Accumulated Other Comprehensive Income, Balance	$2,804	$6,373	'

ACCUMULATED_OTHER_COMPREHENSIV3

ACCUMULATED OTHER COMPREHENSIVE INCOME (Details 2) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2014	Dec. 28, 2013	Sep. 28, 2013	Jun. 29, 2013	Mar. 30, 2013	Dec. 29, 2012	Sep. 29, 2012	Jun. 30, 2012	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Reclassification out of Accumulated Other Comprehensive Income [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Realized net gain on derivatives	'	'	'	'	'	'	'	'	($10,926)	($6,540)	$740
Income tax effect	'	'	'	'	'	'	'	'	-1,253	-11,097	-22,612
Net income	10,184	16,290	16,548	-7,874	12,562	9,904	6,547	9,787	35,148	38,800	66,886
Net Unrealized Gain/loss on Derivatives | Amounts Reclassified from Other Comprehensive Income	'	'	'	'	'	'	'	'	'	'	'
Reclassification out of Accumulated Other Comprehensive Income [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Realized net gain on derivatives	'	'	'	'	'	'	'	'	8,960	4,403	'
Income tax effect	'	'	'	'	'	'	'	'	-390	-1,657	'
Net income	'	'	'	'	'	'	'	'	8,570	2,746	'
Defined benefit plans | Amounts Reclassified from Other Comprehensive Income	'	'	'	'	'	'	'	'	'	'	'
Reclassification out of Accumulated Other Comprehensive Income [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Realized net gain on derivatives	'	'	'	'	'	'	'	'	317	230	'
Income tax effect	'	'	'	'	'	'	'	'	-59	-48	'
Net income	'	'	'	'	'	'	'	'	$258	$182	'

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details) (Subsequent event, USD $)	0 Months Ended
In Millions, unless otherwise specified	Apr. 28, 2014
Subsequent event	'
Subsequent Event [Line Items]	'
Authorized repurchase amount	$100

VALUATION_AND_QUALIFYING_ACCOU1

VALUATION AND QUALIFYING ACCOUNTS (Details) (Allowance for Doubtful Accounts, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Allowance for Doubtful Accounts	'	'	'
Movement in Valuation Allowances and Reserves [Roll Forward]	'	'	'
Balance at Beginning of Fiscal Year	$1,727	$1,480	$1,799
Charged to Costs and Expenses	186	446	-39
Write-Offs (Net of Recoveries)	-237	-199	-280
Balance at End of Fiscal Year	$1,676	$1,727	$1,480